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                               INTRODUCTION 
 Siddha system of medicine is a divine system medicine. It is distinguish from 
other Indian medicine because it is based on 96 philosophes. siddha medicine is 
created by  18 intellectual siddhars. they have well Knowledge about astanga yogam 
and panchapootha theory. 
 siddha medicine not only cures the disease but also it rejuvenate the body. The 
three humors (vatham, pitham, kabam) play a major role in causing the diseases. the 
diseases in siddha are classified into 4448.  
 Kuthambai Siddhar says,  
           “Lh<hq{qkje!nxqbik!&mIgt<< << << <!
!!!!!!!!!!!!!wh<hq{q!kQIh<hivc!< Q << Q << Q < .!Gkl<hib<< << << <!
!!!!!!wh<hq{q!kQIh<hivc!!!ficobiVhK!fe<gib!xqf<kqcz<< Q < < < << Q < < < << Q < < < <!
!!!!!!!!!!!!!YcuqMl<!<<< hq{qOb!.!Gkl<hib<< << << <!
!!!!!!YcuqMl<<<<!hq{qOb!! !
!!!!!!!!!!!!!Sk<k!ujg!kiK!ke<jebxqf<OkiI< < << < << < < !
!!!!!!Sk<k!juk<kqbOe!< << << < .!Gkl<hib<!!Sk<k!juk<kqbOe< < < << < < << < < < !
!!!!!!!!!!!!!uiBouiV!hk<Kl<!uib<f<k!fqjzg{O<miI< < < < << < < < << < < < < !
!!!!!!NBt<!nxquiec!<<< .!Gkl<hib<< << << <!
!!!!!!!!!!!!!NBt<!nxquiec<<< ”!
 According to Yugi vaithiya chinthamani  vatha disease are categarisezed into 
80 types. Among them Kumba vatham is one of the vatha disease. The symptoms of 
Kumba vatham that given in YUGI VAITHIYA CHINDAMANI 800 is mostly 
correlated with the symptoms of periarthrities of shoulder. 
Arthritis of shoulder is a kind of chronic inflammation caused by the strain 
and anaplasia of the parenchyma including muscle, ligament, tendon, joint capsule 
etc, which is clinically manifested by painful shoulder and limited movements. 
The prevalence of the disease is approximately 3% in the general population. 
Occurrence is rare in children & peaks between 40-70 yrs of age common in 
diabetics and in women. 
The clinical manifestation mainly represent as generally pain and tenderness 
of the shoulder (especially abduction, external rotation and post extend are extremely 
restricted) further more the pain exacerbates at night and the atrophy and accretion of 
the muscle around the shoulder are obvious after a period of time. 
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Shoulder joint is the widest range of motion of the body, so it is easy to 
fatigue and injury in the daily living and muscle easier to induce the diseases. 
The morbid change in periarthritis of the shoulder may affect the joint 
capsule, or the periarticular soft tissue, especially the subacromial bursa, the sheath 
of the long head of the biceps and the supra spinatus tendon. Having chronic 
inflammation, fibrotic & degenerative process. 
It can be diagnosed by limits to the active and passive range of motion. An 
arthogram or an MRI may confirm the diagnosis, though in practice this is rarely 
required. 
There is no proper medication in other system of medicine. In modem seience 
they have to use NSAIDS and intra articular (IA injection) 
In chronic use of the above drug is more abundance and    have prospected 
Complications like renal failure, psycological effects etc. so the community is 
looking for treatment which is cost effectivefree from side effects and the one which 
provide good relief from the disease.increased prevalence of the disease and the 
dreadfull effect caused by the disease calculating a suitable treatment for the disease. 
 Santhira  pragasa Mathirai(Internal) with chukku kudineer and Sembai 
Thylam (external) have been taken as the trial medicine .this medicines are also 
mentioned in siddha sastric literature. The internal medicine Santhira  pragasa 
Mathirai is one of the herbo- mineral formulation. The incredients in the Sembai 
thylam which is used for external application have Anti vatha property. So the 
Author select these medicines as a trial drugs for the  treatment of kumbavatham. 
 Massage and fomentation are the best external therapies used in Sirappu 
maruthuvam branch to cure the vatha disease.So I have select these therapies as a 
coplementory therapy along with the trail drug. 
 The trial drugs were prepared by the author and were tried in 40 cases of 
kumba vatham of varied aetiology and the clinical study was undertaken in the Post 
graduate department of sirappu maruthuvam OP and IP. and the follow up study of all 
the cases was done in the post graduate out patient.  
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                                            AIM AND OBJECTIVE 
 
AIM: 
   To evaluate the clinical efficacy of “SANTHIRA PRAGASA MATHIRAI” 
(internal) and “SEMBAI THYLAM”(external)  for the treatment of KUMBA 
VATHAM  (PERI ARTHRITIS). 
 
Primary objective : 
 To evaluate the clinical efficacy of “SANTHIRA PRAGASA MATHIRAI” 
(internal) and “SEMBAI THYLAM”(external)  for the treatment of KUMBA 
VATHAM  (PERIARTHRITIS). 
 
Secondary objective:   
• To study the Siddha basic principles like envagai thervukkal 
including neerkkuri and neikkuri. 
• To evaluate the safety profile of the trial medicine. 
• To Evaluate the pharmacological study of trial medicine  
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
KUMBA VATHAM 
Definition 
 Kumba vatham is a condition the involvement of painful restricted movement 
of the shoulder joint.  A kind of arthritis attended with boring pain in the shoulders 
and arms, restricted movements of upper limb. 
Clinical features of kumba vatham. 
 “fuqzOu!Oki{<lQKr<!gvk<kqe<!lQK!
! ! fzqf<K!olk<k!uikqOb!fsU{<!miGl<!
! guqzOu!ge<eoliM!fbef<!kiEr<!
! ! gMk<KOl!uqXuqXh<H!oliqUr<!gi[l<!
! KuqzOu!Kch<hiGR<!sqvS!ke<eqx<!
! ! Spx<xqOb!fihqg<gQp<!uzqB!L{<mil<!
! nuqzOu!bcfig<gq!zpe<X!gi[!
! ! lzVOl!uVGl<h!uikf<!kiOe/”!
ohiVt<<<<!
! Okim<hm<jm?! jg! Lkzqb! -mr<gtqz<! lqg<g! OfiB{<migq! njugjt!
fQm<mUl<!Lmg<gUl<!ym<milz<!OfikZl<?!ge<eLl<!g{<[l<!gMk<K!uqXuqXk<K!
wiqkZl<?! dmz<! Kck<Kk<! kjz! Sx<xq! lqG! SvL{<mib<! fiuqe<gQp<! uzqBl<?!
ncfig<gqz<!npx<sqBl<!Ngqb!Gxq!G{r<gt<!-f<Ofibqx<!gi[l</!
 
Aetiology 
 Yugi munivar summarized 80 type of vatha disease.  He is mention’s various 
factors for the cause of vatha disease as follows which includes various intrinsic and 
extrinsic factors. 
 “kioee<x!gsh<OhiM!Kui<h<H!jxh<H!
! ! sikglib<!lqR<SgqZl<!sjlk<k!ue<el<!
! Noee<x!nxquK!Hsqk<k!ziZl<!
! ! Ngibk<!OkxzK!Gck<k!ziZl<!
! hioee<x!hgZxg<g!lqviuqpqh<H!
! ! hm<ceqOb!lqgUXkz<!hiv!olb<kz<!
! Okoee<x!olipqbix<!Olx<sqf<jk!bikz<! !
! ! sQg<gqvlib<!uiklK!osuqg<Gf<!kiOe”!
.!!B,gq!sqf<kil{q!
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Intake of excess in bitter, astringent and pungent taste, intake of old cooked 
food items, drinking rain water, sleeping during day time and awakening at night, 
long duration starvation, strain due to excessive weight lifting and sexual perversion. 
! “uikui<k<!kjegiz!OlOki!oue<eqz<!
! ! lVUgqe<x!uieqgi<g<!gmgliGl<!
! Nkjuh<!hsqObiM!giIk<kqjg!ke<eqz<!
! ! nmVOl!lx<xli!kr<gt<!ke<eqz<!
! OhikOu!slqg<Ggqe<x!gizliGl</”!!
. B,gqsqf<kil{q!
The disease mostly seen in Aani to Karthikai 
 “Neie!uve<xjeOb!lkqbi!lif<ki<!
! ! ngkq!hvOksqbi<gm<ge<e!lQbiI!
! Ogieie!GVolipqjb!lxf<k!Ohi<gt<!
! ! ogijzgtU!ohib<gilr<!Gxqk<k!OhIG!
! Deie!smf<ke<eqz<!uikl<!uf<K!
! ! dx<h{qg<Gl<!Oukk<k[{<jlkiOe/”!
. B,gq!sqf<kil{q!
Forgetting the advice of preceptors and mudering people, stealing, speaking lie 
and involving in immoral activities. 
 “hgvOu!uiklZ!Ogihqk<!kh<Ohi!
! ! h{<high<!oh{<Ohig!lKkie<!osb<bqz<!
! fgvOu!ouGK~v!upqf!mg<gqz<! !
! ! ftqvie!gix<XOl!heq!Olx<hm<miz<!
! lqgvOu!gib<gt<!geq!gqpr<G!ke<je!
! ! lqguVf<kq!lQxqOb!kbqi<kie<!ogi{<miz<!
! LgvOu!LKogZl<jh!LXg<gq!ofif<K!
! ! Lpr<giZl<!gj{g<giZl<!gMh<H{<miOl/!
. B,gq!sqf<kil{q!
Indulging in the sexual act during vitiation of vatha, walking for a long 
distance, exposing to cold and dampness, intake of excessive curd after eating fruits, 
tubers and vegetables causes toxic factors which affects bones and muscles. 
Vatha kanma varalaru 
 “F~oze<x!uikl<!uf<k!ujgkiOeK!
! ! K{<jlbib<!ge<lk<kqe<!ujgjbg<!
! gizqOzOkie<xqbK!gMh<hOkK!
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! ! jggizqz<!Lmg<gqbK!uQg<gOlK!
! OgizqOz!hMg<gqe<x!uqVm<slie!
! ! Gpf<jk!lvf<kje!oum<mz<!Olz<Okiz<!
! fitqOz!sQuosf<K!giz<!xxqk<kz<!
! ! fz<zogil<H!kjp!Lxqk<kz<!fzqk<kz<!giO{/”!
. ngk<kqbi<!ge<lgi{<ml<!
The following psychosocial factors such as removing the bark of living trees, 
breaking the legs of animals, cut the leaves and branches of the tree. 
To sum up 
 The following intrinsic and extrinsic factors are attributed to be the causative 
factors for the manifestation of vatha diseases. 
Intrinsic factors 
Dietic 
 Excess intake of bitter, astringent and pungent taste 
 Excess intake like curd after eating fruits, vegetable and tuber and starving 
Psycho social aspects 
 Forgetting the advice of preceptors and wickedness such as murdering 
 Stealing 
 Truthless speech 
 Involving in immoral activities 
 Spoiling the chastity of a woman 
 Abusing the holy men and ritualists 
 Ingratitude towards mother, father and teacher. 
 Refusing the food for destitudes and sannyasins. 
 Cutting the trees, leaves and branches. 
 Breaking the legs of the animal 
Extrinsic factors 
 Physical strain due to excessive weight lifting 
 Sleeping during day time and awakening at night 
 Improper food habits that increasing vatham. 
 Exposure to dampness and cold 
 Precipitation of the disease in the months from Aani to karthigai 
 Walking for a long distance. 
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Patho physiology 
 According to panchapootha principle when elemental composition of altered 
naturally uyir thathugal or the three humours, which are made up of these elements 
get deranged.  This simultaneously lead to derangement of seven udal thathugal which 
produce symptoms.  This is one way of pathology, producing kumba vatham. 
 Another theory which explains as follows, the etiological factors of 
kumbavatham are both diet that produce excessive vayu and other agents which cause 
vitation of vayu aahayam, earth and fire, depending upon this corresponding uyir 
thathu is affected. 
Here: 
 Aahayam + Air - Vatham 
 Earth  + Water - Kabam 
 Fire   - Pitham 
Vatham, pitham and kabam are deranged simultaneously udal thathugal get deranged. 
Jl<H,kl<!Okgk<kqx<G!dt<t!yx<Xjlbiue< < < < < << < < < < << < < < < < !
! “n{<mk<kqz<!dt<tOk!hq{<ml<!
! hq{<mk<kqz<!dt<tOk!n{<ml<!
! n{<mLl<!hq{<mLl<!ye<Ox!
! nxqf<Kkie<!hiIg<Gl<!OhiOk” 
. sm<mLeq!
hqvhR<sl<! Jl<H,klblieK/! ! Okie<xq?! fqjzk<K?! npqf<K! nh<hiz<!
lXhcBl<! Okie<xq! fqjzk<K! npqf<K! OhiGl<! ohiVm<gt<! biUl<! Yiqmk<kqz<!
yMr<Gl</! ! -KOu! hvh<hqvl<ll<! we<hI/! ! Okie<Xl<OhiKl<! nu<uqmk<kqzqVf<Ok!
hjmk<kz<?! gik<kz<?! npqk<kz<! we<El<! sg<kqgTg<gq{r<g! fqgPl<! -u<Uzgl<!
Jl<H,klblieK!we<hI/!!OkgLl<!Jl<H,kg<!ogit<jgg<G!uqzg<gqz<jz/!
! “fqzl<!fQIkQutq!uqSl<Ohijmf<Kl<!
! gzf<klbg<!gLzgl<!-K”!
.!Ofib<fimz<!Ofib<Lkz<fimz<!hGkq!
1. Earth (fqzl<*<<< !
 Gives shape to the body and release its energy. 
 Bones, muscles and tissues represent it in the body. 
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2. Water (fQI*QQQ !
 Makes the earth supple and helps in the transmission of energy, serum, lymph, 
saliva etc.!
 Represent it in the body.!
4/!Fire (kQ*QQQ !
 Steadies the form of the body and gives vigour and stimulation!
 Digestion and circulation represent it in the body.!
5/!Air (utq*!
 Ignites the fire and works as a life carrier and its he support of all contact and 
exchange!
 Respiration and nervous system represent  in the body.!
6/!Ether (uqsl<H*<<< !
 Ether is the creater of life itself in the body. 
 A harmonious, cambination and function of these five elements in the body 
produce a healthy and beautiful life. 
 Man has gross physical body and subtle physical body is immediately behind 
the gross physical body and is closely connected with it. 
Vatham  = Air + Ether 
In kumba vatham both air and ether are affected 
 The life-force which is different from material energy derived from food, 
pervades the gross physical through the subtle physical. 
Jl<H,kr<gm<Gl<?!nXSjugTg<G!Lt<t!yx<Xjlbiue;< < < < < < << < < < < < << < < < < < < !
! “l{<[mOe!Hez<!kQg<giz<!
! ! Ljxbigs<!Osi<f<kqm<miz<!uVOl!-eqh<H!
! kq{<{lqzl<!KuIh<hqvsl<!
! ! skigkqObi!miIkQuq{<!kqmli!Ljxh<Hl<!
! w{<{iqb!gsh<H!L{<mix<!
! ! k{<{Qiqz<!geuqj{h<hi!ozPli!Lui<h<H!
! d{<{iqb!nXSjubqe<!
! ! hqxh<hqokEl<!GVsqk<kVjvk<k!ljxOb”!
. Okix<xg<gqvl! Nvib<s<sqBl<?! sqk<klVk<Ku!
uvziXl</!
! !
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-eqh<H!! .!! hqVk<uq!+ nh<H!
Htqh<H!! .! hqVk<uq!+ OkB!
dui<h<H! .! nh<H! + OkB!
jgh<H!! .! uiB!+ Ngibl<!
giIh<H!! .! OkB!+ uiB!
Kui<h<H! .! hqVk<uq!+ nh<H!
-s<Sjugtqe<! lqGkqjbg<! ogi{<M?! Okgk<kqz<! wh<H,kr<gtqetuig!
wg<Gx<xr<gt<!hq{qg<gh<hm<cVg<gqe<xe!we<hjk!nxqbzil</!
Gl<huikk<kqz<< < << < << < <!
! jgh<H?! giIh<H?! Kui<h<H! Ngqb! Sjugt<! hikqg<gh<hMukiz<! nkx<G!
giv{lie!H,kr<gTl<!hikqg<gh<hMgqe<xe/!
Jl<H,kl<!< << << < .!Lg<Gx<xk<kqx<G!Lt<t!yx<Xjl< < < < < << < < < < << < < < < < !
utq!! .!utq!+ uq{<!
npz<! .!kQ!
Jbl<!.!fQI!+ l{<!
-v{<cv{<M!H,kr<gtqe<!Osi<g<jgbiz<!!dbqi<kiK!d{<migqxK/!
H,kr<gt<!hikqg<gm<hMl<!OhiK!dbqi<k<kiKg<gt<!hikqg<gh<hMgqxK/!
Vatham 
 Represents vayu 
 Pain flatulence 
 Sensitiveness 
 Dryness 
 Lightness  and also air 
Pitham 
 Represents gastric juice 
 Bile 
 Energy 
 Heat 
 Inflammation 
 Anger and irritation etc 
Kabam 
 Heaviness running of the nose 
 Passing of mucoid discharge and also the saliva 
 Represents feeling of cold. 
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Diagnosis 
 sqk<k! lVk<Ku! nch<hjmbqz<! Ofib<! g{qh<hqz<! w{<ujgk<! Oki<U!
Lke<jlbieK/!
lx<x!Oki<Ugtiue/!
 ohixqbix<Oxi<kz<!
 Hzeixqkz<!
 uqeiUkz<!
 dbqIkiKg<gt<!
 dmz<!kiKg<gt<!
 RiOef<kqiqbl<!
 ge<Olf<kqiqbl<!
 kqj{gt<!
 hVugizl<!
ohixqbix<Oxi<kz<< < << < << < <!
2/ &g<G!
3/ fi!
4/ g{<!
5/ Okiz<!
6/ osuq!
lVk<Kui<!Jl<ohixqgjtg<!ogi{<M!Ofijb!g{qg<gLcBl</!!Gl<huikk<kqz<!
g{<!gMk<K!uqXuqXk<K!wiqkZl<?!ncfig<gqz<!npx<sqBl<! gi{h<hMl</! ! weOu!
Jl<ohixqbqz<!g{<?!fi!hikqg<gh<hMgqxK/!
!
3/!Hzeixqkz<<<<!
2/!fix<xl<!)l{l<*!
3/!Sju!
4/!ytq!
5/!DX!
6/!Yjs!
lVk<Kui<!Jl<Hze<gjtg<!ogi{<M!Ofijb!g{qg<gLcBl</!
Gl<huikk<kqz<< < << < << < <!
! Okim<hm<jm?! jg! Lkzqb! -mr<gtqz<! lqg<g! OfiB{<migq! njugjt!
fQm<mUl<!
Lmg<gUl<!ym<milz<!OfikZl<?!ge<eLl<!gMk<K!uqXuqXk<K!wiqkz<!dt<tkiz<!
Jl<Hze<gtqz<!DX!hikqg<gh<hm<Mt<tK/!
!
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4/!uqeiUkz<<<<!
!! lVk<Kui<! Ofibitqbqml<! uqeiUkz<! &zl<! Ofijb! g{qg<gLcBl</!!
Ofibitqbiz<! Ohs!Lcbik! Ofvk<kqz<! nue<! Sx<xk<kiiqmLl<! uqeiUkz<! &zl<!
Ofijb!g{qg<gLcBl</!
w{<ujgk<Oki<U< < << < << < < !
! “fich<hiqsl<!fifqxl<!olipquqpq!
! lzl<!&k<kqvlqju!lVk<Ku!viBkl<”!
.!Ofib<fimz<!Ofib<!Lkz<!fimz<!hGkq!
“olb<g<Gxq!fqxf<okieq!uqpq!fiuqVlzl<!jgg<Gxq”!
.!Okjvbi<!
2/ fic!
3/ <^hiqsl<!
4/ fi!
5/ fqxl<!
6/ olipq!
7/ uqpq!
8/ lzl<!
9/ &k<kqvl<!
Nadi 
 Literally the following indications of Nadi are suggestive of pain in the body, 
pain in the joints difficulty in mobility, constipation, pain in the extremities and 
weakness in the extremities. 
uik!fic!
! “uikolEl<!ficbK!Okie<xqz<!
! sQklf<koliM!ubqXohiVlz<!kqvm<squiB!
! sQkLXr<gqvi{q!lOgikvl<!fQvijl!
! kqvt<uib<U!$jz!uzq!gMh<Hk<kqjv”!
.! skgfic!
Gl<huikk<kqz<?!!
1. uik!hqk<kl< 
2. uik!ghl< 
3. gh!uikl< 
4. gh!hqk<kl< 
“uikk<kqz<!G{Ol!oke<eqz<!ubqxK!OhiVlqg<ogit<Tl<!
kikk<kqz<!Oleq!jggizsf<KOl!gMh<Hk<!Okie<Xl</!
.!Gxqbjmbitfic!
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The patients have symptoms like pain the upper and lower extremities which 
cause alteration in vatha nadi. 
Vatha pitha Nadi 
 “ohiVtie!uikk<kqz<!hqk<kR<!Osi<f<K!
! ! ohiVf<K!G{r<gti!L]<{uiB!sg<kq!
! osiqbijl!Htqk<Okh<hl<!ohiVlz<!fQiqx<!
! ! squh<Hlzl<!hqiqk<kZVf<!kiKfm<ml<!
gVuie!Okglkq!Zjts<sz<!Osil<hz<!
! jggiz<!kxqh<Hfig<!gsg<G!le<el<”!
.!skgfic!
“w{<{qbuikl<!ov{<Ml<!hqk<k!ole<oxPf<kie<!
! H{<o{eUml<H!Ofiuil<” 
.!kqvm<Mfic!
The patients have joint disorders there is alteration in vathapitha naadi. 
Vatha kaba nadi 
 “hir<gie!uikk<kqz<!Osk<Kl!fich<!!
! ! hiqsqk<kiz<!kqlqi<OlU!Ljts<sziGl<!
! kQr<gie!-VlZme<!sf<fq!Okiml<!
! ! Osi<f<kuqml<!ouc$jz!-Vk<Ovigl<!
! uir<gik!=jtlf<!kiv!gisl<”!
.!skgfic!
“lie!Ofib<!uikl<!ov{<Ml<!
sqOzx<he!olie<!oxPf<k!kigqz<!
NeOkiI!siQvfiUr<!jggiz<!kqlqi<k<Kg<!gim<Ml</”!
.!kqvm<Mfic!
If there is alteration in the vatha kabha naadi, when the patient have spastic 
pain and weakness in the upper limb and lower limb. 
Kaba vatha nadi 
 “g{<miObi!sqOzx<hek<kqz<!uikfic!
! ! gzf<kqMgqz<!ubqX!ohiVlz<!gek<k!uQg<gl<!
! d{<miOzi!Yr<givR<!sk<kq!uqg<gz<!
! ! dXkqvm<js!uib<Uuzq!sf<fq!Okiml<”!
.!skgfic!
!
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“uim<hqMR<!Osk<Klk<kqz<!uf<kqMl<!uikligqz<!
fim<cbgiz<gt<!Ohiz!fvl<ohz<zil<!uzqk<K!fqx<Gl<!
%m<cb!hqmiqki[r<!Ge<xOu!uzqg<G!ligqz!
fim<cb!uqpqBOlzib<!fiuK!GtXf<!kiOe”!
.!ngk<kqbi<!fic!
Kaba Pitha Nadi 
 “-mlie!Osk<Klk<kqz<!hqk<kfic!
! ! wPf<k[gqz<!uqmLmOe!uQg<g!L{<mil<!
! kqmlie!Gtqi<gib<s<sz<!lR<st<!OfiUk<!
! ! Okgk<kq!Zjts<szqjth<!hqVlz<!uif<kq”!
.!skgfic!
3/!^<hiqsl<!)okim<Mh<hiIk<kz<*< < < < < << < < < < << < < < < < !
dmz<! ouh<hfqjz?! SvSvh<H?! Okiz<! dzi<f<kqVk<kz<?! Oklz<?! ogih<htl<?!
gm<cgt<?! gpjz?! osixq?! sqvr<G?! hjmuqv{l<?! uQg<gl<?! Dkz<! Ngqbju!
okim<Mh<hiIk<kz<!&zl<!nxqbzil</!
In Kumba vatham patients the sparisam is normal. 
3. fi!
 lih<hcf<kqVf<kz<?!ouTk<kqVk<kz<!
 uib<fQI!ux{<cVk<kz<!
 hqtU!hm<cVk<kz<!
 H{<{ibqVk<kz<!
 Sju!liXhiM!
! Gl<huikk<kqz<!ncfig<gqz<!npx<sq!gi{h<hMukiz<!fi!hikqg<gh<hMgqxK/!
5/!fqxl<<<<!
 Okiz<fqxl<!
 stqs<su<U!
 lbqi<!lx<Xl<!fgl<!Lkzqbux<xqe<!fqxl<!
In kumba vatham patients skin colour is normal. 
5.!olipq!
 yzq!OuXhiM!
 hqkx<xz<!Gtxz<!
 Gvz<!gl<lqb!Ohs<S!
In Kumba vatham patients, no change of voice is present. 
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6.g{<<<<!
 g{<!hiIjubqe<!fqjzjl 
 g{<!squf<kqVk<kz<?!ouTk<kqVk<kz< 
 g{<!wiqs<sz< 
In kumba vatham patients, burning sensation of eyes is present.   
8/!lzl<!
 lzl<!we<hK!dmzqeqe<Xl<!gpqgqe<x!ohiVt<!
 fqxl<!.!Fjv!
 -Xgz<?!-tgz<!
 lzg<gm<M!
In kumba vatham patients, malam is normal 
8.&k<kqvl<!< << << < !
 fQIg<Gxq!
 ofb<g<Gxq!
fQIg<GxqQ <Q <Q < !
! “nVf<Klixq!vkLl<!nuqOviklib<!
! n0gz<!nzi<kz<!ngizU,e<!kuqi<f<kpx<!
! Gx<xt!uVf<kq!dxr<gq!jugjx!
! Ncg<!gzsk<!kiuqOb!giKohb<!
! okiV!L%Ik<kg<!gjzg<Gm<hM!fQiqe<!
! fqxg<Gxq!ofb<g<Gxq!fqVlqk<kz<!gmOe”!
. Ofib<fimz<!Ofib<Lkz<fimz<!hGkq!
! d{<[gqe<x! nXSjuh<! ohiVt<gTl<! ye<Xg<ogie<X!
Oux<XjlbjmbilZl<?! hsqg<Gk<! kg<ghc! Gjxkz<?! nkqgiqk<kz<! gizf<kuxq!
d{<[kz<! Lkzqb! Gx<xr<gT{<migi! u{<{l<! Hsqk<K! dxr<gq?!
uqcbx<gizk<kqz<! hcg! hik<kqvk<kqz<! ohb<k! fQjv! NuqOhigikhc! 4! ¾!
fipqjgg<Gt<! nke<! fqxg<GxqjbBl<! nkqz<! w{<o{b<uqm<Mh<! hiIk<K!
gi{h<hMgqe<x! GxqjbBl<! gueqk<K! hq{qgtqe<! kQVl<?! kQvig<! Gxqgjt!
nxqbzil</!
sqXfQiqe<!ohiKg<G{l<Q < < <Q < < <Q < < <!
! “uf<k!fQIg<giqwjm!l{l<!FjvwR<soze<!
! jxf<kqbZtuju!bjxGK!LjxOb”!
. Ofib<fimz<!Ofib<Lkz<fimz<!hGkq!–!I!
!
!
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ofb<g<Gxq< << << < !
! fQIfqxg<! Gxqbiz<! Ofijbg<! g{<M! hqck<kx<! ohiVm<Ms<! osiz<zqbqVg<gqe<x!
uqkq! ohiVf<kqb! sqXfQiqz<! yV! sqxqbKtq! w{<o{b<! fMuqz<! jgbjsuqeiz<!
w{<o{b<Ktq!sqkxilz<!uqm<M!oub<bqzieK!nf<fQiqz<!hMl<hc!kqxf<K!gix<xieK!
nkqz<! uQsq! nf<k! w{<o{b<k! Ktq! Nmikhc! juk<K! ns<sqXfQiqz<!
uqmh<hm<cVg<gqe<x!w{<o{b<k<!KtqbieK!osz<Zgqe<x!upqbqz<!g{<{xqjuBl<?!
dbqvxqjuBl<! osZk<kq?! nk<Ktq! okiquqg<Gl<! Ofib<! uqtg<gk<jk! okiqf<K!
ogit<tzil</!
 “nvoue!fQ{<ce0Ok!uikl<!
! Npq!Ohix<hvuqe<!n0Ok!hqk<kl<!
! Lk<okik<K!fqx<gqe<!olipquoke<!ghOl”!
. Ofib<fimz<!Ofib<!Lkz<fimz<!
 In Kumbavatham patients during neikuri examination the oil spreads like 
snake and sometimes like ring and pearl. 
UYIR THATHUKKAL 
VATHAM 
Pranan: 
Physiological function: Inspiration and expiration responsible for sneezing  
coughing   and belching 
 Features in Kumba vatham: Not affected 
Abanan:  
   Physiological function: Act with downward movement 
  Features in Kumba vatham: Not affected  
Viyanan: 
  Physiological function: Helps in various movements of body, responsible for 
 sensation 
Features in Kumba vatham: Affected pain and Restricted  movement of 
shoulder joint. 
Udhanan: 
Physiological function: Regulates the higher functions of brain.  Responsible  
for physiological reactions like hiccough and vomiting 
  Features in Kumba vatham: Not affected 
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Samanan: 
   Physiological function: Regulates all other vayus 
   Features in Kumba vatham: Affected 
Nagan: 
Physiological function: Responsible for intelligence helps in opening and 
closing of eyes 
Features in Kumba vatham: Not affected. 
Koorman: 
Physiological function: Responsible for lacrimation.  Helps to visualization of  
all things in the world. 
Features in Kumba vatham: Not affected. 
Kirugaran: 
   Physiological function: Drippling of saliva, Rhinorrhoea. 
  Features in Kumba vatham: Not affected. 
Thevathathan: 
  Physiological function: Responsible for laziness. Rotation of eyeballs 
  Features in Kumba vatham: Affected (Sleeplessness present due to pain). 
Thananjeyan: 
   Physiological function: Responsible for tinnitus oedema. 
  Features in Kumba vatham: Not affected 
PITHAM 
Anar pitham: 
Physiological function: Digests all the ingested particles. 
Features in Kumba vatham:  Not Affected 
Ranjaga pitham: 
Physiological function: Increases the blood and gives blood colour 
Features in Kumba vatham:  Not Affected 
Saathaga pitham: 
Physiological function: Makes the work to complete what mind thinks to do 
Features in Kumba vatham: Affected shoulder pain and restricted  movement 
of shoulder. 
Aalosaga pitham: 
Physiological function: Responsible for clear vision. 
Features in Kumba vatham:  Not Affected. 
 17 
Prasaga pitham: 
Physiological function: Gives colours to skin 
Features in Kumba vatham: Not affected 
KABAM 
Avalambagam: 
 Physiological function: Controls other 4 types of kabam 
 Features in Kumba vatham: Affected (santhigam affected) 
Klethagam: 
 Physiological function: Moistens the food 
 Features in Kumba vatham: Not affected 
Pothagam: 
 Physiological function: Helps to know the taste 
 Features in Kumba vatham: Not affected 
Tharpagam: 
 Physiological function: Gives cooling effect to the eyes 
 Features in Kumba vatham: Affected burning sensation of eye present 
Santhigam: 
 Physiological function: Gives lubrication to joints 
 Features in Kumba vatham: Affected (pain in shoulder joint) 
 
SEVEN PHYSICAL CONSTITUENTS OF BODY 
Saaram: 
 Physiological function: Strengthens the body and mind  
 Features in Kumba vatham: Affected 
Senneer: 
 Physiological function: Preserves brightness, boldness, power&   
 knowledge 
 Features in Kumba vatham: Affected 
Oon: 
 Physiological function: Gives structure and shape to the body. 
 Features in Kumba vatham:  Early stage  - Not affected 
     Later stage  - Affected 
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Kozhuppu: 
 Physiological function: Responsible for movement lubricants   
 the joint 
 Features in Kumba vatham: Affected 
Enbu: 
 Physiological function: Responsible to joint movements 
 Features in Kumba vatham: Affected 
Moolai 
 Physiological function: Present inside the bones and gives    
 strength to  the  bones 
 Features in Kumba vatham: Not affected 
Sukkilamor suronitham: 
 Physiological function:  
 Features in Kumba vatham: Not affected 
 
GNANTHRIYAM 
Mei: 
Physiological function: Feels the sensation of touch 
Features in Kumba vatham: Not affected 
Naa: 
  Physiological function: Analyses taste 
Features in Kumba vatham: Not affected 
Kan: 
  Physiological function: For vision 
Features in Kumba vatham: Not affected  
Mooku: 
Physiological function: For smell 
Features in Kumba vatham: Not affected 
Sevi : 
Physiological function: For hearing 
Features in Kumba vatham: Not affected 
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Kanmenthiriyam 
Kai 
 Physiological function: - Handling the things 
 Features in Kumba vatham: Affected shoulder joint pain 
numbness, Restricted movement of shoulder joint 
Kal 
 Physiological function: - Walking 
 Features in Kumba vatham: Not affected 
Vaai 
 Physiological function: For speaking 
 Features in Kumba vatham: Not affected 
Eruvaai 
 Physiological function: For defaecation 
 Features in Kumba vatham: Not affected 
Karuvaai 
 Physiological function: For reproduction 
 Features in Kumba vatham: Not affected 
THINAIGAL  
Kurinji 
 Place: Mountain and its surroundings 
 Common diseases: Kabanoi,  liver disease are common 
Mullai  
 Place: Forest and its surroundings 
 Common diseases: Pitha and vatha disease liver    
 disease and common 
Marutham 
 Place: Field and its surroundings 
 Common diseases: Safest place to maintain good    
 health 
Neithal 
 Place: Sea and its surroundings  
 Common diseases: Vatha disease and liver     
 enlargement are common 
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Paalai 
 Place: Desert and its surroundings 
 Common diseases: Vatha pitha and kabha disease and common 
 Most of the patients came from Marutha nilam.  Patients were   
 also reported from neithal nilam. 
 
PARUVA KAALANGAL 
Kaarkaalam  
  Aavani and Purattasi(August 16 – October 15)  
 Kuttram- Vatham ↑ ↑Pitham  ↑ 
Koothirkaalam         
 Ayppasi and karthigai(October16 – December15) 
 Kuttram - Vatham (-)Pitham  ↑ ↑ 
Munpanikaalam          
 Maargali and Thai(December 16 – February 15*       
 Kuttram- Pitham  (-) 
Pinpanikaalam           
 Maasi and Panguni(February 16 – April 15* 
 Kuttram- Kabam  ↑ 
Elavenilkaalam        
 Aani and Aadi(April 16 – June 15)  
 Kuttram- Kabam ↑↑ 
Muduvenilkaalam      
 Aani and Aadi(June 16  - August 15*!
! Kuttram- Vatham ↑Kabam (-) 
Differential diagnosis 
sgeuikl<<<<!
! “OgTOl!gPk<kqe<!gQpjvg<G!OlZr<!
! ! oghqbie!gvlqv{<M!lqgOu!ofif<K!
! uiTOl!siQvolz<zil<!gek<kqVg<Gl<!
! ! uizqhi<g<G!ler<g{<[!lbg<gliGl<!
! WTOl!bqv{<M!g{<[!oliqs<sZ{<mi!
! ! Olx<xlib<!szf<kiE!lqXgqg<gi[f<!
! OkTOl!ogim<ceK!Ohix<gMg<Gl<!
! ! sgeui!kk<kqeqOm!kQIg<gf<kiOe”!
! ! ! ! .!B,gq!sqf<kil{q!911!
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! -f<Ofib<! gPk<kqe<! gQpqVf<K! njvbqe<! Olz<ujvBl<! dt<t! -mLl<!
jggiz<gTl<! lqgOfikz<?! dmz<Lx<Xr<! gek<Kg<! gi{z<?! lbg<gL{<mikz<?!
sqXfQIgm<mz<?!dmz<LPjlBl<!Okt<!ogim<cbK!Ohie<X!gMk<K!Ofikz<!Ngqb!
Gxqgjt!ohXl</!
3/!hi{qg<gl<h!uikl<< < << < << < <!
! “liIg<glib<!uib<Ulib<!olb<fqjxf<K!
! ! ubqXkeqx<!hsqbqzi!K~[lx<X!
! fiIg<glib<!Rizk<K!fmg<jgbx<X!
! ! fMg<glib<!jgbqv{<Mf<!kqVlqV{<mil<!
! DIg<gli!Bxg<glqz<zi!K{i<s<sq!bx<X!
! ! dkxqOb!siQv!olr<G!Lzi<f<K!gi[f<!
! hiIg<glib<!uib<uqm<M!nzi<k<kziGl<!
! ! hi{qg<gl<h!uikk<kqe<!hir<GkiOe”!
! ! ! ! .!B,gq!juk<kqbsqf<kil{q!
!
! -f<Ofib<! dmz<! Lx<xqZl<! utqg<Gx<xk<jk! fqjxk<Kh<! hsqk<kQjbg<!
ogMk<K! fmg<g! Lcbijl?! jggiz<! fMg<gl<?! jgkqlqi<kz<! K~g<glqe<jl?!
d{i<s<sqbqe<jl?!dmz<!ux<xqh<Ohikz<?!uib<hqkx<xz<!Ngqb!GxqgjtBl<!gim<cg<!
gijz!lmg<g!Lcbilx<!ogil<jh!Ohiz<!fqjzg<gs<!osb<KuqMl</!
Line of Treatment 
 According to siddha system of medicine, any disease management has three 
stages. 
 Kaapu (or) Prevention 
 Neekam (or) Treatment 
 Niraivu (or) REstoration 
 
Kaapu or prevention 
 Avoid excessive weight lifting 
 Maintain proper posture while sitting 
 Sleep without pillows 
 Avoid watching television for a long period. 
 Avoid excessive cold exposure. 
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Neekam (or) Treatment 
 The main aim of treatment in siddha system in equilizing the lost equilibrium 
in three humour .  Hence the below order in followed in the treatment of Kumba 
vatham. 
 Purgatives 
 Internal and external medicines 
 Diet and advises 
 Kanma neekam 
 
1. Purgatives 
The purgatives are given to correct the deranged vatham. 
 “uqOvsek<kiz<!uikl<!kiPl<”/!
Mostly used purgatives are 
 Vellai ennai – 10-15ml 
 Agathiyar kuzhambu – 50-100mg 
 Merugulli thylam – 10-15ml 
 Vadhanaasa thylam – 10-15 ml 
2. Internal and External Medicines 
 There are numerous medicine which have anti-vadha property.  Some of them 
are 
Internal 
1. Nilavembu kudineer 
2. Parangipattai kudineer 
3. Amukura choornam 
4. Thirikadugu choornam 
5. Silasathu parpam 
6. Muthu parpam 
7. Naga parpam 
8. Sandamarutha chenduram 
9. Arumuga chendhuram 
External 
1. Sivappu kukil thylam 
2. Vidamutti thylam 
3. Arka sheerathi thylam 
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4. Vadha kesari thylam 
5. Chittramutti thylam 
 
2. Diet and advises 
 Pathiyam (or) dietary regulation should be strictly followed while eating 
internal medicines is not followed it may antasonize drug effect and can produce 
unwanted results. 
 “hk<kqbk<kiOz!hzE{<miGl<!lVf<K!
! hk<kqbr<gt<!Ohieiz<!hze<!OhiGl<!.!hk<kqbk<kqz<!
! hk<kqbOl!oux<xqkVl<!h{<ckVg<!gikzqeix<!
! hk<kqbOl!uk<kqobe<X!hiI”!
! ! ! ! .!Okjvbi<!ou{<hi!
5/!Kanma Neekam 
 To expiate the effects of kanmam, following measures are advised. 
 Planting yound trees 
 Laying roads 
 Digging wells 
 Establishing garden’s 
 Constructions temples 
 Charity 
Niraivu or restoration  
 Any residual effects of the disease should be cleared and the patient shouyld 
return to his normal life.  To restore the activities of the life, special therapy of  much 
essential.!
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SIRAPPU MARUTHUVAM FOR KUMBA VATHAM 
1.THOKKANAM 
2. OTTRADAM 
THOKKANAM  
 Thokkanam is the siddha way of touch therapy.  it is the physical manipulation 
of the body usually done with or without oil application.  It is very effective for 
neurological and musculoskeletal problems.  It also promotes mental and physical 
fitness.  According to siddha, disease in the body occur due imbalance of three 
humours that is vatham, pitham and kapham which in turn are governed by five 
fundamental elements – Akayam (Space, vayu (air), Theyu (fire), Appu (water and 
Mann (Earth.  Thokkanam is one of the 32 types of external medicines mentioned in 
siddha literature.  In this technique, the physician uses his hands on the body of the 
patient in 9 different unique ways with or without using medicated oil with acurative 
or palliative point of view.  The 9 different techniques in thokkanam which makes 
siddha medicine unique in all aspects.  They are 
 
1. Thattal or patting technique 
2. Irukkal or tightening 
3. Pidithal or holding 
4. Murukkal or twisting 
5. Kattal or tying 
6. Azhuthal or pressing 
7. Izhuthal or pulling 
8. Mallathuthal or supinating 
 
Benefits of Thokkanam 
 Helps to cure vatha disease even without internal medicines. 
 Chronic disease like spondylosis, lumbago, disc prolapse, hemiplegia, 
neurological conditions etc are managed well through thokkanam. 
 Improve circulation 
 Treats obesity 
 Helps in pain relief 
 Removes indigestion, constipation and flatulence 
 Induce sleep 
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 Helps maintain normal blood pressure 
 Restores vatham, pitham and kapham in normal ratio 
 Regulates vatha humour. 
 Delays the aging process 
 Helps to rejuvenate the body. 
 Helps to increase the quantity of oxygen in the cells. 
 Helps to prevent wrinkles and maintain the complexion of the skin. 
 Tones the muscles 
 Helps to keep the joint flexible 
 Improves the complexion of the skin 
 Improves energy and mental alertness. 
 
Introduction 
 External remedies in siddh are classified as 32 in number.  The unique remedy 
of its kind among all and which is subdivided into nine more procedures in 
thokkanam.  Initially these procedures were used only for royal families to enhance 
rejuvenation and latter turned into a therapeutic application. 
 Thokkanam as a whole focuses on treating disease caused by aggravation of 
‘VATHAM’ the kinetic force of the body.   The humoral theory of siddha states that 
vatham is the acitve force responsible for the physiological functioning of 
neuromuscular as well as musculo skeletal systems.  
 Thokkanam is also useful in disease where pitham as well as kapham is 
deranged.  A simple thokkanam session wipes of sedentary feel which is a kapham 
aggravation. 
Thokkanam is a word framed by combining two words,  Thokku and Anam.  
Thokku means SKIN.  Anam mean support/tones/heat. 
Toning the skin, muscles and nerves where vatham lives.  It is synonymously 
called as Marthanam.  Marthanam is performed by mallars (wrestlers) in older days.  
Mallars are musculine with calibre to perform martial arts including wrestling. 
As per siddha basic principles the meeting points of muscles, nerves, joints 
and skin including hair roots are places of flow of vital vatham energy.  A depletion 
of vatham vital energy may lead to vatham derangements such as pain, altered tone, 
power, twitching, spasticity, rigidity numbness and neuritis. 
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Three humour theory and thokkanam 
 To have a sound knowledge in application of thokkanam clinically it is 
mandatory to know about three humour theory.  Vatham is the force of creation.  Pitta 
is the force of maintenance, and kapham is the force of destruction. 
 Vatham takes care of bodily funciton as below 
1. Respiration  - Uyirkal (Pranan) 
2. Excretion  - Keel nokku kaal (Abanan) 
3. Circulation - Paravukal (Vyanan) 
4. Digestion - Nadukkal (Samanan) 
 
Thattal – Friction and Percussive strokes 
  Friction and perucssive strokes are most used techniques in Thokkanam.  
Thattal covers more than 40% of techniques of Marthanam. 
  Friction strokes are used in joints, muscles and in tendons.  Friction strokes are 
usually relaxing when applied gently.  Therapist should not exceed the toleratble and 
pleasurable pressure. 
 Percussive strokes are sub divided into hacking, cupping and pinching – 
plucking. Hacking is like chopping in a slaughter house.  In hacking palms are open 
and faces each other.   
Cupping is performed effectively in larger areas like trunk, back and abdomen. 
 Lifting little flesh in fingers and sliding them is pinching/plugging. 
Benefits 
1. Improves circulation 
2. Release muscle tension. 
 
Precautions 
 Precussive strokes directly on spine is to be avoided.  Therapist hands and 
wrist should be held relax. 
 
Irukkal 
 Irukkal is squeezing type of pressure.  Irukkal is applied in conditions where a 
good nourishment to muscles and nerves is deficit.  It is also called as wringling.  It is 
usually performed across body and limbs.  Wringing is usually applied in the end 
hours of Thokkanam.  Squeeze and roll the muscle between your neck and shoulder.  
It’s hard to tell from the photo that he’s doing anything other than squeezing the 
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muscle, But you should in addition to squeezing your muscle also pull or roll the 
muscle between your fingers.  Try it.  first squeeze the muscle, just like you did 
above.  Then pull it a little and roll it in a small circle of back and forth.  Try 7 slow 
squeeze and rolls on your trapezius muscle varying the intensity of each stroke.  Let 
your muscles relax. 
 
Purpose 
 Squeezing and Rolling increases your circulation and warms your muscles.                 
It also gives your fingers a good workout. 
 
Stroke description  
This is a two step stroke.  First squeeze the muscle.  Then pull the muscle and 
roll it between your fingers.  the rolling motion moves the muscle up and down.                    
It pulls the muscle away from your body.  It’s similar to kneading dough. 
 
Ilutthal 
Ilutthal is pulling.  In this type of thokkanam, strokes are used to pull and 
stretch the muscles of the trunk and legs.  Pulling is performed before wringing or 
along. 
 
Murukkal 
 Murukkal is kneading.  It is performed to release muscle tension and to 
improve circulation kneading is performed in areas which are fleshy.  Action similar 
to that of kneading dough is to be performed here. 
 
Pidithal 
 Both pressing and draming is performed in this variety.  Press the muscle areas 
gently and drain them slowly.  Draining is performed usually using the heel of the 
hand for larger areas and thumbs for smaller areas.  Pidithal improves circulation and 
relaxes the muscles. 
 
Aluthal 
 Aluthal is the combination of gliding and gentle pressing.  Usually these two 
procedures initiates massage and repeatedly performed in the whole session gliding is 
the technique used to apply oil all over the body.  Gentle pressing all over the body 
following gliding.  Gliding can be done in longitudinal or circular motion. 
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Purpose 
 Gliding is a good beginning for every massage.  It warms your skin and sends 
a message to your body that a massage is coming. 
 
Stroke Description 
 Glide your hand overy your skin. 
 
Note 
 Massage therapists call this stroke by its french name effleurage which means 
gliding or skimming. 
 
Tips 
 Velocity, volume and intensity are three variables you can use to change the 
effect each stroke has on you. 
 
Volume 
 Try covering more skin with each stroke by spreading your fingers wide or 
make a with your hand 
 
Velocity 
 Try varying the speed of your strokes 
 
Intensity 
 Try varying the intensity of each stroke 
 
Squeezing 
 Try it interlace your fingers.  Rest the heels of your hands on either side of 
your thigh and  squeeze your hands into your thigh muscles.  Try 7 slow quad 
squeezes, slightly vary the location and intensity of each squeeze.  Now try it on your 
other leg. 
 
Purpose 
 Squeezing warms muscles, increases circulation and speeds recovery. 
 
Stroke description 
 Bring pressure to bear on a muscle.  Try squeezing your left biceps with your 
right hands.  It really is a simple as squeezing the muscle.  It should feel good. 
 29 
Squeezing & Rolling 
  Try it: Squeeze and roll the muscle between your neck and shoulder.  It’s hard 
to tell from the photo that he’s doing anything other than squeezing the muscle.  But 
you should in addition to the muscle.  Just like you did above.  Then pull it a little and 
roll it in a small circle of back and forth.  Try 7 slow squeeze and Rolls on your 
trapezius muscle varying the intensity of each.  Stroke let your muscles relax. 
 
Purpose 
 Squeezing and Rolling increases your circulation and warms your muscles.  It 
also gives your fingers a good workout. 
 
Stroke description 
 This is a two steopstroke, first squeeze the muscle just like you did above.  
Then pull the muscle and roll it between your fingers.  The rolling motion moves the 
muscle up and down-it pulls the muscle away from your body.  It’s similar to 
kneading dough. 
 
Pressing 
 Try it.  Take off your shoes and socks and give your foot a poke, press your 
thumb into the bottom of your foot and your other four fingers into the top of your 
foot.  Try 7 slow presses.  Experiment by varying intensity and moving your fingers 
slowly over your foot.  Try it on your other foot. 
 
Purpose 
 The press is powerful because it activates acupoints triggers trigger points,  
jump starts circulation, and sends endorphin cocktails flowing to every cell. 
 
Stroke description 
 Press or poke a muscle into the bone, using one or more fingers, elbows.  Hold 
the press from 1 to 30 seconds. 
Note: Massage therapists call this stroke compression 
 
Pressing and Rolling 
 Try it: Starting at your solarplexus.  Press and roll your abs.  Perform a series 
of small circular rolls with your first moving clockwise, until.  You’ve covered your 
entire belly with your first slightly vary the intensity of each stroke.  Alternately, relax 
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and flex your abs.  Feel the difference between pressing  and pressing and rolling your 
abs.  It’s like night and day. 
 
Purpose 
 Pressing and Rolling activates, acupoints triggers trigger points, jump starts 
circulation and sends endorphin cocktails cruising to stimulate every cell in your 
body. 
 
Stroke description 
 The press and roll in the press with a twist.  Press the muscles into the bone to 
compress them.  Then roll or rotate your press.  The fingers, elbows or fists can be 
used to press and roll the muscles. 
Note: This stroke can be used for deep tissue massage. 
 
Drumming 
  Try it: Drum your quads, use the sides of your hands to tap your thighs.  
Slightly vary the location of each stroke.  Let your leg relax.  focus on the rhythm and 
feeling of each stroke. 
 
Purpose 
 Drumming is an energizing, stimulating stroke, used to get you moving. 
 
Stroke description 
 Lightly drum or tap your hand on your body.  By varying the part of your hand 
drumming your body.  The feeling of the stroke changes some examples are open flat 
hand open cupped hand site of hand, first, knuckles, side of fist and fingertips. 
 
Note 
 Massage therapists call this stroke trapotement  It means drumming. 
 When you need to target a specific area of your body, switch over to manual 
mode.  Customize your massage and choose from several programs to suit your needs 
for both upper and lower body.  The upper body massages. 
 The thadavu murai is classified into two main parts.  They are 
1. Podhu thadaval murai 
2. Uzhl thadaval murai 
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The pothu thadaval murai methods do proper alignment of the nerves, blood 
vessels, bones and muscles.  With the help of medicated oils we should do the 
techniques.  After that we have to realign the sara ottam and jeeva ottam in all varma 
points.  By this we can give good health to the patient. 
 After doing this, we should check whether the patient needs uzhlthadaval 
murai or not.  It it is needed we have to align and stimulate the tissues and internal 
organs.  
 In the first three days of treatment we should only do podhu thadaval methods, 
then in the 4th and 5th day podhu thadaval is done followed by uzhlthadaval. 
 Usually the treatment takes seven days.  In the 6th and 7th day.  We should only 
do podhu thadaval. 
 At the end of the thadaval murai in all the days of the treatment. 
 We have to give otradam, after that the patient should take hot water bath.  
After that the patient should take chukku kanji.  The patient may take their food after 
an hour of these treatment methods.  During the treatment days the patient must avoid 
sleep in the day time. 
 According to the patients health condition we have to give medicines such as 
karungozhi decoction.  Karungozhi nei or vellattu nei. 
 The patient should follow the following food restrictions after the thadaval 
murai.  Chicken, uriddhal, small gram and tamarind during the treatment days.  
Because it may lower the effects of the treatment. 
 The patient should take 3 months rest after the treatment.  Importantly he/she 
should not have sexual contact and severe exercises during the rest periods. 
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of these 2 of the methods are very much beneficial in treating cervical spondylosis. 
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! It is made on the upper fibers of trapezius muscle and the underlying bone. 
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! Done for sternocleidomastoid muscles. 
 The treatment normally starts with applying the medicated oil on the affected 
area.  It directly acts on lymphatic, muscular, nervous and vascular system. 
 Strengthens muscle and skin 
 Relaxes whole body 
 Regulates nerve function 
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 Improve blood circulation 
 Improve sleep 
Through massage, the medicated oil applied permeates through the skin and 
reaches the tissues under them.  It releives pain and tension by stimulation the sensory 
and motor nerves. 
 
Benefits 
 It reduces the production of some hormones such as cortisol and nor 
epinephrine which are responsible for stress. 
 Brings fresh oxygen to the affected tissues. 
 Swelling and thickening of tissues are reduced. 
 
FOEMENTATION 
Definition 
A fomentation consists of a local application of moist heat to the body surface.  
A fomentation is usually made of blanket material.  50% wool to retain heat and 50% 
cotton to retain moisture and be more durable. 
Physiologic effect 
1. Promotes increase in circulating white blood cells. 
2. Increases blood flow to the skin, thereby relieving internal congestion. 
3. Relieves muscle spasm by increasing circulation and releasing muscle tension. 
4. Relieves pain in muscles and joints by counter-irritation and de congestion. 
5. Reflexly relieves pain from internal organs. 
6. Increases elimination by promoting sweating 
7. Stimulates or sedates according to the temperature of the application. 
Indications 
1. Joint pain 
2. Neuralgia and Neuritis pain 
3. Muscle tension 
4. Insomnia 
5. To warm the tissues in preparation for massage. 
6. To prepare for cold procedures. 
  
 34 
Contra indications and cautions 
1. Loss of skin sensation due to unconsciousness paralysis of the part legs and 
feet of diabetic 
2. Leg or feet oedema, varicose veins, advanced vascular disease. 
3. Malignancy 
4. Tendency to bleed (haemorrhage) 
5. Stomach or bowel ulcers. 
6. Omit cold in extreme pain such as pleurisy, Renal colic and dysmenorrhoea. 
!
yx<xml<!< << << < (Fomentation) 
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! It is also one of the 32 external theraphies of siddha medicine by application of 
hot medicated packs. 
 The medicated pouches are made up of leaves that contains. 
 Pelonex elata (uik!fivib{e<!-jz* 
 Tamarindus indicus (Htqbqjz* 
 Vitex negundo (ofis<sq* 
 Cleodendrum phlomoidis (kPkijp* 
Uses 
 Increases blood circulation and reduces pain.!
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MODERN ASPECT 
SHOULDER JOINT 
Classification: 
  It is the synovial polyaxial and the ball and socket joint. 
 
Bone taking part: 
  Glenoid cavity of the scapula and the head of the humerus. 
 
Glenoid cavity: 
  It is pear shaped, shallow articular cavity situated at the lateral angle of the 
scapula. It is covered with the hyaline cartilage. A flattened impression is pressure at 
its periphery for attachment of fibrocartilaginous structure known as glenoid 
labrum.immediately below the cavity less a small rough tubercle. It is known as 
intraglenoid tubercle a similar tubercle lies above the cavity and it known as 
supraglenoid cavity. It is significant to note that the glenoid cavity is directly forward 
and laterally. 
  The movement of flexion and extension take place along this plane and 
bringing the flexed arm in front of the chest the size of the head of the humerus is 
grossly disproportionate to the size of the glenoid cavity which is smaller, which 
contributes the free mobility of the joint. 
 
Head of humerus: 
  The head is hemispherical and is covered with hyaline cartilage. The layer of 
hyaline cartilage is thick in the centre of the head and thin at the periphery. Reverse is 
the case with the glenoid cavity. 
  Head of the humerus is protected above by coracoacromion arch which is 
formed by the coracoids process, coraco acromial ligament and the acromion process. 
The coracoacromial arch is considered as the secondary socket for the head of the 
humerus. This prevents upward displacement of the head of humerus which impinges 
against the coraco acromial arch. 
 
Attachment of the capsule: 
  Proximally the capsule is attached to the rim of glenoid cavity beyond the 
glenoid labrum. Superiorly it includes the supraglenoid tubercle. Which gives origin 
to the long head of biceps and hence the long head of biceps is intracapsular but extra 
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synovial epiphyseal line of the upper end of humerus lies with in the capsule. This 
results is involvement of the joint in case of osteomyelities of the upper end of 
humerus. 
  Distally the capsule is attached to  the anatomically neck of the humerus, 
immediately beyond the articular area of the head. However, capsular attachment 
decents 1 to 1.2cm below on the medial aspect of the shaft. It is interrupted at the 
upper end of the bicipital groove the long head of the biceps along with its synovial 
sheath. As a result decent of the capsular attachment of the joints on the medial side 
of the neck of humerus it become loose and weak. This allows abduction of the 
shoulder without much tension on the interior part of the capsule. However it helps 
osteomyelitis of the upper end of humerus to reach the shoulder joint 
 
Ligaments of the shoulder: 
• Capsular ligament 
• Glenohumoral ligament 
• Coracohumoral ligament 
• Transverse ligament 
• Glenoidal ligament 
  Glenohumoral ligament is divided into three separate bands (ex. Superior, 
middle, and the inferior gleno humoral ligament) 
  Members of the rotator cuf (ex. Subscapularis, supraspinatus, infraspinatus 
and the teres minor form the musculotendinous cuff along with the capsule of the 
shoulder joint. It is known as rotator cuff) 
There are three openings in the capsule they are 
1. Opening for communication with suprascapular bursa. It lies between the 
superior and middle glenohumoral ligaments. 
2. Opening for the long head of biceps with its synovial membrane  
3. The third one is inconstant and when presents its communication with the 
bursa of the infraspinatus muscle. 
  Opening between the superior and the middle glenohumoral ligaments is 
meant for the subscabular bursa. It provides the weak spot for escape of the head of 
humerus during dislocation. Subscapular bursa of a size of a hens egg and is placed 
between between the neck of the scapula and the subscapularis muscles. 
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Gelenohumoral ligaments: 
  Cavity and the humerus they are three in numbers namely the superior, middle 
and the inferior. All the three can very well be examined from inside the capsule. 
Medially they are attached to the medial margin of glenoid cavity. Its upper part here 
they practically fused with the glenoid labrum. Laterally the superior and the middle 
ligaments gain their attachment on the lesser tubercle. 
  The inferior glenohumoral ligament is attached to the lower part of the 
anatomical neck of the humerus. The part of the capsule near the attachment of the 
superior band of the inferior glenohumoral ligaments. It known as axillary power in 
interior dislocation of the shoulder joints the inferior glenohumoral ligament is form 
along with the damage to the superior band of the inferior glenohumoral ligament and 
the part of the glenoidal labrum helps recurrent dislocation of the shoulder. However 
recently absence or advancement of middle glenohumoral ligament extending on the 
scapular neck is consider as an important feature in recurrent dislocation of the 
shoulder. 
 
Coracohumeral ligaments: 
  It is increases the strength of the upper part of the capsule it runs from the root 
of  coracoid process to the anterior part of the greater tubercle of the humerus during, 
it is course practically fuses with the supraspinatus tendon. 
 
Transverse humoral ligament: 
  It bridges the gap between the two tubercles of humerus converting the upper 
part of the bicipital groove in to the canal. Its attachment lies above epiphyseal line 
functionally it acts as a retinaculam for retention of the tendon of the long head of 
biceps. 
 
Glenoid labrum: 
  It is a fibrocartilaginous ring situated along the margin of glenoid cavity. It 
presents of a base, which is fixed to the flattened impression at the periphery of the 
glenoid cavity and the sharp free edge, it lying free, for the contact with the humeral 
head. Superiorly two fascicule of the tendon of long head of biceps fuse with the 
anterior and the posterior parts of the glenoidal labrum are 
1. Deepens the cavity 
2. Maintaining the bony contact and protects the edges of the glenoid cavity. 
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Synovial membrane: 
  The synovial membrane of the joints covers the capsule from inside and other 
structure except articular areas there is a separate tubular sheath of synovial 
membrane for the long head of biceps the synovial membrane of subscabular bursa is 
continuous with synovial membrane of the joints through the opening for subscabular 
bursa. 
 
Bursae around the joints. 
• Subscapular bursa 
• Infraspinatus bursa 
• Subacromial bursa 
• Supra acromial bursa 
• Subcoracoid bursa 
• Bursa between coracobrachialis and the capsule. 
• Bursa between teres major and long head of biceps 
• Bursa in front and behind the tendon of latissimus dorsi. 
• Subscabular bursa is the only bursa which communicate with the joint cavity. 
 
Subacromial bursa: 
  It is situated between the supra spinatus tendon below and the coraco acromial 
arch above. This is the longest of the bursa in the body. When it extents below the 
deltoid muscle it is known as subacromial, subdeltoid bursa. In subacromial bursitis 
patiently experiences pain when pressed below the acromian. After abduction of the 
arm the pain disappears and the tenderness is missing. 
 
Supra-acromial bursa: 
  It is placed above the acromian while the corocoid bursa lies below the 
corocoid process. 
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Relation of the joints: 
  Following are the relation of the joints. 
 
Superior relations: 
• Deltoid 
• Coracoacromial arch 
• Subdeltoid subacromial bursa 
• Tendon of supraspinatus 
Posterior relations: 
• Deltoid  
• Subscapularis 
• Subscabular bursa 
• Coracobrachialis 
• Short head of biceps 
• Clavicular head of pectoralis major 
Posterior relation: 
• Deltoid 
• Infraspinatus 
• Teres minor 
Inferior relations: 
  They are important as the axillary nerve along with the posterior circumflex 
humoral artery and long head of the triceps lie below the joints. Apart from these 
relation axillary artery must be mentioned as the rupture of the artery is likely to 
occur, during dislocation of the shoulder and reduction of an old dislocation. 
 
Nerve supply: 
• Axillary 
• Suprascapular 
• Lateral pectoral nerve 
• Lateral pectoral nerve supplies pectoralis major 
• Suprascapular nerve supplies supraspinatus and infraspinatus muscle 
• Axillary nerve supplies deltoid and te teres minor 
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Blood supply: 
Three arteries supply in the joint 
• Anterior circumflex artery 
• Posterior circumflex artery 
• Suprascapular artery 
 
Biomechanics of the shoulder: 
Kinematics: 
  Abduction is a very importent movement at the shoulder. It is well known that 
bpoth abduction in the coronal plane from 0 to 180 degree and forward flexon in the 
sagital plane from 0 to  180 will plane the upper limb in the same position with the 
medial epicondyle pointing medially and forwards. This is because of the fact that in 
abduction in the coronal plane, the humerus relates externally to prevent impigment of 
the greater tuberosity on the coraco acromial arch. The greater tuberosity rotates 
posteriorly to allow full abduction. Persons with internal rotation contracture of  
abduction due to this reason. The plane of the scapula is 30 degree anterior to the 
coronal plane of the shoulder and in this plane no rotation of the humerus is required 
for full abduction of the shoulder. 
  The full range of abduction involves 120 degree of glenohumoral and 60 
degree of scapulothoracic motion. The scapula thoracic rhythm is the rotation of the 
glenohumoral to the scabulothoracic movement.the rotation is depend on the plane of 
abduction for aduction in the true coronal plane the ratio of glenohumoral to 
scapulothoracic movement is 2:1 and for abduction in the scapular plane, the ratio is 
1:35:1 scapulothoracic movement in the sum of movement at the acromioclavicular 
and sternoclavicular joints. The clavicle abduction 4degree for each 10 degree of 
abduction beyond 90 degree of abduction, further movement of the clavicle is 
negligible. The acromioclavicular joints moves about 20 degree during abduction of 
the shoulder. This movement occurs during the first 30 degree and beyond 135 degree 
of abduction between 30 and 135 of abduction. The movement at the 
acromioclavicular joint is negligible movement at the sternoclavicular and an 
acromioclavicular joint is made possible due to rotation of the clavicle. The clavicle 
rotates by about 50 degree during abduction and is this rotation is prevented. Shoulder 
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abduction is limited to 110 degree the curvature of the clavicle acts as a crankshaft 
allows in elongation of the coracoclavicular ligament. 
 
The force couple: 
  The deltoid and supraspinatus are the main abductors of the shoulder. The 
infraspinatus, Subscapularis and teres minor tend to depress the humeral head during 
abduction. Since the glenoid fossa is shallow, the action of the deltoid alone would 
displace the humeral head out of the socket with the arm by the side, the deltoid tends 
to pull the humerus up and sublux the humerus head superiorly the rotator cuff muscle 
prevent this subluxation by pressing the humeral head into the glenoid. The deltoid 
and the rotator cuff are part of the force couple acting on the humeral head. The force 
couple consists of two opposing forces acting on an object and separated from each 
other by some distance, so that they rotate the concerned object. The multipennate 
nature of the deltoid adds power to its contractions. In a multipennate muscle the 
overall change in length required for a given contraction force is less than that for a 
muscle with parallel arrangement of fibres such as the biceps. Also as the scapula 
rotates during abduction the distance between the acromion and the deltoid insertion 
increases and this maintains the length of the deltoid near to us resting length. 
  In the scapula, the upper portion of the trapezius, levator scapulae and upper 
portion of serratus anterior form a force couple with the lower trapezious and lower 
portion of the serratus anterior causing rotation of the scapula during abduction of the 
shoulder. 
Adduction of the shoulder is carried out by pectoralis major, teres major and 
latissimus dorsi forward  flexon is done by pectoralis major, anterior fibres of the 
deltoid and biceps. Extension is carried out by latisimus dorsi and posterior fibres of 
deltoid internal rotation is the function scapularis and teres major external rotation is 
done by infraspinatus, teres minor and posterior fibres of deltoid. 
 
Stability of the shoulder: 
  Equilibrium is a state in which the body is at rest or in uniform motion under a 
given set of leads. Instability has been defined as an abnormal response to applied 
leads characteristic by motion in the motion segment beyond the normal constraints 
pope and panjab have shown that an object may be in stable, unstable or neutral 
equilibrium. 
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  For the humeral head to be stable in all position the resultant of all the forces 
acting on the humeral head must pass somewhere through the glenoid arc. 
If a passes outside the glenoid arc, stabilityoccurs. The glenoid is slightly concave and 
much smaller than the humeral head. This make the joint essentially unstable in the 
absence of other stabilizer glenohumoral joint stability depends on passive and active 
stabilizers 
Passive stabilizers are as follows: 
  Bony features-retroversion of humeral head (35degree-40degree) and slight 
upward undination of the glenoid Negative intra-articular pressure exerts a suction 
effect. Synovial fluid adhesion and cohesion (due to its high tensile strength and low 
shear strength) Glenoid labrum-deepens the glenoid, although only slightlythe 
articular cartilage of the glenoid is thicker at the margins that at the centre. This also 
increase the concavity. 
 
Ligaments and capsule 
  The volume of the shoulder capsule is twice that of the humeral head to permit 
mobility freely at the sometime, the capsule has condensations which form the 
glenohumoral which form the glenohumoral and coracohumeral ligaments that act to 
provide stability. 
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PERIARTHRITIS SHOULDER (FROZEN SHOULDER) 
(Syn : Periarthritis, Adhesive capsulitis) 
 
INTRODUCTION: 
  Adhesive capsulities was first describe by nevisar in 1945. Both the entities, 
adhesive capsulities and frozen shoulder are generally thought to be the same. 
A frozen shoulder (or) adhesive capsulitis is a glenohumoral joint with pain and 
stiffness that cannot be explained on the basis of joint incongruity it is the restriction 
to passive movement that is the hallmark of this disease. 
  Adhesive capsulitis occurs mainly during the fifth to seventh decade of life 
and affects women more frequently than men bilateral involvement occure in 10 to 40 
percent cases. Once the syndrome resolves it generally does not recur on the same 
shoulder. Unless there are other predisposing factors like diabetes mellitus, bicipital 
tendinitis, rheumatoid arthritis ect. 
  Frozen shoulder is a very common disability causing shoulder pain and 
stiffness. its pathogenesis is not fully understood. It is the end result of many different 
pathological conditions. If the shoulder is immobilized for a long time due to any 
reason, it results into pain and stiffness. 
 
ETIOLOGY: 
   The most common causes are cervical spine degenerative disease or 
radiculopathy, subacromial impingement syndrome, acromio clavicular arthritis post 
trauma bursitis and inflammatory synovitis of the shoulder. It is also found in 
association with other medical problems such as diabetes mellitus and also with 
cardiothoracic surgery, shoulder immobilization for feature in the upper limb of 
adhesive capsulities. Muscle imbalance is another important cause. It also occurs due 
to immobilization of the upper limb after fracture. Eg. colleins fracture. There is a 
higher than normal association between frozen shoulder and diabetes mellitus. 
Depalma(1953) considered that bicipital tenosynovitis played an important part. 
 
PATHOLOGY: 
  Dense adhesions are present between the humeral head and the glenoid cavity 
adhesion increase as the disease progresses. The interval between the humeral head 
and the glenoid gets progressively narrowed. Capsular contracture is noticed. The 
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dependent told of the capsule gets obliterated with adhesions. The synovium is 
thickened reddish and eleminatous. 
  It has been found at surgery that a volume of the joint is reduced, and the joint 
capsule is tight and contracted. Appear that the coracohumoral ligament is particularly 
affected. Shortened coracohumoral ligament restricts external rotation and always 
require release during the open release. 
 
CLINICAL FEATURES: 
  Patients complaints pain and stiffness of shoulder. often the pain is severe this 
condition accounts for more cases of shoulder disability than does spraspinatus 
tendinitis. It affects males and female equally over the age of 40 years. 
  In the classic descripton of adhesive capsulitis, there are three clinical phases 
1. Painfull phases: 
  Initially the patient will complain about an aching discomfort about the 
shoulder pain gradually increases. Night pain often awakening him or her from shee is 
a common complaint. 
2. A phase of progressive stiffness: 
  As the pain increases the movements of the shoulder get progressively 
restricted. This leads to stiffness of the shoulder with further restriction of movement 
the stiffness about the shoulder gradually increases thus a vicious cycle tends to occur. 
The movement most affected are external and internal rotation and abduction. There 
is usually no discrepancy between active and passive ranges of motion. 
3. A thawing with gradual return of motion: 
   This usually occurs after 10 to 12 months or even after 3 years. The pain and 
stiffness reduces. Frozen shoulder is usually self-limitting, but symptoms can persists 
for 6 months or more, and it takes many more months for all ranges of movements to 
return to normal. 
 Movements  : 
  Let  the  patient  stand  with    his  upper  limbs  hanging  by  the  side  
of  the  chest   in  anatomical  position  i.e.  shoulder  adducted,   elbow  extended  and  
forearm  supinated.    Elicit  the  movements  (active  and  passive.  If the  active  
movement  is  restricted,   possible  passive  range  of  movement  can  be  tested  by  
holding  the  patient’s  hand by  examiner’s  one  hand,  while  his  90º  flexed  elbow  
is  supported  by  the  examiner’s  other  hand. 
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S.No. Movements Range Prime Muscles Assisted by Root Control 
1. Flexion 
Patient stands with arm hanging by the 
side, elbow extended and forearm 
supinated. Ask him to take hand 
towards the midline 
0°-180° 
Pectoralis major, Pectoralis 
minor, Anterior fibres of 
deltoid, coraco brachialis 
Biceps brachi C5 
2. Extension 
Diametrically opposite to that of 
flexion 
0° -  45° Latissimus dorsi 
Posterior fibers 
of the deltoid, 
Teres major 
C5, C6 
3. Abduction 
Extended elbow moving away from the 
. The glenohumeral and 
scapulothoracic components of 
abduction can be tested as follows  
Stand beind the patient and hold the 
Inferior angle of scapula in between 
thumb and Index finger of one hand. 
While doing abduction, so long as the 
movement is at glenohumeral joint 
scapula will not resist. The moment 
scapulo thoracic gliding starts, 
resistance is flet by the holding hand. 
Note :  The extent of each component  
(Normal 90° +90° 
0° -  180° 
Supraspinaturs, middle fibers 
of deltoid, seratus anterior, 
trapezius, latissimus dorsi.   
(Gliding Mechanism - Turek 
S.L. 1951) 
- 
C5, Accessory 
nerve 
4. 
 
 
 
Adduction 
Diametrically opposite to abduction 180° - 0° 
Pectoralis major, Latissimus 
dorsi, Teres major Gravity C5, 6 
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5. External rotation 
While arm is by the side of the chest 
elbow flexed at 90° and forearm 
supinated move the extended hand 
outwards 
0° - 70° Teres minor, infraspinatus, posterior fibers of deltoid - C5 
6. Internal rotation 
While the position as above, move the 
extened the hand towards the mid body 
plane 
0° - 80° 
Subscapularis, pectoralis 
major, Teres major, 
Latissimus dorsi 
Anterior fibers 
of deltoid C5, 6, 7, 8 
7. Circumduction 
With the upper limb extened at the 
elbow and wrist, complete a circle 
starting from the adduction position of 
the arm 
360° Combination of all the above - C5 & C6 Accessory nerve 
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Measurements  : 
a.  Linear 
b.  Circumferential 
Linear  : 
1.  Apparent  measurements 
2.  True  measurements 
3.  Segmental  measurements  should  also  be  done. 
 
1. Apparent  measurement   : 
It  is  not  of  so  much  value  as  in  the  lower  limbs.    However,  it  can  
give some  idea. 
Method  with  the  affected  upper  limb  in  a  position  as  kept  confortably  
by  the  patient  the  opposite  upper  limb  is  put  parallel  to  it.   Measure  from  the  
tip  of  the  seventh  cervical  spine  to  the  tip of  radial  styloid  on  both  sides  while 
the  trunk  is  alined  to  the  limbs. 
2.True  measurements  prerequisities   : 
   Limbs  must  be  kept  in  identical  position  at  each  joint  i.e.  
shoulder,  elbow  and  wrist.   Palpate  and  mark  the  angle  of  acromion.  (pass  a  
finger  laterally  on  the  spine  of  scapula,  at  the  extreme  outer  end  posteriorly,  
an  angle  is  formed  known  as  the  angle  of  acromion),  lateral  epicondyle  of  the  
humerus  and  tip  of  the  styloid  process  of  radius. 
   Total  linear  measurement  of  the  upper  limbs  is  done  by  
measuring  from  the  angle  of  acromion  to  the  tip  of  radial  styloid  process. 
   Segmental  measurements  are  for  arm  and  forearm  components.   
For  the  arm,  measure  from  acromial  angle  to  the  tip  of  the  lateral  epicondyle  
and  for  the  forearm,  from  the  lateral  epicondylar  tip  to  the  tip  of  the  radial  
styloid  process.  If  the  lateral  epicondylar  tip  is  not  discernible  (e.g. in  
comminuted  fratures,  congential  absence,  iatrogenic)  identical  fixed  bony  points  
can  be  taken  for  comparative  measurement  (e.g.  medial  epicondylar  tips,  radial  
head,  oleocranon  tips). 
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Circumferential  Measurements  : 
   Besides  noting  the  wasting  at  the  mid-arm  level,  or  at  equidistant  
from  the  acromial  angles,  circumferential  measurements  should  also  be  done  
around  the  shoulder  joint  i.e.  across  the  base  of  axilla  to  the  top  of  the  
shoulder.   For  all  practical  purpose,  any  increase  in  this  measurement  indicates  
an  increase  in  the  girth  of  the  shoulder  joint  and  vice  versa. 
   The  anterior  and  posterior  axillary  folds  should  be  measured  and  
compared  with  the  other  side. 
   Method  abduct  the  shoulder  as  far  as  practicable  upto  90 º.   Keep  
the  opposite  shoulder  in  the  same  position.    Axillary  folds  stand   prominent.   
Measure  from  the  junction  of  the  axillary  folds  with  the  arm  to  their  junction  
with  the  trunk. (Both  anterior  and  posterior  folds). 
Local  examination   : 
Prerequisites  : 
 Patient  must  be  examined  standing  on  the  floor  or  sitting  on a  
stool. 
 Neck  to  the  tip  of  fingers  be  exposed  fully  from  all  sides. 
 Opposite  shoulder  must  be  examined  for  comparison. 
 The  limb  should  be  kept  freely  hanging  by the  side  of  chest  in  
anantomical  position  i.e.,  elbow  extended  and  forearm  supinated  
as  far  as  practicable. 
Attitude   : 
   Attitude  of  the  patient  in  relation  to  the  shoulder  is  sometime  
typical.     The  position  of  the  neck,  the  shoulder  point,  the  supported  or  
unsupported  upper  limb  should  be  noted.    Many  a  times  the  attitude  itself  is  
diagnostic,  e.g., patient  with  fracture  clavicle  inclines  his  neck  to  the  affected  
side  and  supports  the  elbow  in  opposite  hand  keeping  the  arm  by  the  side  of  
the  chest,  Patient  with  anterior  dislocation  of  shoulder  loses  the  contour  of  
shoulder,  develops  flattening  of  deltoid  bulge,  drooping  of  axillary  fold  and  
keeps  the  elbow  away  from  the  chest.,    In  luxation  erecta,  the  arm  is  kept  
widely  abducted  and  internally  rotated,  elbow  extended,  forearm  pronated,  wrist  
partially  flexed,  thumb  in  palm  and  fingers  semiflexed  i.e.  position  of  the  
policeman  receiving  tip. 
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  In  Klippel  -  Feil  syndrome  (congential  webbed  neck),  hairline  
lies  almost  on  shoulder  level  with  or  without  high – placed   scapula.    In  
Sprengel’s  shoulder  -   congential  elevation  of  scapula,  upper  border  of  which  
may  lie  well  above  the  shoulder.    In  deltoid  contracture,  there  is  fixed  
abduction  deformity  at  the  shoulder. 
 
Inspection  : 
  Inspect  from  the  front,  side,  back  and  the  top  simultaneously  
comparing  with  the  opposite  side.    Note  the  condition  of  skin,  its  vascularity,  
presence  of  any  swelling,  abnormal  pulsation,  wasting,  fasciculation  etc., 
  From  the  front -  Relation  of  the  two  clavicles  from  the  sterno – 
calvicular  to  acromio – clavicular joint, anterior deltoid bulge, supraclavicular   
fossae,  infraclavicular  fossae  pectoral  bulge,  anterior  axillary  line  and  folds,  
contour  of  the  shoulder  and  approximation  of  the  elbow  to  the  chest. 
  From  the  sides  -  The  deltoid  bulge  and  the  side  of  the  arm. 
  From  the  top – Acromio  -  clavicular  elevation  and  angle  of  
acromion,  the  bulge  of  the  shoulder. 
  From  the  back  -  Right  from  a mid-spinal  line,  medial  border  of  
scapula  and  scapular  prominence,  scapular  (supra  and  infra-spinus)  fossae,  level  
of  inferior  angle  of  scapula,  posterior  deltoid  bulge,  posterior  axillary  line  and  
folds.   Any  abnormality  in  comparison  to  the  other  side  must  be  noted. 
 
Palpation  : 
a. Superficial 
b. Deep  - locate  and  palpate  the  followings,  and  note  any  abnor mally.         
Palpate   : 
  clavicle  from  sternoclavicular  to  acromiclavicular  joint, 
   tip  of  the  coracoid  process, 
   angle  of  acromion, 
   the  body  and  angles  of  scapula, 
   hollowness  of  the  base  of  axilla, 
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   palpate  the  supraclavicular  region  for  pulsation  or  any  other  
abnormality  of  the  subclavian  artery  and  upper  medial  aspet  of  the  arm  
for  the  brachial  artery, 
  hollowness  or  fullness  of  infraclavicular  fossae, 
  palpate  the  different  groups  of  lymph  glands  in  axillary  and  
supraclavicular  regions,  in  acute  traumatic  cases  palpate  for  any   
dislocated  articulating  end  or  displaced bony  fragment,  and  in  late  ones  
for  any  myositis  or  myositis  mass. 
 
Tenderness  of  the  shoulder  joint  is  mainly  elicited  at  two  regions: 
    Just  laternal  to  the  caracoid  priocess  anteriorly,  and  just  below  
and  behind  the  acromial  angle  posteriorly.    In  bicipital  tendinitis,  tenderness  is  
along  the  biceps  tendon  on  the  antero-superior  slop  of  the  shoulder  bulge.   
Tenderness  over  the  region  of  glenoid,  head  of  humerus,  tuberosities  and  upper  
humeral  shaft  should  be  noted  separately. 
  A  cyctic  swelling  around  the  shoulder  should  be  confirmed  by  
the  usual  methods  of  demonstration.    Collection  in  the  shoulder  joint  is  usually  
localized  anteriorly,  posteriorly  or  infero-medially.    However,  when  the  
collection  increases,  cross-fluctuation  (anteroposteriorly)  can  be  demonstrated.   A  
cystic  hygroma,  having  typical  compressibility  and  very  clear  trans illumination,  
may  manifest  anteriorly. 
  In   doubtful  cases  of  fasciculation,  tapping  over  or  squeezing  the  
deltoid  muscles  can  be  useful  in initiating  the  bout. 
  Since  the  muscular  padding  is  very  thick  almost  all  around,  on 
palpation  one  gets  very  little  clue  about  the  fracture  ends  unless  they  are  quite  
obvious.     One  should  not  attempt  to  elicit  crepitus  and  abnormal   mobility.     
Most  of  the  fractures around  the  shoulder  are  generally  impacted  and  require  
hardly  any  interference.   Over enthusiastic  attempts  at  demonstrating  crepitus  
and  abnormal  movements  may  disimpact  the  fractured  ends. 
  If  on  inspection,  the  roundness  of  the  shoulder  is  lost,  search  for  
abnormal  position  of  the  head  of  the  humerus.     In  dislocations  it  usually  lies  
in  the  infraclavicular  fossa  (anterior),  and  rarely  just  posterior inferior  to  the  
acromion  or  its  spious  process  (posterior)  of  the  sublenoid  region  (inferior) .   In  
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fresh  cases  of  dislocations  the  finding  of  depressed  contour  should  be  enough  
to diagnose  it.   Any  attempt  to  move  the  shoulder,  to  note  the  movement  of  
the  head  under  the  palpating  fingers,  will  initiate  endless  pain  and  spasm.    In  
the  paralytic shoulder,  the  delotoid  mass  thins out.  the  head of  the humerus  
stands  prominent  much  below  the  acromial  process,  thereby  having  a  step  in  
between  the  acromion  and  the    head  of  the  humerus  in  which  the  finger  can  
be  well  insinuated.     Atrophy  of  the  deltoid,  abnormal  mobility  of  the  shoulder  
(mainly  passive)  and  the  ‘step  sign’ are  diagnostic  paralytic  subluxation   or  
dislocation. 
 
Special  Tests  : 
Hamilton  Ruler  Test  : 
  In a normal  shoulder,  a  straight  ruler  cannot  touch  the  acromial  process  
and  lateral  epicondyle  of  humerus at  the  same  time  because  of  the  prominence  
of  the  deltoid  bulge,  which  is  supported  the  the  head  of  humerus.    If  the  
support  is  lost,  the  ruler  can  touch  both  the  points  (e.g. dislocation  of  the  
shoulder,  congential  absence  or  iatrogenic  excision  of  the  head  of  humerus;  
complete   paralytic  atrophy  of  the  deltoid,  as  in  polio ,  paralysis;  dissolution  of  
humeral  head  in  septic  arthritis). 
 
Callaway’s   Test  : 
 The  girth from  axillary  base  to  shoulder  top  are  symmetrical  and  same 
on  both  sides.     If  the  head  of  himerus  occupies  an  abnormal  position  e.g.  in  
dislocation,   the girth  increases  on  the  affected  side. 
 
Duga’s  Test  : 
 Normally,  after  full  flexion  at  the  shoulder  the  elbow  can  be  brought  to  
near  aboutl  the  mid  body  plane  and  the  hand  to  the  opposite  shoulder  top.    In  
dislocation  of  the  shoulder  joint,  the  full  flexion  of  the  shoulder  cannot  be  
brought  to  the  mid  body  plane  and  hand  cannot  be  taken  to  the  opposite  
shoulder. 
Bryant’s  Sign  : 
 In   anterior  subcoracoid  dislocation  of  the  shoulder,  the  anterior  axillary  
fold  looks  elongated  and  seems  to  be  at  lower  level. 
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Test  for  integrity  of  the  Brachial  Plexus   : 
 Test  for  the  integrity  of  the  brachial  plexus  is  essential  as  it  may  be  
variably  damaged  in  anterior  dislocation  of  shoulder. 
 Erb’s  palsy  (upper  brachial  palsy) – look  for  the typical  attitude  and  test  
of  the  muscle  supplied  by  C (see  the  chapter  on  peripheral  nerve  injury). 
Test   for  integrity  of  the  Axillary  Nerve  : 
   It  is  manifested  by  loss  of  deltoid  action  i.e.  abduction  of  
shoulder  (though  initiation  is  possible)  and  sensory  loss  over  the  ‘regimental  
badge’  area  at  upper  outer  aspect  of  the  arm. 
 
Radial  Nerve: 
   Manifested   by  wrist  drop. 
 
Test  for  Thoracic  inlet  syndrome  : 
 Thia  syndrome  comprises  the  pathologies  in  which  there  is  compression  
of  the  subclavin  artery  and  /  or  lower  roots  of  the  brachial  plexus  e.g.  
scalenus  anticus syndrome,   costoclavivular  lsyndrome,  subclavian  aneurysm,  
cervical  ribs.   Pancoast  tumor,  exubearnt  callus  in  fracture  clavicle  etc.,   
 
Tests  for  Bicipital  Tenosynovitis   : 
i. Yergason’s  sign  patient  flexes  the  elbow  and  then  supinates  the  
forearm  against  resistance.     The  resulting forceful  contraction   of  
biceps  effects  distal  movement  of  the  tendon  and  causes  pain  in  
the  bicipital  groove.  
 
ii. The elbow  is  flexed  90  º  and  examiner’s  three  fingers  are  firmly  
placed  along  the  antero  superior  slope  of  the  deltoid  bulge  (line  
of  bicipital groove);  ask  the  patient  to  alternately  rotate  the  
shoulder  externally  and  internally  patient  will  complain  of  pain  
when  the  inflamed  tenosynovitis will  pass  under  the  pressing  
fingers. 
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Test  for  complete  Rupture  of  supraspinatus   : 
  It is  difficult  to categorically  distinguish  pure  supraspinatus  and  
other  rotator  cuff  ruptures  from  any  pathology  of  the   subacromial  region.    
However,  in  complete   rupture,  a  gap  may  be  felt  beneath  the  acromion, which  
will be  tender.   Patient  cannot  initiate  active  abduction  at  the  shoulder  (gleno-
humeral  joint),  but  one  the arm  is  passively  abducted  to  about  90 º,  he  can  
sustain  and  further  actively  abduct  the  shoulder  due  to  deltoid  action.   
  Incomplete  rupture  of  the  supraspinatus  and  other  rotator  cuff  
muscles  can  be  diagnosed  by  infiltrating  local  anesthetic  in  the  affected  area,  
which  abolishes the  pain  and  spasm,  allowing  the  patient  to  abduct  the   
shoulder  from  the  very  beginning. 
 
Neer’s  Impingement  Test  : 
  It  is  done  to  differentiate  impingement  syndrome  (mainly  
subacromial  pathology)   from  ‘frozen  shoulder’   arthritis.    Here  the  clinician  
prevents  scapular  rotation  with  one  hand,  while  with  the  other  hand  he  raises  
the  affected  arm  in  forced  forward  flexion  and  abduction,   thus  causing  the  
greater  tuberosity  to  impinge  against  the  acromion.   Pain  is  produced  in  all  the  
above  conditions.    If  the  pain  is  primarily  the  result  of  impingement,  it  can  be  
reduced  or  eliminated  by  injecting  by  injecting  10ml  of  1  lignocaine  beneath  
the  anterior  acromion. 
Apley’s Scratch Test:  
Purpose : 
  Tests for liminations in motions of the upper extremity Each motion is 
performed bilaterally to compare 
Description: 
Action 1:   
  The subject is instructed to touch the opposite shoulder with his/ her hand. 
This motion check Glenohumeral adduction, Internal rotation, horizontal adduction 
and Scapular protraction. 
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Action 2:  
  The subject is instructed to place his/ her arm over head and reach behind the 
neck to touch his/ her upper back. This motion check Glenohumeral abduction, 
external rotation and scapular upward rotation and elevation. 
Action 3:  
  The subject puts his/ her hand on the lower back  and reaches upwards as far 
as possible. this motion checks internal rotation and scapular retraction with 
downward rotation 
 
 
DIFFERENTIAL DIAGNOSIS: 
• Locked posterior and anterior dislocation  
• Subacromial impingement  
• Rotator cuff lesions 
 
Complications    : 
 Later  intensive  physical  therapy  with  pain  mediation  is  given.    The  
complications  of  manipulation  is  humeral  fracture,  dislocation,  rotator  cuff  
lesion  and  biceps  tendon  rupture.   
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   Beacon   Bayley  have  cautioned  this  and  have  suggested   accurate  
positioning  of  the  surgeon’s   hand,  so  that  only  a  short  leverage  is  appliec  to  
the  humerus.   
  Edmondas  and  Taylor  (1982)   have  shown  in their  series  that  
manipulation  with  intraarticular  steroid  and  physical   therapy  produces  good  
results in  case  of  adhesive  capsulitis. 
INVESTIGATIONS   
  Besides  the  routine  X-ray,  haematological  investigations  and  urine  
analysis,  some  special  investigations  may   also  be  required  according  to  
indications. 
 
X-ray : 
  It is  of  great  importance  in  any  shoulder  affection.    It  is  always  useful  
to  take  a  comparative   X-ray  of  the  opposite  shoulder.     The  shoulder  girdle  
must  be  fully  exposed along  with  a  minimum  of  the  upper  one-third  of  the  
arm.   In  suspected  referred  pain  around  the  shoulder,   X-ray  of  cervical  is  
spine  is  necessary. 
 Antero-posterior  X-ray  patient  lies  supine  with  the  arm  adducted.   The  
plate   is  kept  behind  the  shoulder  and  beam  in  focused  from  the front  at  the  
shoulder  level.    With  any suspicion  of  subluxation  /  dislocation  of  the  acromio  
-  clavicular  joint,  antero-posterior  X-ray  should  be  taken,  while  the  patient  
stands,  keeping  his  upper  limbs  hanging  by  the  side  of  his  chest,  with  some  
weight  tied  to  his  hand.   Standing  position   X-ray  should  also  be  taken  in  case  
of  paralyzed  shoulder. 
 Lateral  axillary  (trans  axillary)  view  -  the  shoulder  is  abducted  to  about  
90 º and  the  plate  is  kept  on  the  shoulder  top.    The  X-ray  is  shot  through  the  
base  of  the  axilla. 
 
Special  Antero-posterior  projection  : 
 The  special  X-ray  projection  demonstrates  the  Hill-Sach’s  in  recurrent 
dislocation  of  the  shoulder. 
 While  shoulder  is  abducted  about  30º  and  internally  rotated  about  40º to  
60 º,  the  plate  is  placed  behind  the  shoulder  and  the  beam  is  shot  from  the  
front  at  the  shoulder  level.   In  certain  recurrent  anterior  dislocations,  a  
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radiological  step  can  be  delineated  on  the  postero-supero-lateral  aspect  of  the  
head  of  the  humerus  (Hill-Sach’s  lesion  or  Broca  lesion),  presumably  due  to  
repeated  compression  over  the  head  by  impaction  against  the anterior  marging  
of  the  glenoid,   though  it  may  also  be  congential  defect.   A  similar  defect  may  
be  seen  on  the  antero  medial  sector  of  the  head  in  recurrent  posterior  
dislocation  of  the  shoulder. 
 
ARTHROGRAM: 
  Arthrogram will show lessof the normally loose dependent fold of the joint. 
The dye does not fill in to this dependent told. Also the amount of the contrast 
material that can be injected into the joint is reduced. 
 
ARTHROSCOPY: 
  Arthroscopically, adhesive capsulities can be divided into four stages. 
 
Stage I (pre adhesion stage) 
  This stage mimics impigment syndrome or rotator cuff lesion. Clinically this 
stage shows signs and symptoms of impingement syndrome. There is minimal 
restriction of motion. Arthroscopically, erythematous fibrinous pannus is seen over 
the synovium. 
 
Stage II (acute adhesive synovitis) 
Clinically there is severe less of motion in all planes with pain in all ranges of motion. 
Arthroscopically , the synovium appears red, angry and thickened. It can visualize 
adhesions growing across the dependent told in to the humeral head. There is less of 
normal interval between the humeral head and biceps tendon. 
 
Stage III (maturation of adhesion) 
  This is also called as the stage of pink synovitis. Here the erythematous panner 
over the synovium appears pale. The dependent fold is reduced to half of its normal 
size. Humeral head remains pressed against the glenoid. 
 
Stage IV ( chronic adhesion phase) 
  In this stage, there is no synovitis. The dependent fold is severely lost. Motion 
is at its worst. 
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TREATMENT: 
  Treatment varies according to the stage of the disease. 
 
Painful phase: 
  Anti inflammatory drug are effective and a short course of systemic steroids 
may be needed for patients with severe pain, physiotheraphy is effective during this 
stage 
 
Stiff phase: 
  During this phase, physiotheraphy to improve the range of movement is 
occasionally helpfull by relief is unpredictable. 
 
Recovery phase: 
  Physiotherapy or manipulation under anaesthetic may produce an increase in 
movement arthoscopic surgery to release the capsule has been shown to speed up the 
relieve.                                 
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SHOULDER X-RAY  LEFT  (AP VIEW) 
 
SHOULDER X-RAY  RIGHT (AP VIEW) 
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MATERIALS AND METHODS 
 The clinical study on kumba vatham was carried out in the post graduate 
sirappu maruthuvam department of Government siddha medical college and 
Palayamkottai In these study 40 patients (who are selected by inclusion and exclusion 
criteria) were treated as OP and IP patients. 
 
Selection of the patients: 
Age:  
          30 years to 60 years  
Sex: 
          Male and Female 
 
The history details were taken from the patient about:  
• Occupation. 
• Social economic status. 
• Psychological condition. 
 
INCLUSION CRITERIA : 
• Age : 30-60 years 
• Sex : Both Male and Female 
• Patient having main symptoms of shoulder joint pain radiating towards 
upper arm and forearm, numbness, restricted movement of upper limb, 
loss of abduction and forward flexion followed by stiffness of the 
shoulder joints. 
• Patient willing to sign the informed consent stating that he / she  will 
consciously stick to the treatment during 20 days. 
• Willing for doing laboratory investigations and X-Ray, imaging. 
• Willing to cooperate with the proper clinical examination. 
• Controlled Diabetes mellitus 
• Controlled hypertension 
 
EXCLUSION CRITERIA : 
• Rheumatoid arthritis 
• Ischaemic heart diseases  
• Pregnancy and lactation 
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• Recent shoulder dislocation 
• Recent shoulder fracture 
TESTS AND ASSESMENTS : 
• Clinical assessment  
• Siddha assessment  
• Laboratory Investigations 
• Radiological assessment  
CLINICAL ASSESSMENT : 
• Acute shoulder joint pain  
• Benumbed feeling  
• Wasting in the shoulder region and arms 
• Restricted movement of the upper limbs 
• Loss of abduction 
• Loss of forward flexion 
• Stiffness of the shoulder joint 
• Dizziness 
PAIN ASSESMENT : 
OXFORD SHOULDER SCORE : 
Interpreting the Oxford Shoulder Score 
Score 0 to 19 Indicate sever shoulder arthritis  
Score 20 to 29 Indicate moderate to severe  
Score 30 to 39 Indicate mild to moderate 
Score 40 to 48 Indicate satisfactory joint function 
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SIDDHA ASSESSMENT: 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
• Neerkkuri  
• Neikkuri  
Diagnosis: 
   The diagnosis was made by following Siddha diagnosis methods 
Nilam,Kaalam,Pulanal arithal Poriyal arithal vinaathal Mukkutra Nilaigal Udal 
Thathukal Nilai and Envagai thervugal,and the diagnosis of Kumba vatham were 
obtained which correlated with diagnosis of Peri arthritis by the X-Ray findings. 
 
LABORATORY INVESTIGATIONS: 
Blood: 
• TC 
• DC 
• ESR 
• Hb 
• Blood Sugar 
   Fasting 
  Random  
Post prandial 
• Blood urea 
• Serum Creatinine 
• Serum Cholesterol 
 
Urine: 
 Albumin 
 Sugar 
 Deposits 
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SPECIFIC INVESTIGATIONS: 
RADIOLOGICAL INVESTIGATION: 
 X- Ray:  Shoulder joint AP view and lateral view. 
 ECG in selected cases 
 Arthrogram and MRI in required cases 
 
Treatment 
     On the first day of treatment 15 ml of Vellai ennai was given at morning with 
hot water was given.  
  All the patients were treated with the following medicines. 
1.Santhira pragasa mathirai (Internal) 
 1 tablet(130 mg) with Chukku kudineer  
2. Sembai thylum: 30ml (external) 
 As External application 
    Otradam and fomentation was given as a complementary therapy for Ip 
patients. All the patients were advised to follow dietary regimen (or) pathiyam. 
 The Bio-Chemical analysis was done in the Biochemistry Department and 
Pharmacological analysis was done in the Pharmacological laboratory of KMCH 
college of Pharmacy, Coimbatore. 
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RESULTS AND OBSERVATION 
For the clinical study 40 patients were selected and treated in PG-III Sirappu 
Maruthuvam Department, Government Siddha Medical College and Hospital, 
Palayamkottai.  Results were observed with respect to the following criteria. 
1. Sex distribution 
2. Age distribution 
3. Kaalam 
4. Thinai 
5. Paruva kaalam 
6. Occupation 
7. Socio-Economical status  
8. Disturbance in vadha 
9. Disturbance in pitha 
10. Disturbance in kabha 
11. Envagai Thervugal 
12. Udal Thathukkal 
13. Duration of illness 
14. Mode of onset 
15. Associated disease 
16. Naadi 
17. Nei kuri  
18. Clinical manifestations 
19. Duration of treatment 
20. Assesment  the effect of therapy 
21. Effect of complementry therapy massage 
22. Effect of complementry therapy Ottradam 
23. Effect of therapy trial drug alone 
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1.SEX DISTRIBUTION  
Table 1. Illustrates sex distributions in relative percentage. 
S.no Sex 
No. of cases 
Percentage 
Op Ip 
1. Male 8 5 32.5 
2. Female 15 12 67.5 
3. Total 23 17 100 
 
 
Inference :  
Out of 40 patients, 32.5% were males and 67.5% were females. 
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2. AGE DISTRIBUTION 
Table2. Illustrates the age distribution and its relative percentage 
S.no Age No. of patients Percentage(%) 
1 16 – 20 -  
2 21 – 30 -  
3 31 – 40 12 30 
4 41 – 50 9 22.5 
5 51 - 60 19 47.5 
 Total 40 100 
 
 
Inference 
 Among 40 patients, most of the age group affected were 51-60 (47.5%). 
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3. KAALAM 
Table 3. Illustrates the life span and the relative percentage 
S.no kaalam No. of patients Percentage(%) 
1 Vatha kaalam(1-33yrs) 13 32.5 
2 Pitha kaalam(34-66yrs) 27 67.5 
3 Kaba kaalam(67-100yrs) - - 
 
 
 
Inference :  
Out of 40 patients, 
32.5% of cases were in the vadha kaalam 
67.5% of cases were in the pitha kaalam 
0 % of cases were in the kabha kaalam 
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4. THINAI (THE HABITAT OF THE PATIENTS) 
Table 4. Illustrates the thinai and its percentage 
S.no Thinai or Land No. of patients Percentage(%) 
1 Kurinji - - 
2 Mullai - - 
3 Marutham 36 90 
4 Neithal 4 10 
5 paalai - - 
6 Total 40 100 
 
 
Inference 
Among the 40 patients 90% were from marutham and 10 % cases were 
from Neithal thinai. 
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5. PARUVAKALAM 
Table 5. Illustrate the paruvakalam and its percentage 
S.no Paruvakalam Month No. of patients  Percentage(%) 
1 Kaarkalam Avani-puratasi 
(15 aug – 14 oct) 
6 15 
2 Koothirkaalam Ippasi-karthigai 
(15 oct – 14 dec) 
7 17.5 
3 Munpanikaalam Margazhi-thai 
(15 Dec – 14 feb) 
10 25 
4 Pinpanikaalam Maasi-panguni 
(15 feb – 14 apr) 
5 12.5 
5 Elaveenirkaalam Chitthirai-vaigasi 
(15 apr – 14 jun) 
3 7.5 
6 muthuvenirkaalam Aani-aadi 
(15 jun– 14 aug) 
9 22.5 
 
 
Inference 
  Among 40 cases, 25% of patients were affected in Munpani kaalam 12.5% of 
patients were affected in pinpani kaalam and 22.5% were affected in 
mudhuvenirkaalam patients and 17.5% of patients were affected in Koothir kaalam  
15% were affected in kaarkalam patients and 7.5% patients were affected in Elavenil 
kaalam . 
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6. OCCUPATION  
Table 6. Illustrates the occupation and its percentage 
S.no Occupation No. of patients Percentage(%) 
1 Tailor 5 12.5 
2 Retd govet officer - - 
3 Farmer 13 32.5 
4 House wife 14 35 
5 Driver - - 
6 Manual worker 5 12.5 
7 Hotel 3 7.5 
 
 
 
 
Inference  
Out of 40 cases, in this study the rate of incidence is higher in former 
(32.5%) , house wife (35%) , manual worker (12.5%), Tailors(12.5%),  
hotel worker  (7.5%) 
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7. SOCIO- ECONOMICAL STATUS 
Table 7. Illustrate socio-economical status and its percentage 
S.no Socio - Economical 
status 
No. of patients Percentage(%) 
1 Low class 10 25 
2 Middle class 28 70 
3 High class 2 5 
 
 
 
Inference 
  The above study consisted of  5% of cases from rich class, 70% of cases from 
middle  class and  25%% of low class. 
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8. DISTURBANCE  IN VATHAM 
Table 8. Illutrates the disturbance in vatham and its percentage 
S.no Vatham No. of patients Percentage(%) 
1 Piranan - - 
2 Abanan 18 45 
3 Vudhanan - - 
4 Viyanan 40 100 
5 Samanan 40 100 
6 Naagan - - 
7 Koorman - - 
8 Kirukaran - - 
9 Thevathathan 12 30 
10 Thananjayan - - 
 
 
Inference 
Among the 10 types of vatha, Samanan and viyanan were affected in all 
the cases (100%).  Abanan was noted to be deranged in 45% and 
Devathathan was abnormal in 30%. 
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9. DISTURBANCES IN PITHAM 
Table 9. Illustrates the disturbances in pitham and its percentage 
S.no Pitham No. of patients Percentage(%) 
1 Anarpitham 3 7.5 
2 Ranjagapitham 5 12.5 
3 Sathagapitham 40 100 
4 Aalosagapitham - - 
5 Pirasagapitham - - 
 
 
Inference 
  The five types of pitham were analyzed in all 40 cases, Sathaga pitham was 
altered in all cases (100%) evidenced as difficulty in handling their regular duties 
because of pain in shoulder and radiating pain in upper limb.  Ranjaga pitham was 
affected in12. 5% patients denoting low haemoglobin count. 
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10. DISTURBANCES IN KABAM 
Table 10. Illustrates the disturbances in kabam and its percentage 
S.no kabam No. of patients  Percentage(%) 
1 Avalambagam  - - 
2 Kilethagam  - - 
3 Pothagam  - - 
4 Tharpagam  - - 
5 Santhigam  40 100 
 
 
Inference 
Santhigam was observed to be affected in all the cases.   
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11.DIAGNOSTIC PARAMETERS 
ENVAGAI THERVUGAL 
Table 11. Illuestrate the envagaithervugal and its percentage 
S.no Envagai thervugal No. of patients Percentage(%) 
1 Naa   
2 Niram   
3 Mozhi   
4 Vizhi   
5 Malam 18 45 
6 Moothiram   
7 Naadi(thontha naadi) 40 100 
8 Sparisam   
 
 
 
Inference 
It was learnt during the study that thontha naadi was noted in all 40 cases, 
malam was affected in 45% of cases  
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12. UDAL THATHUKKAL 
Table 12. Illustrates the udal thathukkal and its percentage 
S.no Udal kattukal No. of patients Percentage(%) 
1 saaram 3 7.5 
2 senneer 5 12.5 
3 oon 30 75 
4 kozhuppu 0 0 
5 enbu 35 87.5 
6 Moolai 35 87.5 
7 Sukkilam / 
suronitham 
0 0 
  
 
Inference 
It was diagnosed during the study all the udal kattugal affected in all  
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13. DURATION OF ILLNESS BEFORE STARTING TREATMENT 
Table 13. Illustrates duration of illness before starting treatment and its percentage 
S.no Duration of illness 
(in months) 
No. of patients Percentage(%) 
1 0 - 1 3 7.5 
2 1 - 3 7 17.5 
3 3 - 6 12 30 
4 6 - 12 16 40 
5 12 - 24 2 5 
6 24 - 36 - - 
 
 
Inference 
Most of the patients have the duration of illness is 6 – 12 months. 
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14. MODE OF ONSET 
Table 14. Illustrates the mode of onset and its percentage 
 
S.no 
 
 
Mode of onset 
Out patients In patients 
No.of 
cases 
percentage No.of 
cases 
percentage 
1 Acute 3 13.04 2 11.76 
2 Insidious 20 86.96 15 88.24 
 
 
Inference 
Mode of onset is  insidious  in 88.24% cases 
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15. ASSOCIATED DISEASES 
Table 15. Illustrates the associated diseases and its percentage 
S.no Associated diseases No. of patients Percentage(%) 
1 Deformity - - 
2 Diabetes mellitus 
(type2) 
19 47.5 
3 Cervical spondylosis 5 12.5 
4 D.M & H.T 16 40 
5 Fracture - - 
6 hypertension 16 40 
 
 
 
Inference 
Most of the patients have the  associated features is diabetes mellitus 
47.5% 
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16. NAADI 
Table 16. Illustrates the naadi and its percentage 
S.no parameters No. of patients Percentage(%) 
1 Vatha pitham 27 67.5 
2 Pitha vatham 12 30 
3 Kaba vatham 1 2.5 
 
 
Inference 
It was learnt during the study that thontha naadi was noted in all 40 cases, 
malam was affected in 45% of cases  
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17. NEIKURI REFERENCES 
Table 17. Illustrates the neikuri references and its percentage 
S.no neikuri No. of patients Percentage(%) 
1 Vatham – aravena 
neendathu 
26 65 
2 Pitham – aazhipol 
paraviyathu 
13 32.5 
3 Kabam – 
muththothu nitral 
1 2.5 
 
 
Inference 
  In neikuri analysis 65 % of the cases presented with vatha neer, 32.5% with 
kaba neer, 2.5% with pitha neer 
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18. CLINICAL MANIFESTATIONS 
Table 18. Illustrates the clinical manifestations and its percentage 
 
s.no 
 
 
Sign and symptoms 
Out patients In patients 
No.of 
cases 
percentage No.of 
cases 
percentage 
1 Pain in shoulder joint 23 100 17 100 
2 Tenderness 7 30.43 4 23.5 
3 Restricted movement 23 100 17 100 
4 Radiating pain in the both  
upper limb 
12 52.2 11 64.7 
5 Numbness 9 39.1 6 35.3 
 
 
Inference 
  It was noted that, clinical manifestations like pain in the shonlder, restriction 
of movements and radiation of pain to other parts were remarkably reduced after 
treatment when compared to that of before treatment, Numbness and tenderness 
showed moderate reduction after treatment. 
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19. DURATION OF TREATMENT 
Table 19. Illuestrates the assessment of therapy and its percentage 
S.no Duration of treatment No. of patients Percentage 
1 Below 20 days 10 25 
2 21 – 30 days 5 12.5 
3 31 – 40 days 25 62.5 
4 Above 40 days - - 
 
 
Inference 
Most of the patients treated in 31 – 40  (62.5%) days and give a good 
improvement 
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20. ASSESSMENT OF THE EFFECT OF THERAPY 
Table 20. Illustrates the assessment the of the effect of therapy and its percentage 
S.no Grade No. of 
patients(Ip) 
Percentage No. of 
patients(Op) 
Percentage 
1 Good 12 70.6 21 82.5 
2 Average 4 23.5 2 15 
3 poor 1 5.9 - 2.5 
 
 
 
Inference 
Administration of trial drug along with complementary therapies had a 
good response 82.5% average with 15% and mild with 2.5% 
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Table 21.  Effect of Complementory therapy along with trail drug (Massage)  
S.no Effect of therapy No. Of patients  Percentage(%) 
1 Good 7 70 
2 Moderate effect 2 20 
3 Mild effect 1 10 
 
 
 
Inference 
Administration of trial drug along with complementary therapy (massage) had a 
good response 70% average with 20% and mild with 10% 
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Table 22. Effect of therapy along with trail drug(Ottradm) 
S.no Effect of therapy No. Of patients  Percentage(%) 
1 Marked effect 5 71.4 
2 Moderate effect 2 28.6 
3 Mild effect 0 0 
 
 
 
Inference 
Administration of trial drug along with complementary therapy (Ottradam) had a 
good response 71.4% average with 28.6%.  
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Table 23. Effect of trail drug alone 
S.no Effect of therapy No. Of patients  Percentage(%) 
1 Good 21 91.3 
2 Average 2 8.7 
3 Poor 0 0 
 
 
Inference 
Administration of trial drug alone had a good response 91.3% average with 8.7%.  
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DISCUSSION 
 Kumba vatham is one among the 18 varaity of vatha diseass mentioned in yugi 
vaithiya chinthamani 800, kumbavatham clinical features resembles with periarthritis 
of shoulder in modern medicine. Twenty three op cases and 17 IP cases selected for 
treatment . The main clinical features of kumba vatham is pain in shoulder joint and 
upper limb, stiffness and restricted movement. Siddha method of diagnosis was 
carried out with the help of modern investigation in the diagnosis was carried out with 
the help of modern investigation in the diagnosis was confined and treatment with 
trail medicine is clearly observed. 
 The above said, quote from siddha literature predicts the fact that we should 
chose medicines for diseases and nor diseases for medicine. The trail drug was 
internal Santhira Pragasa Mathiraiand external sembai thylam. 
Incidene with age distribution: 
  The dominant of the disease was found to be higher in the age group of 51 – 
60 years (47.5%).  
Incidence with sex distribution: 
  Among the 40 patient selection the dominant of the disease was found to be 
higher in females(67.5%)  
Incidence with reference to socio economic status: 
  I this clinical study most of the patients belongs to middle socio economic 
status(70%) 
Disturbances in vatha 
 Viyanan and Samanan was affected in all 40 cases (100%) abanan affected in 
18 patients (45%). 
Disturbances in Pitha 
 Sathagapitham was affected in all 40 cases (100%), ranjagam affected in 
12.5% patients and anar pitham 7.5% patients 
Disturbances in Kabha 
 Santhigam was affected in all 40 cases (100%). 
Thinai 
About 90% of patients from maruthanilam and remaining 10% from the neithal 
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Seasonal distribution 
 Most of the patients came during muthuvenir kalam 22.5% and remaining 
patients are came from Munpani kaalam 25% koothir kaalam 17.5%, Pinpani kaalam 
12.5%, Elavenil kaalam7.5%. 
Occupational status 
 The rate of incidence is higher in occupational group which includes home 
maker (35%) and farmer (32.5%), Tailors (12.5%), manual worker (12.5%).  
Homemakers are mostly affected. 
Clinical Manifestations 
 Pain in the shoulder joint  is present in all forty cases (100%), 64.7% of cases 
had radiating pain in upper limbs 100% of cases had restricted movement. Hence 
symptoms associated very well with the disease as proved by the statistical tests. 
Duration of illness 
 Most of the patient with the disease Kumbavatham reflected its symptoms 
over a period of 6 - 12 months which was confirmed during the history taking while 
40% of the patients reported the data. 
Udal Thathukkal 
 In this study the patients was affected by Enbu, moolai 87.5%, Saaram 
affected in 7.5%, Oon affected in 7.5% cases. 
Envagai Envagai Thervugal 
 In this study thontha naadi was noted in all 40 cases,  malam was affected in 
45% of cases  
 In naadi 67.5% were vatha pitha naadi, 30% were pitha vatha naadi and 
remaining were kabavathanaadi. 
Investigation 
 Laboratory investigations were done in all the cases before and after treatment.  
The significant variation occur in parameters like ESR and HB, while other 
parameters have insignificant variation. 
Pre clinical studies 
 The biochemical study of santhira pragasa mathirai had revealed the presence 
of sulphate, chloride, calcium, phosphate, unsaturated compound and amino acid 
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Pharmacological studies 
 The pharmacological studies done in Santhira Pragasa Mathirairevealed the 
presence of actions such as 
 
 Anti – inflammatory action 
 Analgesic activity. 
Toxicity studies 
 Acute and subacute toxicity studies in rats for “Santhira Pragasa Mathirai” 
revealed that it has no toxicity effect. 
Treatment 
 The treatment was aimed to retain the deranged thoshas and providing relief 
from symptoms.  Before treatment the patients were advised to take vellai ennai 15ml 
with hot water during morning for first day of treatment. 
 From the second day onwards Internal medicine Santhira Pragasa Mathirai 
130mgs two times a day after food and sembai thylam  is given as external. 
 At the time of treatment the patients were advised to follow pathiyam and 
specifically advised to avoid foods which increase vadha. 
 Along with the course of treatment the complementary therapies like 
Thokkanam and Ottradam therapy were given additionally to some of the patients. 
 The outcome of this study is mainly assessed by reduction in pain in shoulder 
joint.  Increased range of reduction of restricted movements and improvement in 
quality of life oxford pain assessment scale was also used to detect proper outcome.  
No adverse effect was noted for both internal and external medicine along with the 
course of treatment. 
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SUMMARY 
 40 cases with Kumbavatham were diagnosed clinically based on yugi 800 and 
admitted in the inpatient ward and outpatient ward of post graduate department of 
sirappu maruthuvam, Government Siddha Medical College Hospital, palayamkottai 
and treated by the trial medicines. 
 Laboratory diagnosis of Kumbavatham was done by siddha diagnostic 
principles and endorsed by modern methods of investigations. 
 The various siddha aspects of examination of the disease were carried out and 
were recorded in the proforma. 
 The trial medicine chosen for both internal and external treatments were 
Santhira Pragasa Mathirai130 mgs/days in BD sembai thylam (External) for 
forty days as per the severity of the diseases, 
 Before starting the treatment careful detailed history was carried out and 
recorded for the forty selected cases. 
 During the period of treatment all the patients were put under pathiyam (A 
specific dietary regimen) 
 A periodical laboratory investigation was made for all the cases along with the 
radiological investigations. 
 The observations made during the clinical study shows that the main internal 
drug for Santhira Pragasa Mathirai is clinically effective. 
 Though there was appreciable clinical improvement, there were not much 
remarkable radiographic changes. 
 The action of external application  sembai thylam with Thokkanam and 
Ottradam is also quite remarkable. 
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CONCLUSION 
 All 40 patients (23 OPD and 17 IP – 10 patients with trial medicines and 
Massage, 7 with ottradam along with trial medicines). were treated for this 
dissertation work with Santhira Pragasa Mathirai 130 mgs/day in BD and sembai 
thylam (externally) 
 In the pre clinical study pharmacological evaluation of the trial drug shows. 
- Significant analgesic effect 
- Significant Anti inflammatory effect (Internal medicine) 
In the preclinical study toxicity study of “chanthra prakasa mathirai” shows that 
the trial drug had no acute toxicity. 
The overall effect of the clinical trial drug are  
 good effect  - 82.5% 
 Average effect           -  15% 
 poor effect  - 2.5% 
 This result of the clinical trial illustrates the marked effect of the drugs and 
complementary therapy. 
 The trial drug Santhira Pragasa Mathirai and external sembai thylam is 
effective.  No adverse effects were noticed during the treatment period.  So the trial 
medicine is safe and easily preparable medicine.  
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LIST OF OUT PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT GIVEN  
1.SANTHIRA PRAGASA  MATHIRAI – INTERNAL    2. SEMBAI THYLAM – EXTERNAL 
S.no Op.no Name Age/sex Occupation Date of 
admission 
Date of 
discharge 
Total no. of 
days treated 
Results 
 1 64725 Thirumalai kumar 41/M Manual worker 29.07.17 06.09.17 40 days Good 
2 65233 Balasubramaniyan 34/M Manual worker 31.07.17 04.09.17 36 days Good 
3 65635 Subramaniyan 60/M Hotel worker 02.08.17 10.09.17 40 days Good 
4 65831 Arumugam 52/M Farmer 02.08.17 10.09.17 40 days Good 
5 66491 Prakash kumar 42/M Farmer 04.08.17 12.09.17 40 days Good 
6 67590 najima 38/F House wife 08.08.17 16.09.17 40 days Good 
7 68051 Fathima 44/F Tailor 09.08.17 14.09.17 37 days Average 
8 68986 Seethayammal 60/F Manaual worker 12.08.17 20.09.17 40 days Good 
9 71494 Marybakiyam 58/F House wife 21.08.17 29.09.17 40 days Good 
10 109709 Jeya 33/F Tailor 12.12.17 20.01.18 40 days Good 
11 110284 Seyathu alima 40/F Tailor 13.12.17 19.01.18 38 days Good 
12 112014 Mariyammal 45/F Manaual worker 19.12.17 27.01.18 40 days Good 
13 113841 Vanitha 40/F House wife 25.12.17 02.02.18 40 days Good 
14 6473 Pattammmal 58/F House wife 19.01.18 27.02.18 40 days Good 
15 6474 Muthulaxmi 38/F Tailor 19.01.18 25.02.18 38 days Average 
16 6475 Bathma 42/F House wife 19.01.18 27.02.18 40 days Good 
17 7765 Latchmi 44/F House wife 23.01.18 03.03.18 40 days Good 
18 13668 Ramamoorthi 60/M Farmer 09.02.18 19.03.18 39 days Good 
19 16535 Mariyammal 52/F Farmer 17.02.18 29.03.18 40 days Good 
20 17482 Rajamani 48/M Farmer 20.02.18 27.03.18 36 days Good 
21 30642 Seyath alif fathima 34/F House wife 02.04.18 11.05.18 40 days Good 
22 35323 Kaleeswari 38/F Farmer 18.04.18 27.05.18 40 days Good 
23 35324 rajeswaran 52/M Farmer 18.04.18 27.05.18 40 days Good 
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LIST OF IN PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT GIVEN  
1.SANTHIRA PRAGASA  MATHIRAI – INTERNAL    2. SEMBAI THYLAM – EXTERNAL 
S.no Ip.no Name Age/sex Occupation Date of 
admission 
Date of 
discharge 
Total no. of 
days treated 
Results 
1 3226 Bagavathi 60/f Farmer 10.12.17 29.12.17 20 days Good 
2 3237 Mary 60/f Farmer 11.12.17 02.01.18 23 days Good 
3 3259 Madasamy 58/m Farmer 13.12.17 06.01.18 26 days Good 
4 3283 Ramaiah 60/m Farmer 14.12.17 06.01.18 24 days Average 
5 3303 Rani 49/f Tailor 18.12.17 06.01.18 20 days Good 
6 03 Lakshmi 60/f Housewife  01.01.18 21.01.18 21 days Good 
7 13 Latha 36/f Housewife 02.01.18 21.01.18 20 days Good 
8 185 RamaLakshmi 35/f Housewife 25.01.18 23.02.18 30 days Good 
9 324 saraswathi 60/f Housewife 08.02.18 23.02.18 16 days Average 
10 370 arumugam 55/f Farmer 12.02.18 05.03.18 22 days Good 
11 572 issakiyammal 35/f Farmer 02.03.18 17.03.18 16 days Average 
12 576 Nagammal 60/f Housewife 03.03.18 17.03.18 15 days Average 
13 900 Maharaja 48/m Manual worker 04.04.18 23.04.18 20 days Good 
14 923 Meenatchi 55/f Housewife 05.04.18 24.04.18 20 days Good 
15 933 Pandaram 60/m Hotel worker 06.04.18 15.04.18 10 days Poor 
16 934 Kaliyappan 52/m Hotel worker 06.04.18 15.05.18 40 days Good 
17 1142 Devi 37/f Housewife 26.04.18 04.06.18 40 Days Good 
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INVESTICATION OF RANGE OF MOTION IN OUTPATIENTS 
 
S.No OP. No FLEXON 
(IN DEGREES) 
EXTENSION ABDUCTION (IN 
DEGREES) 
AST-I.R AST-E.R RESULT 
BT AT BT AT BT AT BT AT BT AT  
1 64725 70 180 25 30 60 180 +ve N +ve N Good 
2 65233 60 160 20 25 55 150 +ve N +ve N Good 
3 65635 120 180 20 30 65 160 +ve N +ve N Good 
4 65831 60 180 15 30 75 180 +ve N +ve N Good 
5 66491 150 180 20 35 45 180 +ve N +ve N Good 
6 67590 90 180 15 25 70 180 +ve N +ve N Good 
7 68051 80 150 10 20 50 145 +ve N +ve N Average 
8 68986 110 160 25 35 60 180 +ve N +ve N Good 
9 71494 60 140 10 25 65 160 +ve N +ve N Good 
10 109709 150 180 25 40 110 170 +ve N +ve N Good 
11 110284 150 140 25 30 70 140 +ve N +ve N Good 
12 112014 90 180 20 40 75 180 +ve N +ve N Good 
13 113841 70 160 25 35 110 170 +ve N +ve N Good 
14 6473 100 180 20 35 120 180 +ve N +ve N Good 
15 6474 40 110 10 15 60 90 +ve +ve +ve N Average 
16 6475 120 180 15 45 120 180 +ve N +ve N Good 
17 7765 80 180 20 35 90 180 +ve N +ve N Good 
18 13668 45 110 10 20 35 100 +ve +ve +ve N Good 
19 16535 100 180 25 45 100 175 +ve N +ve N Good 
20 17482 80 180 20 45 100 170 +ve N +ve N Good 
BT-Before Treatment AT – After Treatment AST- Apley’s Scratch Test  ER – External Rotation IR-Internal Rotation
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INVESTICATION OF RANGE OF MOTION IN IN-PATIENTS 
 
S.No IP. No FLEXON 
(IN DEGREES) 
EXTENSION ABDUCTION (IN 
DEGREES) 
AST-I.R AST-E.R RESULT 
BT AT BT AT BT AT BT AT BT AT  
1 30642 60 180 30 45 75 160 +ve N +ve N Good 
2 35323 50 165 25 35 80 170 +ve N +ve N Good 
3 35324 70 170 15 40 110 180 +ve N +ve N Good 
4 3226 80 110 25 30 75 145 +ve N +ve N Good 
5 3237 55 145 20 25 70 155 +ve N +ve N Good 
6 3259 60 180 15 35 45 160 +ve N +ve N Good 
7 3283 70 165 15 25   +ve N +ve N Average 
8 3303 100 180 20 45 70 180 +ve N +ve N Good 
9 3 60 155 20 25 60 135 +ve N +ve N Good 
10 13 45 180 15 40 75 165 +ve N +ve N Good 
11 185 70 180 25 45 50 160 +ve N +ve N Good 
12 324 40 125 10 15 45 100 +ve N +ve N Average 
13 370 55 135 10 25 50 145 +ve N +ve N Good 
14 572 65 140 15 30 55 135 +ve N +ve N Average 
15 576 45 110 10 20 45 110 +ve N +ve N Average 
16 900 70 180 10 40 100 180 +ve N +ve N Good 
17 923 60 165 15 35 90 175 +ve N +ve N Good 
18 933 70 110 15 20 45 100 +ve +ve +ve +ve Poor 
19 934 90 170 30 45 110 180 +ve N +ve N Good 
20 1142 100 180 20 45 60 180 +ve N +ve N Good 
BT-Before Treatment AT – After Treatment AST- Apley’s Scratch Test  ER – External Rotation IR-Internal Rotation  
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BLOOD INVESTICATION BEFORE AND AFTER TREATMENT – OP PATIENT 
S.NO OP.NO TC DC HB ESR BLOOD SUGAR BLOOD  SERUM 
        N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
 1 64725 7400 7500 72 72 25 26 3 2 0 0 0 0 11.0 12 12 12 92 100 136 141 29 28 190 192 
2 65233 7900 8400 64 62 34 36 2 2 0 0 0 0 12.4 13 11 10 148 151 193 194 32 32 158 157 
3 65635 7500 7900 65 66 33 34 2 2 0 0 0 0 13.7 13.9 16 13 115 115 164 170 25 24 210 211 
4 65831 9200 9300 67 67 30 31 3 2 0 0 0 0 8.7 9.6 18 14 92 109 124 125 27 26 160 165 
5 66491 8800 8900 62 63 34 34 4 3 0 0 0 0 14 14.5 9 10 84 106 137 134 40 35 154 155 
6 67590 8200 8300 60 61 38 37 2 2 0 0 0 0 13.5 13.6 17 17 172 170 240 247 35 34 170 179 
7 68051 7500 7800 67 67 32 31 1 2 0 0 0 0 10.4 11.3 13 10 155 151 270 265 31 32 112 110 
8 68986 8200 8900 66 66 32 33 2 1 0 0 0 0 9.5 9.7 10 8 96 97 126 120 34 33 212 200 
9 71494 7800 7600 62 64 33 34 5 2 0 0 0 0 11.7 13.6 26 20 170 167 290 277 28 32 160 169 
10 109709 8500 8200 67 63 27 35 6 2 0 0 0 0 10.6 11.5 18 15 84 101 222 121 39 35 216 201 
11 110284 7600 8300 59 62 31 33 10 5 0 0 0 0 9.2 9.5 20 25 153 150 175 186 37 36 190 195 
12 112014 7000 7700 64 64 28 30 8 6 0 0 0 0 13.1 12.9 22 26 114 116 190 180 30 33 226 227 
13 113841 8800 8900 64 64 29 33 7 3 0 0 0 0 12.8 13.1 19 15 142 147 210 205 33 29 190 195 
14 6473 7600 8300 65 67 28 29 7 4 0 0 0 0 10.6 11.7 8 12 103 117 145 151 29 25 195 190 
15 6474 7500 8300 70 70 27 26 3 4 0 0 0 0 10.5 10.9 24 19 86 97 121 131 28 28 218 217 
16 6475 9200 9200 67 66 28 31 5 3 0 0 0 0 11.2 12.8 21 13 135 145 164 162 26 27 160 163 
17 7765 7600 8100 69 64 28 33 3 3 0 0 0 0 11.6 13.4 16 12 98 112 120 122 35 34 196 172 
18 13668 8800 9100 59 66 32 30 9 4 0 0 0 0 8.4 8.3 22 13 93 99 114 120 37 37 182 180 
19 16535 8000 7900 69 68 26 30 5 2 0 0 0 0 12.2 14.5 21 15 135 135 175 170 39 35 175 177 
20 17482 6900 7100 66 67 31 31 3 2 0 0 0 0 11.4 13.6 12 11 145 142 255 250 37 33 187 189 
21 30642 7200 7900 58 63 37 34 5 3 0 0 0 0 12.5 12.7 14 15 105 117 155 155 35 37 169 167 
22 35323 8800 9100 63 69 36 30 1 1 0 0 0 0 11.5 12.5 18 13 120 118 147 149 38 35 192 189 
23 35324 6800 7100 67 68 30 30 3 2 0 0 0 0 13.5 14.7 13 14 80 85 162 171 25 27 214 211 
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BLOOD INVESTICATION BEFORE AND AFTER TREATMENT – IP PATIENT 
S.NO IP.NO 
DC HB ESR BLOOD SUGAR BLOOD SERUM 
Tc N L E M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT  
1 3226 9200 9100 61 63 35 34 4 3 0 0 14.5 14.5 15 13 155 161 220 221 35 36 200 201  
2 3237 8700 8300 70 69 28 29 2 2 0 0 10.5 11.2 17 16 85 89 142 145 40 39 175 179  
3 3259 8300 8400 59 61 31 35 10 4 0 0 9.5 9.5 9 11 103 103 151 149 27 25 163 161  
4 3283 7900 7800 69 67 27 29 4 4 0 0 15.5 15.7 11 13 135 137 257 253 32 31 179 173  
5 3303 8100 7900 63 64 30 33 7 3 0 0 13.5 14 13 12 110 111 157 156 34 35 185 182  
6 03 7700 7700 67 63 29 35 4 2 0 0 10.5 11.5 19 17 145 149 260 265 33 33 189 184  
7 13 6900 7100 62 63 29 30 9 7 0 0 14.2 14.5 21 20 115 117 147 149 28 29 193 191  
8 185 9200 9300 66 65 30 31 4 4 0 0 15.2 14.5 24 21 85 93 152 157 31 30 200 203  
9 324 8600 8700 67 64 31 33 2 3 0 0 10.5 11.5 19 16 138 135 230 229 32 31 219 214  
10 370 9300 9100 63 67 32 30 5 3 0 0 13.5 12.5 23 21 90 89 143 141 39 37 167 169  
11 572 9700 9600 65 62 29 31 6 4 0 0 11.5 12.7 27 25 141 139 243 247 36 39 173 171  
12 576 7300 7100 61 64 33 32 6 4 0 0 13.5 14.5 22 20 151 149 281 289 33 32 164 162  
13 900 6900 7000 58 65 39 32 3 3 0 0 16.5 16.7 19 17 147 146 262 254 36 32 186 184  
14 923 7100 7300 63 62 31 34 6 4 0 0 13.5 13.8 9 8 128 131 231 227 39 40 197 193  
15 933 6300 6900 64 63 33 34 3 3 0 0 11.9 12 11 9 136 136 222 226 28 27 164 166  
16 934 6700 6800 67 67 29 31 4 2 0 0 13.5 14 8 8 89 90 160 157 31 33 179 173  
17 1142 9100 9300 69 68 25 29 6 3 0 0 12.5 12.8 7 11 93 91 165 159 29 31 205 201  
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URINE EXAMINATION BEFORE & AFTER TREATMENT – OUT  PATIENTS 
S.no 
 
OP.NO Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 64725 NIL NIL NAD NIL NIL NAD 
2 65233 NIL + NAD NIL NIL
 
NAD 
3 65635 NIL NIL NAD NIL NIL NAD 
4 65831 NIL NIL NAD NIL NIL NAD 
5 66491 Trace NIL 1-3 pus cells NIL NIL NAD 
6 67590 NIL ++ NAD NIL ++ NAD 
7 68051 NIL ++ NAD NIL ++ NAD 
8 68986 NIL NIL NAD NIL NIL NAD 
9 71494 NIL ++ NAD NIL ++ NAD 
10 109709 Trace NIL 1-2 pus cells NIL NIL NAD 
11 110284 NIL + NAD NIL + NAD 
12 112014 Trace NIL 1 – 2 pus cells NIL NIL NAD 
13 113841 NIL + NAD NIL + NAD 
14 6473 NIL NIL NAD NIL NIL NAD 
15 6474 NIL NIL NAD NIL NIL NAD 
16 6475 NIL + NAD NIL + NAD 
17 7765 NIL NIL NAD NIL NIL NAD 
18 13668 NIL NIL NAD NIL NIL NAD 
19 16535 NIL + NAD NIL + NAD 
20 17482 NIL ++ NAD NIL ++ NAD 
21 30642 NIL NIL NAD NIL NIL NAD 
22 35323 Trace NIL 1 – 3 pus cells NIL NIL NAD 
23 35324 NIL NIL NAD NIL NIL NAD 
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URINE EXAMINATION BEFORE & AFTER TREATMENT – IN PATIENTS 
S.no 
 
Ip.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 3226 Nil ++ NAD Nil ++ NAD 
2 3237 Trace Nil 1 -2 pus cells Nil Nil NAD 
3 3259 Nil Nil NAD Nil ++ NAD 
4 3283 Nil ++ NAD Nil Nil NAD 
5 3303 Nil Nil NAD Nil Nil NAD 
6 03 Nil ++ NAD Nil ++ NAD 
7 13 Nil Nil NAD Nil Nil NAD 
8 185 Nil Nil NAD Nil Nil NAD 
9 324 Nil + NAD Nil + NAD 
10 370 Nil Nil NAD Nil Nil NAD 
11 572 Nil ++ NAD Nil ++ NAD 
12 576 Nil + NAD Nil + NAD 
13 900 Nil ++ NAD Nil ++ NAD 
14 923 Nil + NAD Nil + NAD 
15 933 Nil + NAD Nil + NAD 
16 934 Trace Nil 1 – 3 puscells Nil Nil NAD 
17 1142 Nil Nil NAD Nil Nil NAD 
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INGREDIENTS OF  SANTHIRA PRAGASA MATHIRAI (INTERNAL) 
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INGREDIENTS OF  SEMBAI THYLAM  (EXTERNAL) 
  
gVR<osl<jh< << << < !
 
fz<oz{<o{b<< < << < << < <!
!
Cg<gilz<zq< << << < !
!
htqr<G!sil<hqvi{q< << << < !
!
out<Tt<tq< << << < !
!
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SANTHIRA PRAGASA MATHIRAI 
 
SEMBAI THYLAM 
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ANNEXURE  - I 
PROPERTIES OF TRIAL DRUGS 
 
INTERNAL MEDICINE 
1. our<givl<< << << <!
Chemical Name : BORAX 
OuXohbi<gt<!! ;! ohiiqgivl<?!givl<?!dVg<gqel<?!dVg<G!lqk<kqve<?!!
mr<g{l<?!K~lk<jkbmg<gq!
Sju! ! ! ;! -eqh<Hme<!%cb!Kui<h<Hs<Sju!djmbK/!
uQiqbl<!! ! ;! ouh<hl<!
osb<jg! ! ;! GtqIs<sqB{<mig<gq?!sqXfQIohVg<gq?!VKd{<mig<gq?!!
hqvsugiiq?!gx<gjvs<sq!
ohiKG{l<<<<!
! “osixqHjmob{<!Ge<lxjl!Osiiq!bisl<!
! hxqgqvg{q!gz<Z~{l<!he<Oeib<!.!ofxqjbk<!
! kmr<g{r<g!hr<gqVlq!si<h<huqmR<!sf<fq!
! bqmr<g{r<g!zg<gqx<Ohi!ol{<” 
!
our<givk<kqeiz<?! kujts<osixq?! Hjm?! w{<ujgg<! Ge<ll<?! kqeU?!
-vk<k&zl<?! ypg<Gg<gqvg{q?!n^<liq?! hr<Guikl<?! hz<Ofib<!&k<kqvgqiqs<svr<gt<!
ghikqg<gl<?!HP?!hil<H!Lkzqbjugtiz<!d{<miGl<!fR<S?!sf<fqhikl<!Lkzqb!
Ofib<gt<!fQr<Gl</!
3/!lqtG!
Botanical Name : PIPERNIGRUM 
Family   : Piperaceae 
OuXohbi<gt<!! ;!! gzqje?! gtq?! gibl<?! Ogitgl<?! kqvr<gz<?! lqiqbz<?!
sVlhf<kl<?!!
ut<tqsl<?!lisl<?!GXlqtG?!ljzbitq!
Sju! ! ! ;! jgh<H?!giIh<H!
ke<jl! ! ;! ouh<hl<!
hqiqU! ! ! ;! giIh<H!
uti<-bz<H! ! ;! ogic!
osb<jg! ! ;! gixZ{<mig<gq?!ngm<Muib<ugx<xq?!Ljxouh<hgx<xq?!!
kch<H{<mig<gq?! ouh<hL{<mig<gq?! uiklmg<gq?!
uQg<gr<gjvs<sq/!
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ohiKG{l<<<<!
! “ntjuBxig<givl<!njmf<kqVg<Gl<!uik!
! uqjtjuobz<!zilXg<Gl<!olb<Ob!–!lqtgqe<gib<!
! g{<mui<g<Gl<!-e<hlil<!giiqjgOb"!sQp<&zr<!
! ogi{<mui<g<G!fe<lVf<kir<!%X/” 
. ngk<kqbi<!G{uigml<< < << < << < <!
-keiz<! Gtqi<Svl<?! hi{<M?! Ogijp?! gpqs<sz<?! Ge<ll<?! uiB?!
Sjubqe<jl?! ouxq?! &zl<?! se<eqbisl<?! nh^<livl<?! hqvOlgl<?! -Vlz<?!
hg<guikl<?! Gb<bOvigl<?! Osi{qkuikl<?! gtOfib<?! osuquzq?! -vk<kGe<ll<?!
osiqbijl?!gilijz!-ju!OhiGl</!
!
Chemical constituents 
Alkaloids  - Piperine (or) Pipirine,  Piperidine, Balsamic volatile essential 
oil chavicin, starch, lignin, gum, fat. 
 
3. fihq!
Botanical Name : ACONTIUM NAPELLUS 
Family   : Ranunculaceae 
OuXohbi<gt<!! ;!! fihqfihl<?!usfihq?!uk<sfihq?!uqml<?!lVkl</!
Sju! ! ! ;! jgh<H 
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! giIh<H 
uti<-bz<H! ! ;! osc 
osb<jg! ! ;! uqbi<juh<ohVg<gq?!sqXfQih<ohVg<gq?!Ljxouh<hgx<xq?!!
Kbvmg<gq?kihglx<xq?!ouh<hmg<gq?!&Is<jsB{<mig<gq?!!
kiKouh<hgx<xq 
ohiKG{l<<<<!
 “uikuzq!lf<klxz<!lixig<!ghh<hq{qgt<!
! YKGm<M!Ge<lf<Okt<!YMr<gi{<!.!gikzi<kl<!
! Hk<kqObi!miVbqVl<!H,Ul<!ujtGpOz"!
! Sk<kqosb<k!fiuqbqe<Ohi<!osiz<” 
. ngk<kqbi<!G{uigml<!
-K! gQp<uig<gMh<H?! osiqbijl?! Jbh<hq{qgt<?! ohVOfib<?! Ge<ll<?!
Okt<fR<S!Ngqbux<jx!Ohig<Gl</!
Chemical constituents :  
Aconitine, Picroaconine, aconine, benzyl aconine, homonapelline. 
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4. -R<sq<<< !
Botanical Name : ZINGIBER OFFICINALE 
Family   : Zingiberaceae 
OuXohbi<gt<!! ;!! nz<zl<?!NIk<kvgl<?!Nk<kqvgl<?!-zig<ogim<jm?!!
fXlXh<Hlkqz</!
Sju! ! ! ;! giIh<H 
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! giIh<H 
uti<-bz<H! ! ;! kjvgQp<k{<M 
osb<jg! ! ;! ngm<Muib<ugx<xq?!hsQk<kQk<K~{<c?!dlqp<fQIh<ohVg<gq?!!
osiqh<H{<mig<gq?!ouh<hL{<mig<gq?!kch<H{<mig<gq 
ohiKG{l<<<<! !
! “-R<sqg<!gqpr<Gg<!gqVlz<Jbl<!yg<gitl<!
! uR<sqg<GR<!se<eqSvl<!ue<Ohkq!–!uqR<Sgqe<x!
! $jzbXl<!uikl<Ohif<!K~{<mik!kQhelil<!
! OujzBXr<!g{<{ib<!.!uqtl<H!
! -R<sqbqeiz<! -Vlz<?! =jt?! out<Otig<gitl<?! npz<Gx<xl<?! utq$jz?!
Lg<Gx<x!Ofib<gt<?!Ogijpg<%m<ml<?!osiqbig<gpqs<sz<!-juOhil</!hsqB{<miGl</!
!
Chemical constituents 
 Aromatic volatile oil, camphene, Phellandrone, Zingiberine, cineol and 
borneol, K-oxalate. 
 
EXTERNAL MEDICINE 
2/ gVR<osl<jh< << << < !
Botanical Name : SESBANIA AEGYPTICA 
Family   : Fabaceae  
Sju! ! ! ;! jgh<H?!Kui<h<H 
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! giIh<H 
osb<jg! ! ;!! ouh<hL{<mig<gq?!VKU{<mig<gq?!Kui<h<hq?!!
Hpg<ogiz<zq?!sqXfQIohVg<gq?!uQg<gr<gjvs<sq 
! !
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ohiKG{l<<<<!
! “uqh<HVkqh<!H{<{iXl<!uQXgvh<!hiEl<Ohif<!
! kh<hilz<!Olgf<!k{qBr<gi{<!.!ouh<hiI!
! ghOvig!OlGR<!gVR<osl<jh!obie<Xg<!
! gqhli!LjzliOk"!w{<”!
gVR<osl<jh! -jzbiz<?! out<jt?! H{<?! gm<c?! gvh<hie<?! Jbl<?!
kQg<Gx<xr<gt<!Ngqb!-jugt<!OhiGl</!
!
Chemical constituents 
 Seeds contains: fat - 4.8 PC 
 Albumin oils  - 33.7 PC 
 Carbohydrate  - 18.2 PC 
 Cellulose  - 28.3 PC 
 Ash   - 4.2 PC 
 
2. out<Tt<tq< << << < !
Botanical Name : ALLIUM SATIVUM 
Family   : Liliaceae 
OuXohbi<gt<!! ;!! out<jtH,{<M?!-zSel<?!H,{<M?!gibl<!
Sju! ! ! ;! giIh<H 
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! H,{<M 
uti<-bz<H! ! ;! dvlig<gq?!dmx<Oxx<xq?!ouh<hL{<mig<gq!
!
ohiKG{l<<<<!
 se<eqobiM!uikf<!kjzOfiU!kit<uzq!
! le<equV!fQIg<Ogiju!ue<sQkl<!.!ne<eOl"!
! dt<Tt<tq!g{<hib<!djt&z!OvigLl<!Ohil<!
! out<Tt<tq!ke<eiz<!ouV{<M!
sqxqb!gm<cgt<?!osuqM?!fim<hm<m!-Vlz<?!-jvh<H?!ubqx<Xh<HP?!Lh<hq{q?!
utqOfib<gt<?!Jbk<kjzuzq?!uib<Ofib<?!fQOvx<xl<?!sQkg<gpqs<sz<?!&zl<!kQVl</!
!
Chemical constituents 
 Diallyl disulfide 
 Diallyl trisulfide 
 Allicin 
 Vinyldithins 
 Ajoene 
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4/!fz<oz{<o{b<< < << < << < <!
Botanical Name : Sesamum Indicum 
Family   : Pedaliaceae 
OuXohbi<gt<!! ;!! kqzl<?!wt<ofb<!
Sju! ! ! ;! -eqh<H!
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! -eqh<H!
 
ohiKG{l<<<<!
! Hk<kqfbeg<Gtqi<s<sq!H,iqh<H!olb<h<HtgR<!
! sk<Kur<!gf<kq!keqbqtjl!–!olk<kU{<mir<!
! g{<O{ib<!osuqOfib<!ghizupz<!gisOfib<!
! H{<O{ib<<Ohi!ol{<o{b<bix<!Ohix<Xl</!
Hk<kqg<Gk<! oktqU?! uqpqgTg<Gg<! Gtqi<s<sq?! dmz<H,iqh<H?! dmz<ue<jl!
Ngqbux<jxk<! kVuOkiM?! g{<O{ib<?! giKOfib<?! kjzg<ogikqh<H?! osixq?!
sqvr<G?!H{<!LkzqbjugjtBl<!Ohig<Gl</!!!
 
Chemical constituents 
 Palmitic acid 
 Stearic acid 
 Archidic acid 
 Linoleic acid 
 Oleic acid 
5/!htqr<G!sil<hqvi{< << << < q!
Botanical Name : STYRAX BENZOIN 
Family   : Styraceae 
OuXohbi<gt<!! ;!! oh{<!GjlR<sie<?!K~hl<?!lzig<gis<!sil<hqvi{q!
Sju! ! ! ;! giIh<H 
ke<jl! ! ;! ouh<hl< 
hqiqU! ! ! ;! giIh<H 
uti<-bz<H! ! ;! osc 
osb<jg! ! ;! ouh<hL{<mig<gq?!Ogijpbgx<xq?!kch<H{<mig<gq?!!
sqXfQIh<ohVg<gq!
! !
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ohiKG{l<<<<!
! “uiksQ!kr<g{<O{ib<!lixik<!kjzuzqBl<!
! YkLX!hQesLl<!ym<Mr<gi{<!.!H,kzk<kqz<!
! Oul<hqKkie<!we<e!lqGgsh<jh!uib<g<gtqg<Gl<! !
sil<hqvi{q!we<El<!svg<G” 
-keiz<! utq?! JbOfib<gt<?! g{<O{ib<?! fQr<gik<kjzOfib<?! fQIh<hQesl<!
uqzGl</!
Chemical constituents 
 Benzoic acid 
 Cinnamic acid 
 Vanillin 
 Volatile oil 
 
6/Cg<gilz<zq< << << < !
Botanical Name : Gardenia Gummifera 
Family   : Rubiaceae 
Part used ! ;!! Resin 
 
Chemical constituents 
 It contains 89.9% resins,  
 0.1% volatile oils 
 Besides these it contains certain 
 Alkaloids and minerals 
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ANNEXURES -II 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
BIO-CHEMICAL ANALYSIS OF SANTHIRA PRAGASA MATHIRAI (IN 
POWDER FORM) 
Preparation of the extract:   
  5gms of the drug was weighed accurately and placed in a 250ml clean beaker.  
Then 50ml of distilled water is added and dissolved well.  Then it is boiled well for 
about 10 minutes.  It is cooled and filtered in a 100ml volumetric flask and then it is 
made to 100ml with distilled water.  This fluid is taken for analysis. 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  
TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution 
No white precipitate 
is formed 
Absence of 
calcium 
2. 
TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
A white precipitate is 
formed 
Indicates the 
presence of 
sulphate 
3.  
TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 
A white precipitate is 
formed 
Indicates the 
presence of 
chloride 
4. 
TEST FOR CARBONATE 
The substance is treated with 
concentrated HCL. 
No Brisk 
effervescence is 
formed 
Absence of 
carbonate 
5. 
 
TEST FOR STARCH 
The extract is added with weak iodine 
solution 
No Blue colour is 
formed 
Absence of 
starch 
6.  
TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour is 
formed 
Absence of ferric 
iron. 
7. 
TEST OF FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thio cyanide 
No Blood red colour 
is formed 
Absence of 
ferrous iron. 
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solution. 
8.  
TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
Molybdate and concentrated nitric acid 
Yellow precipitate is 
formed 
Indicates  the 
presence of 
phosphate 
9.  
TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent 
No Yellow 
precipitate is formed 
Absence of 
Albumin. 
10.  
TEST FOR TANNIC ACID 
The extract is treated with ferric chloride. 
No Blue black 
precipitate is formed 
Absence of 
tannic acid. 
11.  
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It gets decolourised. 
 
Indicates the 
presence of 
unsaturated 
compound. 
12.  
TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 mts and add 8-10 drops of the extract 
and again boil it for 2 minutes. 
No colour change 
occurs 
Absence of 
reducing sugar. 
13.  
TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried it well. 
Violet colour is 
formed. 
Indicates the 
presence of 
Amino acid. 
14. 
TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc. 
 
Inference: 
  The given sample of “SANTHIRA PRAGASA MATHIRAI” contains  
Sulphate, Chloride,  Phosphate, Unsaturated compound, Reducing sugar, Amino acid. 
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PHARMACOLOGICAL ANALYSIS 
EFFECT OF SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM ON 
ACETIC ACID INDUCED WRITHING IN MICE1 
1. Kaneria MS, Naik SR, Kohli RK. Anti-inflammatory,antiarthritic and 
analgesic activity of a herbal formulation. Indian J.Experimental Biol. 2007; 
45: 279. 
       Acetic acid induced writhing method was adopted for evaluation of analgesic 
activity. Writhing is defined as a stretch, tension to one side, extension of hind legs, 
contraction of the abdomen so that the abdomen of mice touches the floor, turning of 
trunk (twist). Any writhing is considered as a positive response. 
 
MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. 
All the animals were obtained from Animal house of the KMCH College of 
Pharmacy, Coimbatore. The animals were housed comfortably in a group of six in a 
single clean plastic cage with a metal frame lid on its top. They were housed under 
standard environmental conditions of temperature (24±1°C) and relative humidity of 
30-70 %. A 12:12 h light dark cycle was followed. All animals had free access to 
water and standard pelletized laboratory animal diet ad libitum. All the experimental 
procedures and protocols used in this study were reviewed and approved via the 
Approval No. ----------------------------- by the Institutional Animal Ethical Committee 
(IAEC) of KMCH College of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA 
Dated 21st August 2002 constituted in accordance with the guidelines of the CPCSEA, 
Government of India. 
 
DRUGS: 
         Acetic acid (Sigma Chemical Co. Bangalore, India) and Indomethacin were 
purchased from (Ranbaxy, India). All drugs were dissolved in saline. The different 
doses of SANTHIRA PRAGASA MATHIRAI were prepared CHUKKU 
KASAYAM.The control group received vehicle as control. All drugs were prepared 
just before use. 
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 PREPARATION OF ACETIC ACID: 
         A solution of acetic acid (1% v/v) in distilled water was prepared. 
 
CONVERSION FORMULA: 
Human dose is 130 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 30 gm of Mice 
130 mg x 2(a) x 0.018 (b) = 2.34 (c) /30 gm of Mice 
2.34/1000x30 = 0.070 mg /kg 
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
 
1 Vehicle Control -- 1 ml 
 
2 Therapeutic Dose 0.070 mg /kg 
 
1 ml 
3 Middle  Dose 0.351mg/kg 1 ml 
 
4 High Dose 1.755mg/kg 1 ml 
 
EXPERIMENTAL PROCEUDRE: 
        GROUP 1 – CONTROL (IP injection of 0.1 ml 1% acetic acid) 
       GROUP 2 -- IP injection of 0.1 ml 1% acetic acid + Indomethacin (5mg/kg, i.p) 
       GROUP 3 -- 0.1 ml 1% acetic acid (ip) + SANTHIRA PRAGASA MATHIRAI 
WITH CHUKKU KASAYAM  0.070 mg /kg (po)                        
                                      
       GROUP 4 -- 0.1 ml 1% acetic acid (ip) + SANTHIRA PRAGASA MATHIRAI 
WITH CHUKKU KASAYAM  0.351mg/kg (Po) 
 
      GROUP 5 -- 0.1 ml 1% acetic acid (ip) + SANTHIRA PRAGASA MATHIRAI 
WITH CHUKKU KASAYAM  1.755mg/kg (po) 
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 PROCEDURE: 
            Wister albino mice of either sex were divided into five different groups each 
containing  Six animals, the animals were marked individually. Food was withdrawn 
12 hours prior to drug administration till completion of experiment. The animals were 
weighed and numbered appropriately. The test and standard drugs were given orally. 
After 60 minutes writhing was induced by intra-peritoneal injection of 1% acetic acid 
in volume of 0.1 ml/10g body weight. The writhing episodes were recorded for 30 
minutes; stretching movements consisting of arching of the back, elongation of body 
and extension of hind limbs were counted. 
  Anti-nociceptive  activity was expressed as the percentage inhibition of 
abdominal constrictions using the ratio:  
             (Control mean – Treated mean) × 100/Control mean 
EFFECT OF SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAM ON ACETIC ACID INDUCED WRITHING IN MICE1 
GROUP No of Writhing (30min) Inhibition (%) 
CONTROL 45.33±4.807 --- 
Indomethacin (5mg/kg, i.p) 22.67±1.764** 49.98 % 
S M 0.028mg/kg(po) 59.67±2.728* 31.63 % 
S M 0.014mg/kg(po) 37.67±2.963ns 16.85 % 
S M 0.28mg/kg(po) 32.67±3.333ns 
 
27.92 % 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAMON HOT PLATE METHOD IN MICE1 
1. Turner RA. Screening methods in pharmacology. In: Turner, R., Hebborn, P. 
(eds.). Academic press, New York. 1965; 100.  
 
            The paws of mice and rats are very sensitive to heat at temperatures which are 
not damaging the skin. The responses are jumping, withdrawal of the paws and 
licking of the paws. 
 
 MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. 
All the animals were obtained from Animal house of the KMCH College of 
Pharmacy, Coimbatore. The animals were housed comfortably in a group of six in a 
single clean plastic cage with a metal frame lid on its top. They were housed under 
standard environmental conditions of temperature (24±1°C) and relative humidity of 
30-70 %. A 12:12 h light dark cycle was followed. All animals had free access to 
water and standard pelletized laboratory animal diet ad libitum. All the experimental 
procedures and protocols used in this study were reviewed and approved via the 
Approval No. ----------------------------- by the Institutional Animal Ethical Committee 
(IAEC) of KMCH College of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA 
Dated 21st August 2002 constituted in accordance with the guidelines of the CPCSEA, 
Government of India. 
      The hot plate, which is commercially available, consists of a electrically heated 
surface. The temperature is controlled for 55° to 56 °C. This can be a copper plate or a 
heated glass surface. The animals are placed on the hot plate and the time until either 
licking or jumping occurs is recorded by a stop-watch. 
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EXPERIMENTAL PROCEUDRE: 
 
       GROUP 1 – CONTROL  
       GROUP 2 – Pentazocine (10mg/kg, I.P) 
       GROUP 3 -- SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM   
                                   0.54 mg /kg(po)           
              
       GROUP 4 – SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM   
                                    2.7mg/kg(po) 
 
      GROUP 5 -- SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM   
                                    13.5mg/kg(po) 
 
PROCEUDRE: 
  Mice were screened by placing them on a hot plate maintained at 55±1ºC and 
recording the reaction time in seconds for forepaw licking or jumping. Only mice 
which reacted within 15sec and which did not show large variation when tested on 
four separate occasions, each 15min apart, were taken for the test. The time for 
forepaw licking or jumping on the heated plate of the analgesiometer maintains at 
55ºC was taken as the reaction time. Prior to treatment, the reaction time of each 
mouse (licking of the forepaws or jumping response) was done at 0- and 10-min 
interval. The average of the two readings was obtained as the initial reaction time 
(Tb). The reaction time (Ta) following the administration of the ---------------, 
Pentazocine and distilled water was measured at 0.5, 1, 2, and 3h after latency period 
of 30min. 
 
The following calculation was:  
 
          Percentage analgesic activity = Ta-Tb/Tb × 100 
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EFFECT OF SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAMBY HOT PLATE METHOD IN MICE:- 
 
GROUP 
 
Reaction time in seconds at time (minutes) (mean ± sem) (mean ± sem) 
 
O mints 60 mints 90 mints 120 mints 180 mints 
 
CONTROL 
 
3.297±0.1584 3.187±0.1683 3.79±0.3027 3.663±0.1641 3.29±0.06028 
 
STANDARD 
 
4.26±0.03215 5.57±0.421* 7.36±0.2691*** 6.85±0.2836** 6.063±0.1419** 
S M + LOW 
DOSE 
3.993±0.4619 6.613±0.07623*** 7.767±0.3184*** 7.107±0.1272*** 6.663±0.178*** 
S M + 
MIDDLE 
DOSE 
4.263±0.3283 7.16±0.3523** 7.89±0.3557*** 7.027±0.3555*** 6.217±0.1725** 
S M + HIGH 
DOSE 
 
4.01±0.125 6.473±0.2972** 8.02±0.1159 6.913±0.2885* 6.22±0.4917** 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ***P< 0.001, **P < 0.01,*P < 0.05 
calculated by comparing treated group with CONTROL group. 
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EFFECT OF SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAM ON CARRAGEENAN-INDUCED LOCALISED 
INFLAMMATORY PAIN IN RATS 
SUMMARY 
  The study plan was developed based on the guidelines of Vogel1 and also it 
has reference to Chao Ma and Jun-Ming Zhang2 and Walker et al. 3, Winter CA, 
Risley EA, Nuss GW. Carrageenin induced edema in hind paw of the rat as an assay 
for anti-inflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544–7. 
OBJECTIVE 
  To study the anti-inflammatory effect of SANTHIRA PRAGASA 
MATHIRAI were prepared WITH CHUKKU KASAYAM in the rat model of 
Carrageenan-induced localized inflammation.  
Methods: 
Test System 
Species : Rat   
Strain : Albino Wister 
Age : 6-8 weeks at the time of dosing 
Total no. of Rats : 24 
Sex : Male 
Weight                   :    150 gm 
 
 The animals were housed in polypropylene cages with stainless steel top grills 
having facilities for holding pellet food and drinking water in bottle with stainless 
steel sipper tube. Each cage contained 6 rats. All rats had free access to potable water 
and standard pelleted laboratory animal diet ad libitum. Paddy husk was used as 
bedding material. The animals were divided into 5 groups (6 rats/group). Localized 
inflammatory pain was induced in all groups of animals by intraplantar injection of 
carrageenan (50 µl of 3% suspension).  
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 One day before the experiment, three basal readings of hind paw in each rat 
were recorded. Group 1 received vehicle orally, Group 2 received a standard drug 
Diclofenac sodium (10 mg/kg i.p), whereas groups 3,4and 5 received SANTHIRA 
PRAGASA MATHIRAI. The doses of SANTHIRA PRAGASA MATHIRAI were 
prepared WITH CHUKKU KASAYAM, whereas Diclofenac sodium was dissolved 
in normal saline. After 30 min, the rats were challenged with subcutaneous injection 
of 0.1 ml of 1% w/v solution of carrageenan into the sub plantar region of left paw. 
The paw was marked with ink at the level of lateral malleolus and immersed in 
mercury up to the mark. The paw volume was measured at 0, 1, 2, 3, 4, 5 and 6th hr 
after carrageenin injection using Digital Plethysmometer. The difference between 
initial and subsequent reading gave the actual edema volume.  
 
CONVERSION FORMULA: 
Human dose is 130 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
130 mg x 2(a) x 0.018 (b) = 2.34 (c) /150 gm of Rat 
2.34/1000x150 = 0.351 mg /kg 
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of 
administration 
 
1 Vehicle Control CHUKKU KASAYAM 
1 ml 
 
2 Therapeutic Dose 
0.351 mg /kg 
 
1 ml 
3 Middle  Dose 1.755mg/kg 1 ml 
 
4 High Dose 8.775mg/kg 1 ml 
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EXPERIMENTAL DESIGN: 
Group-I:   Served as a negative control (0.1ml of 1% carrageenin) 
Group-II: Served as standard received Diclofenac sodium (10mg/kg, i.p) + 
                  (0.1ml of 1% carrageenin) 
Group-III: Received SANTHIRA PRAGASA MATHIRAI were prepared with 
CHUKKU KASAYAM 
        (0.351 mg /kg) + (0.1ml of 1% carrageenin) 
Group IV: Received SANTHIRA PRAGASA MATHIRAI were prepared with 
CHUKKU KASAYAM 
                   (1.755mg/kg) + (0.1ml of 1% carrageenin) 
Group V: Received SANTHIRA PRAGASA MATHIRAI were prepared with 
CHUKKU KASAYAM 
                   (8.775mg/kg) + (0.1ml of 1% carrageenin) 
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TABLE: EFFECT OF SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAM ON Carrageenin -INDUCED PAW EDEMA IN RATS (BODY 
WEIGHT in gms) 
 
Group Control carrageenan + Standard 
carrageenan + 
LD 
carrageenan 
+ M D 
carrageenan 
+ H D 
 
INITIAL 
BODY 
WEIGHT 
155.3±4.807 
 
170±1.155 
 
168±1.155 
 
162±7.211 
 
152±2.309 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated 
by one way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated 
by comparing treated group with control group. 
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EFFECT OF SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAM ON Carrageenin -INDUCED PAW EDEMA IN RATS 
 
 Values are expressed as the mean ± S.D. Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s. ns- not significant **P< 0.05 calculated 
by comparing treated group with control group. 
      
 
   
 
      
 
 
 
 
 
 
 
Group 
Mean paw 
volume 
before 
carrageen
an 
injection 
Paw Volume after induction with carrageenin 
Increase in paw volume (ml) after carrageenan injection (mean 
± SEM)/Percent 
inhibition of edema 
0 min 30 min 1h 2h 3h 4h 5h 6h 
 
Control 
 
4.15± 
0.2211 
 
7.383± 
0.2176 
 
7.353± 
0.0864
7 
 
8.537
± 
0.122 
 
8.333
± 
0.118
9 
 
7.87± 
0.1124 
 
8.203± 
0.4072 
 
7.923± 
0.3217 
 
Standard 
 
4.19± 
0.1739 
 
7.007±0 
.1444 
 
7.773± 
0.2764 
 
7.923
± 
0.297
3 
 
8.057
± 
0.260
3 
 
7.907± 
0.0536
4 
 
6.183± 
0.0636 
 
5.81± 
0.3308 
carrageen
an + LD 
 
3.55± 
0.2994 6.867±0.23
38 
 
 
7.51± 
0.1097 
8.007
± 
.1981 
 
8.073
± 
0.173
7 
 
 
7.58± 
0.3014 
 
6.76± 
0.5107 
 
6.14± 
0.4158 
carrageen
an + M D 
 
4.303±0 
.1302 
 
7.117±0.12
41 
 
7.71±0 
.02309 
 
7.677
± 
0.131
7 
 
8.137
± 
0.147
1 
 
7.787± 
0.0120
2 
 
6.36± 
0.1286 
 
5.667± 
0.0664
2 
carrageen
an + H D 
 
4.293± 
0.2959 
 
7.367± 
0.2896 
 
7.587± 
0.1622 
 
7.803
± 
0.496
5 
 
7.82± 
0.322
3 
 
7.2± 
0.1644 
 
6.97± 
0.0750
6 
 
6.21± 
0.2857 
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TABLE: EFFECT OF SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM ON 
Carrageenin -INDUCED PAW EDEMA IN RATS  
 
           
                ONLY CARRAGEENIN                                   CARRAGEENIN+ STD                 
          
              CARRAGEENIN+ L.D                                            CARRAGEENIN+ M.D 
 
CARRAGEENIN+ H D 
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ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF SANTHIRA PRAGASA MATHIRAI WITH 
CHUKKU KASAYAM 
 
Table 1. Test substance details 
Name of the test substance SANTHIRA PRAGASA MATHIRAI  
Colour of the test substance BROWN 
Nature of the test substance Powder 
 
Table 2. Experimental protocol 
Name of the study Acute toxicity 
Guideline followed OECD 423 method-acute toxic class 
method 
Animals Healthy young adult female wister rats, 
nulliparous, non-pregnant 
Body weight 150-200 g 
Sex  female 
Administration of dose and volume 2000 mg/kg in 200g body weight, single 
dose in 1 ml 
Number of groups and animals 
5 groups and 3 animals in each group 
100mg,250mg,500mg,1000mgand 
2000mg/kg 
Route of administration Oral Cavage (po) 
Vehicle CHUKKU KASAYAM 
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Table3. Housing and feeding conditions 
Room temperature 22°C  ±  3°C 
Humidity 40-60% 
Light 12 h : 12h (light : dark cycle) 
Feed 
Standard laboratory animal food pellets 
with water ad libitum 
 
Table 4. Study period and observation parameters 
Initial once observation First 30 minutes and periodically 24 h 
Special attention First 1-4 h after drug administration 
Long term observation Upto 14 days 
Direct observation parameters 
Tremors, convulsions, salivation, 
diarrhea, lethargy, sleep and coma. 
Additional observation parameters 
Skin and fur, eyes and mucous 
membrane, respiratory, circulatory, 
autonomic and central nervous systems, 
somato motor activity and behavior 
pattern etc. 
  
  The time of death, if any, is recorded. (Complete observations: annexure I). 
After administration of the drug, food is withheld for a further 1-2 hours. 
 
Study procedure 
  Acute oral toxicity was performed as per organization for economic co-
operation for development (OECD) guideline 423 method. The SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAM was administered in a single dose by 
tuberculin syringe. Animals are fasted 3 h prior to dosing (food was withheld for 3 h 
but not water). Following the period of fasting animals was weighed and test 
substance was administered orally at a dose of 100mg,250mg,500mg,1000mgand 
2000mg/kg. After the SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM 
administration, food was withheld 2 h in mice. Animals are observed individually 
after at least once during the first 30 minutes, periodically during the first 24 hrs, with 
special attention given during the first 4 hrs, and daily thereafter, for a total of 14 
days.  
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REPORT 
Toxicological evaluation of SANTHIRA PRAGASA MATHIRAI WITH 
CHUKKU KASAYAM 
Table:5 Effect of SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAM on acute toxicity test in female rats. 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM to Female 
Wister rats did not induce drug-related toxicity and mortality in the animals up to 
2000mg/kg in 200g female Wister rats. So No-Observed-Adverse-Effect- Level 
S.N 
 
 
Response 
Head Body Tail 
Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal Normal 
2 Grooming Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal Normal 
5 Pain response Normal Normal Normal Normal Normal Normal 
6 Tremors Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal Normal 
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflux Present Present Present Present Present Present 
12 Writhing Absent Absent Absent Absent Absent Absent 
13 Pupils Normal Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal Normal 
15 Salivation Normal Normal Normal Normal Normal Normal 
16 Skin colour Normal Normal Normal Normal Normal Normal 
17 Lacrimation Normal Normal Normal Normal Normal Normal 
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(NOAEL) of SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM 
is 2000 mg/kg equal to human dose 
DISCUSSION 
SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM was 
administered single time at the doses of 100mg, 250mg, 500mg, 1000mg and 
2000mg/kg to female Wister rats and observed for consecutive 14 days after 
administration. Doses were selected based on the pilot study and literature review. All 
animals were observed daily once for any abnormal clinical signs. Weekly body 
weight and food consumption were recorded. No mortality was observed during the 
entire period of the study. Data obtained in this study indicated no significance 
physical and behavioral signs of any toxicity due to administration of SANTHIRA 
PRAGASA MATHIRAI WITH CHUKKU KASAYAM at the doses of 100 mg, 
250mg ,500mg, 1000mg and 2000mg/kg to female Wister rats  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
observed. Handheld activities like Reactivity, Handling, Palpebral closure, 
Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominal tone, Limb tone 
were observed. Functional and behavioral examination was normal in all treated 
groups. Food consumption of all treated animals was found normal as compared to 
normal group. 
 
                               SUMMARY & CONCLUSION: 
Summary: 
The present study was conducted to know single dose toxicity of SANTHIRA 
PRAGASA MATHIRAI WITH CHUKKU KASAYAM on female Wister rats. The 
study was conducted using 15 female Wister rats. The female animals were selected 
for study of 8- 12 weeks old with weight range of within ± 20 % of mean body weight 
at the time of randomization. The groups were numbered as group I, II, III, IV and V 
and dose with 100mg, 250mg, 500mg, 1000mg and 2000mg/kg of SANTHIRA 
PRAGASA MATHIRAI WITH CHUKKU KASAYAM. The drug was 
129 
 
administered by oral route single time and observed for 14 days. Daily the animals 
were observed for clinical signs and mortality.  
There were no physical and behavioral changes observed in Female Wister 
rats during 14 days. Mortality was not observed in any treatment groups. 
Conclusion: 
The study shows that SANTHIRA PRAGASA MATHIRAI WITH 
CHUKKU KASAYAM did not produce any toxic effect at dose of 100mg, 250mg, 
500mg, 1000mg and 2000mg/kg to rats. So No-Observed-Adverse-Effect-Level 
(NOAEL) of SANTHIRA PRAGASA MATHIRAI WITH CHUKKU KASAYAM 
is 2000 mg/kg. 
7.0 ABBREVIATIONS 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o  peros 
ML  Milliliter 
%   percentage 
R&D   Research and Development 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments 
on Animals 
 
 
8.0 REFERENCES: 
 
1. OECD. Guideline for Testing of Chemicals 423, Acute oral toxicity (acute 
toxic class method). December 2001. 
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SUB-ACUTE TOXICITY STUDY IN WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF SANTHIRA PRAGASA MATHIRAI WITH 
CHUKKU KASAYAM 
      Objective 
 The objective of this study is to evaluate the toxic effects, if any, as a result of 
the repeated once daily oral administration of SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAM to Wister Albino rats for a 
minimum period of 28 consecutive days. This study will provide information on 
any major toxic effects, target organs and a rationale for concluding the No-
Observed-Adverse-Effect-Level (NOAEL) and/or No Observed Effect Level 
(NOEL) / LOEL (Low Observed Effect Level) and risk assessment in humans. 
1. Test Guidelines  
This study plan is prepared as per the following guidelines: 
Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
OECD – 407 – Repeated dose 28-day Oral Toxicity Study in Rodents, Adopted 3 
October, 2008. 
1.1. Test System Details 
Species : Rat 
Strain  : Wister Albino  
Source    : Sree Venkateshwara Enterprises Pvt Ltd, Bangalore  
Age : 6-8 weeks  
Sex : Male / Female (nulliparous and non-pregnant) 
Body weight   : 160.0to 180.0 g 
1.2.  Acclimatization 
Animals will be allowed to acclimatize to the experimental room conditions 
for five days prior to the commencement of dosing. During the acclimatization 
period, the animals will be observed daily for any apparent adverse clinical 
signs. Prior to assignment to the study and commencement of treatment, a 
detailed physical health examination will be performed on all animals by a 
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veterinarian and animals with any evidence of ill health or poor physical 
condition will not selected for the study. 
1.3. Randomization and Grouping 
On the starting day of dosing, the animals will be weighed and health 
examination will be performed by veterinarian. Animals will be randomly 
allocated to different groups according to their body weight by using MS-
Excel sheet as described in the randomization SOP. Animals will be divided 
into four groups (vehicle control, low, intermediate, and high dose). At the 
initiation of the treatment, the body weight variation between the groups did 
not exceed ±20% of the mean weight of each sex. 
1.4. Animal Identification 
In each cage, animals will be identified with numbers by marking at the base 
of the ear. The cages will be identified with an attached colored cage label 
showing study number, study code, group number, sex, dose, strain, species, 
cage number, route of administration and animal number. 
2. Animal Husbandry 
2.1. Animal Welfare and approval 
The study was approved by the IAEC (SLS) and Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA registration 
number: Abc14).Their recommendations regarding animal care and handling 
will be followed. 
2.2. Environmental Conditions 
The temperature of the experimental room will be maintained at 22±30C and 
the relative humidity between 30-70 %. The photoperiod will be 12 hours light 
and 12 hours dark cycles  
2.3. Housing Conditions 
Two animals will be housed in autoclaved polypropylene rat cages (Size in 
mm=L x W x H: 430 x 290 x 160) using paddy husk as the bedding material. 
Each cage will be fitted with a top grill having provision for keeping rodent 
pellet feed and an autoclaved polypropylene water bottle with stainless steel 
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drinking nozzle. Cages will be placed on 3-tier racks and cage rotation will be 
performed every week. Cages will be changed at least twice a week. The cages 
and water bottles will be cleaned and autoclave sterilized. 
2.4. Sanitation 
Each day, the floor of the animal room will be swept and mopped. Cages and 
bedding material will be changed once in three days and water bottles will be 
changed daily. All the experimental procedures will be done in a clean 
environment. 
2.5. Feed 
The experimental animals will be provided with irradiated rodent pellet feed 
ad libitum supplied from Sai feeds Pvt ltd, Chennai . Feed will be withheld for 
four hours prior to blood collection and necropsy. 
2.6. Drinking Water 
Animals will be provided with filtered drinking water ad libitum  passed 
through water filter system (Aquaguard™) in autoclaved polypropylene 
bottles. Water bottles will be changed daily. Microbial analysis of water will 
be carried out once monthly and the report is maintained in the study file. 
3. Personnel Safety 
All personnel handling animals undergo regular medical examination. Protective 
clothing like apron, face mask, head cap, and gloves will be used to maintain 
hygienic conditions. 
4. Materials and Methods  
4.1. Preparation of Dose formulation 
The dose formulation will be prepared under aseptic conditions as per SLS, 
SOP.  
4.2. Route of Administration and Justification 
Administration will be by oral gavage, as it is one of the possible routes of 
exposure. 
4.3. Frequency and Duration of Administration  
Once daily for 28 consecutive days 
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4.4. Dosing Procedure 
The test item will be administered in once daily by oral gavage using a 
suitable intubation cannula fitted with a graduated syringe. The scheme of 
dosing and sacrifice time points are presented in the below below Table. 
4.5. Experimental Procedures 
All experimental procedures will be performed in accordance with the Study 
plan and Standard Operating Procedures (SOPs) of SLS. 
CONVERSION FORMULA: 
Human dose is 130 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
130 mg x 2(a) x 0.018 (b) = 2.34 (c) /150 gm of Rat 
2.34/1000x150 = 0.351 mg /kg 
Experimental Doses Calculated as per the standard procedures are 
S.No Groups Dose /kg, weight 
 
Volume of 
administration 
 
1 Vehicle Control CHUKKU KASAYAM 1 ml 
2 Therapeutic Dose 
0.351 mg /kg 1 ml 
3 Middle  Dose 1.755mg/kg 1 ml 
4 High Dose 8.775mg/kg 1 ml 
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1.1.1 Experimental Design 
 
Observations 
  Animals will be observed daily throughout the treatment period at regular 
intervals. During the treatment period, animals will be observed twice daily for any 
clinical signs of toxicity, morbidity and mortality. All the surviving animals will be 
sacrificed at the end of scheduled period and subjected to gross necropsy and 
histopathological evaluations. 
Clinical Signs 
  All the animals will be subjected to cage-side (home-cage) observations twice 
a day for any clinical signs of toxicity, preferably at the same time each day and 
considering the peak period of anticipated effect. In addition to home cage 
observations, a detailed clinical examination will be performed once prior to dosing 
and weekly thereafter during treatment period.  
  
Group 
No. Group 
Dose                          
(mg/kg  
b.wt /day) 
No. of Animals 
Male Female 
G1 Vehicle control CHUKKU KASAYAM 5 5 
G2 
Low dose of   SANTHIRA 
PRAGASA MATHIRAI WITH 
CHUKKU KASAYAM 
0.351 mg /kg 5 5 
G3 
Intermediate dose SANTHIRA 
PRAGASA MATHIRAI WITH 
CHUKKU KASAYAM  
1.755mg/kg 5 5 
G4 
High dose  SANTHIRA 
PRAGASA MATHIRAI WITH 
CHUKKU KASAYAM  
8.775mg/kg 5 5 
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Morbidity/ Mortality 
  All animals will be examined twice a day for mortality and signs of morbidity.  
Body Weights 
  Body weights will be recorded at the beginning of acclimatization, before 
randomization, there after at weekly intervals and at the time of necropsy. 
Feed Consumption 
  Feed consumption will be calculated on a weekly basis throughout the study 
period. 
Hematology and Clinical Biochemistry  
  Hematology and clinical biochemistry tests will be performed with terminally 
collected blood samples on day-29 from all animals. Animals will be deprived of feed 
overnight and blood samples will be collected by tapping the ear for visibility of the 
vein site and inserted the needle into the marginal ear vein and collected the blood 
into micro centrifuge tube. Approximately 0.5 ml of blood will be collected in vials 
containing 1% EDTA (20µl) as an anticoagulant for hematological analysis. 
  Approximately 2 ml blood will be collected from each animal in micro 
centrifuge tubes containing 15µl of heparin (19 units) and the plasma will be 
separated by centrifugation at 4000 rpm for ten minutes at 4oC. The plasma will be 
stored at -20 oC ± 2 and used for all clinical chemistry analysis. 
Hematology 
  Erythrocyte count (RBC), Total Leucocyte count (WBC), Hemoglobin (Hb), 
Hematocrit (HCT), Mean Corpuscular Volume (MCV), Mean Corpuscular 
Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC) and 
Platelet (PLTC). 
Clinical Biochemistry  
  Glucose, Alanine Aminotransferase (ALT), Aspartate Aminotransferase 
(AST), Alkaline phosphatase (ALP), Total protein, Albumin, Creatinine, Urea, 
Cholesterol, Triglycerides, Sodium, Potassium, Calcium, and  Chloride. 
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Pathology 
  All animals will be euthanized by CO2 asphyxiation and subjected to necropsy 
under the supervision of the veterinary pathologist. Different tissues/organs of 
thoracic, abdominal and cranial cavities will be examined for any gross pathological 
changes. Tissues from vehicle control and high dose groups will be subjected to 
detailed histopathological analysis (Ovaries/ testes,  kidneys, liver, lungs). The organs 
will be fixed using Bouin’s (reproductive organs) and 10% neutral buffered formalin 
(kidneys, liver, spleen, lungs).Processing of tissue will be done by spin tissue 
processer, embedding of the tissue by tissue embedder. The tissues will be initially 
trimmed to 10-20µ thickness and later 3-6µ to obtain thinner tissue sections by using 
rotary microtome. Haematoxylin and Eosin staining will be performed for all tissues. 
Organ Weights 
  Absolute weights of adrenal glands, brain, ovaries/testes, epididymis/uterus, 
heart, kidneys, liver, spleen and lungs will be recorded for all the animals after 
trimming adherent tissue immediately after dissection from the animal. Paired organs 
will be weighed together. Relative weights of these organs against fasting animal 
body weights will be calculated and reported. 
Data Compilation  
  Data will be summarised in a tabular form showing the number of animals, 
experimental design, dose groups, dose volume and concentrations, test item and 
vehicle control details. All findings like clinical signs, mortality and morbidity data, 
time of death, body weights, feed consumption, clinical signs, and necropsy and 
pathology observations will be recorded and given in the final report. One original 
copy of the final report is issued to the sponsor.  
Statistical Analysis 
  All the parameters of treated groups of both sex, viz. body weight, feed 
consumption, organ weights (absolute and relative), biochemical parameters, and 
hematology parameters will be analyzed using SPSS software, version 16.0 by using 
one-way ANOVA test with multiple comparison (vehicle controls treated groups) in 
the study report, and p value < 0.05 is considered as statistically significant.  
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MATERIALS AND METHODS 
         ESTIMATION OF HEMATOLOGICAL PARAMETERS: 1 
Collection of blood for hematological studies 
  After the treatment period the animals were anaesthetized by ketamine 
hydrochloride and the blood was collected from Retro-orbital sinus by using capillary 
into a centrifugation tube which contains EDTA for haematological parameters The 
haematological parameters like RBC, WBC and Hb percentage, Differential cell 
count, MCV, MCHC, Hematocrit, MCH, platelet count were estimated by the 
following procedures. 
1. ENUMERATION OF RED BLOOD CELLS: 1    Ramnic 2007) 
  Reagents : RBC diluting fluid 
 Procedure: 
         Using a red blood cell pipette of haemocytometer, well mixed blood was drawn 
up to 0.5 mark and RBC diluting fluid was taken up to mark II. The fluid blood 
mixture was shaken and transferred onto the counting chamber. The cells were 
allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get 
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dried. Using 45X or high power objective the RBC’s were counted uniformly in the 
larger corner squares.   
The cells were expressed as number of cells x1012/l 
2. ENUMERATION OF WBC: 2    John 1972) 
 Reagents: 
  Turk’s fluid: Turk’s fluid was prepared by mixing 2ml of acetic acid with 100 
ml of distilled water. To this 10 drop of aqueous methylene blue 3 %    w/v) was 
added. This solution haemolysis the red cells due to acidity so that counting of white 
cells becomes easy. 
Procedure:     
              Using a white blood cell pipette of haemocytometer, well mixed blood was 
drawn up to 0.5 mark and WBC diluting fluid was taken up to mark II. The fluid 
blood mixture was shaken and transferred onto the counting chamber. The cells were 
allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get 
dried. 
  Using 10X or low power objective the WBC’s were counted uniformly in the 
larger corner squares.   
  The cells were expressed as number of cells/10mm. 
3. DIFFERENTIAL LEUCOCYTE COUNT: 3      JOHN 1972) 
Reagent: 
              Leishmann’s stain: 150mg of powdered leishmann’s stain was dissolved in 
133ml of acetone free methanol. 
Procedure: 
 A blood film stained with leishmann’s stain was examined under oil 
immersion and the different types of WBCs were identified. The percentage 
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distribution of these cells was then determined. Smears were made from anticoagulant 
blood specimens and stained with leishmann’s stain. The slides were preserved for 
counting the number of lymphocytes and neutrophils, per 100 cells were noted.  
 From the different Leukocyte count and WBC count, absolute lymphocyte and 
neutrophil count were calculated. 
                                 Number of neutrophils  
 Absolute neutrophil count =   _______________________________   x  TWBC 
                             100  
                                                                  Number of lymphocytes  
 Absolute lymphocyte count =   _______________________________ x TWBC 
                             100 
DETERMINATION OF BIOCHEMICAL PARAMETERS: 
 
For assessment of biochemical parameters, blood samples were collected from the 
animals by puncturing the retro-orbital plexus and centrifuged. The serum collected 
after centrifugation was analyzed for various biochemical parameters like SGOT, 
SGPT, ALP,TC.TG,HDL All of the above biochemical parameters were estimated 
using semi autoanalyzer (Photometer 5010 V5+, Germany) with enzymatic kits 
procured from Piramal Healthcare limited, Lab Diagnostic Division, Mumbai, India. 
1. Total Cholesterol (TC)  
 Principle 
Determination of cholesterol is done after enzymatic hydrolysis and oxidation. 
The colorimetric indicator is quinoneimine, which is generated from 4-
aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of 
peroxidase (trinder’s reaction). 
Cholesterol ester + H2O       CHE       Cholesterol + Fatty acid 
Cholesterol + O2          CHO      Cholesterol-3-one +H2O2 
140 
 
2H2O2  + 4- Amino antipyrine + Phenol      POD          Quinonelimine + 4 H2O2 
Method  
 CHOD-PAP: Enzymatic photometric test 
Table 6: Reagents 
Goods buffer (pH 6.7) 50 mmol/ l 
Phenol 5 mmol/l 
4-aminoantipyrine 0.3 mmol/l 
Cholesterol estrase >  200 U/l 
Cholesterol oxidase >  100 U/l 
Peroxidase 3 KU/l 
Standard (5.2 mmol/l) 
 
Assay procedure 
a. 1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b.  Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C   for 5 min. 
d. Read the test sample. 
 
NORMAL RANGE: < 200 mg/dl in serum.      
1. Deeg R, Ziegenhorn J, Kinetic enzymatic method for automated determination 
of total cholesterol in serum, Clin. Chem., 1983, 29:1798-802. 
2. Triglycerides 
Principle 
Determination of triglycerides (TG) alters enzymatic splitting with lipoprotein 
lipase. Indicator is quinoneimine which is generated from 4-aminoantipyrine and 4- 
chlorophenol by hydrogen peroxidase under the catalytic action of peroxidase. 
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Triglycerides              LPL           Glycerol + fatty acid 
Glycerol + ATP              GK            Glycerol-3-phosphate+ ADP 
Glycerol-3-phosphate +O2         GPO         Dihydroxyaceton phosphate + H2O2 
2H2O2  + 4- Amino antipyrine + 4- chlorophenol         POD     Quinonelimine + HCL + 
4H2O2 
Method 
 Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO). 
Reagents 
Components and concentrations in the test Goods buffer pH 7.2, 50 mmol/ l 
Table 7: Reagents 
4-chloroPhenol 4 mmol/l 
ATP 2 mmol/l 
Mg2+ 15 mmol/l 
Glycerokinase > 0.4 Kµ/l 
Peroxidase > 2 Kµ/l 
Lipoprotein lipase > 4 Kµ/l 
4-aminoantipyrine 0.5 mmol/l 
Glcerol-3-phosphate- oxidase > 1.5Kµ/l 
Standard (2.3 mmol/l) 
 
Assay procedure 
a.  1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b. Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample. 
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 Normal Range: < 200 mg/dl in serum. 
1. Cole T.G, Klotzsch S.G, Mcnarmara J, Measurement of triglyceride 
concentration, In Rifai N, Warnick G.R, Dominiczak M.H, Handbook of 
lipoprotein testing, Washington:AACC, Press, 1997, 115-26. 
3. HDL Cholestrol 
 Principle  
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic acid 
and magnesium ions to the sample. Centrifugation leaves only the HDL in the 
supernatant. The cholesterol content in it is determined enzymatically. 
Method 
Phosphotungstic acid precipitation method. 
Table 8: Reagents 
Phosphotungstic acid 0.55 mmol/l 
Magnesium chloride 25 mmol/l 
Assay procedure 
A.  Preparation of supernatant for the HDL-CHL estimation 
    Added 200 µl of serum to the 500 µl of HDL-Cholesterol precipitating reagent 
(from HDL kit) in 1.5 ml centrifuge tube and mixed well. Centrifuged the above 
solution at 4000 rpm for 10 min. 
B. Preparation of test sample for the estimation of HDL-Cholesterol 
a. Taken 1000 µl of reagent-1 (from cholesterol kit) in a 5 ml test tube. 
b. Added, 100 µl of supernatant from above centrifuged solution 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample.  
Normal Range: > 60 mg/dl in serum. 
1. Friedewald W.T, Levy R.T, Frederickson D.S, Estimation of VLDL and LDL 
cholesterol, Clin. Chem., 1972, 18:499-502. 
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ESTIMATION OF SERUM GLUTAMATE PYRUVATE TRANSAMINASES 
(SGPT/ ALT) 
1. Determination of aspartate aminotransferase (AST) 
      Aspartate aminotransferase, also known as Glutamate Oxaloacetate 
Transaminase (GOT) catalyses the transamination of L-aspartate and α keto glutarate 
to form oxaloacetate and L- glutamate. Oxaloacetate formed is coupled with 2,4- 
Dinitrophenyl hydrazine to form hydrazone, a brown coloured complex in alkaline 
medium which can be measured colorimetrically. 
Reagents  
  Buffered aspartate  (pH 7.4); 2,4- DNPH reagent;  4N sodium hydroxide;  
working pyruvate standard; solution I (prepared by diluting 1 ml of reagent 3 to 10 ml 
with purified water). 
Procedure  
 Rietman and Frankle method was adopted for the estimation of SGOT. 
(Reitmann S, Frankel S, 1957. A colorimetric method for the determination of serum 
oxaloacetic and glutamic pyruvate transminases. American Journal of Clinical 
Pathology.28: 56-63.The reaction systems used for this study included blank, 
standard, test (for each serum sample) and control (for each serum sample). 0.25 ml of 
buffered aspartate was added into all the test tubes. Then 0.05 ml of serum was added 
to the test group tubes and 0.05 ml of working pyruvate standard into the standard 
tubes. After proper mixing, all the tubes were kept for incubation at 37oC for 60 min, 
after which 0.25 ml each of 2,4- DNPH reagent was added into all the tubes. Then, 
0.05 ml of distilled water and 0.05 ml of each serum sample was added to the blank 
and the serum control tubes respectively. The mixture was allowed to stand at room 
temperature for 20 min. After incubation, 2.5 ml of solution I was added to all test 
tubes. Mixed properly and optical density was measured in a spectrophotometer at 
505 nm within 15 min. 
The enzyme activity was calculated as:-  
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AST (GOT) activity in IU/L) = [(Absorbance of test - Absorbance of control)/ 
(Absorbance of standard - Absorbance of blank)] x concentration of the standard         
2.  Determination of alanine aminotransferase (ALT) 
 Alanine aminotransferase, also known as Glutathione Peroxidase (GPT) 
catalyses the transamination of L-alanine and α keto glutarate to form pyruvate and L- 
Glutamate. Pyruvate so formed is coupled with 2,4 – Dinitrophenyl hydrazine to form 
a corresponding hydrazone, a brown coloured complex in alkaline medium which can 
be measured colorimetrically. 
Reagents 
Buffered alanine (pH 7.4), 2,4–DNPH, 4N sodium hydroxide, working pyruvate 
standard, solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with purified 
water). 
Procedure  
 Rietman and Frankle method was dopted for the estimation of SGPT. The 
reaction systems used for this study included blank, standard, test (for each serum 
sample) and control (for each serum sample). 0.25 ml of buffered alanine was added 
into all the test tubes. This was followed by the addition of 0.05 ml of serum into the 
test group tubes and 0.05 ml of working pyruvate standard into the standard tubes. 
After proper mixing, all the tubes were kept for incubation at 37oC for 60 minutes, 
after which 0.25 ml each of 2,4- DNPH reagent was added into all the tubes. Then, 
0.05 ml of distilled water and 0.05 ml of each serum sample was added to the blank 
and the serum control tubes respectively. The mixture was allowed to stand at room 
temperature for 20 min. After incubation, 2.5 ml of solution I was added to all test 
tubes. Mixed properly and optical density was read against purified water in a 
spectrophotometer at 505 nm within 15 min. 
  The enzyme activity was calculated as:- ALT (GPT) activity in IU/L) = 
[(Absorbance of test - Absorbance of control)/ (Absorbance of standard - Absorbance 
of blank)] x concentration of the standard.        
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3. Determination of alkaline phosphatase (ALP) 
  Alkaline phoshatase from serum converts phenyl phosphate to inorganic 
phosphate and phenol at pH 10.0. Phenol so formed reacts in alkaline medium with 4-
aminoantipyrine in presence of the oxidising agent potassium ferricyanide and forms 
an orange-red coloured complex, which can be measured spectrometrically. The color 
intensity is proportional to the enzyme activity. 
Reagents: 
Buffered substrate 
Chromogen Reagent 
Phenol Standard, 10 mg% 
Procedure: 
  ALP was determined using the method of Kind (Kind PRM, King EJ, 1972. 
In-vitro determination of serum alkaline phosphatase. Journal of Clinical Pathology 7: 
321-22\). The working solution was prepared by reconstituting one vial of buffered 
substrate with 2.2 ml of water. 0.5 ml of working buffered substrate and 1.5 ml of 
purified water was dispensed to blank, standard, control and test. Mixed well and 
incubated at 370C for 3 min. 0.05 ml each of serum and phenol standard were added 
to test and standard test tubes respectively. Mixed well and incubated for 15 min at 
370C. Thereafter, 1 ml of chromogen reagent was added to all the test tubes. Then, 
added 0.05 ml of serum to control. Mixed well after addition of each reagent and the 
O.D of blank, standard, control and test were read against purified water at 510 nm. 
  Serum alkaline phosphatase activity in KA units was calculated as follows  
[(O.D. Test-O.D. Control) / (O.D. Standard- O.D. Blank)] x 10 
 
4. Determination of bilirubin  
  In toxic liver, bilirubin levels are elevated. Hyperbilirubinemia can result from 
impaired hepatic uptake of unconjugated bilirubin, such a situation can occur in 
generalized liver cell injury, certain drugs (e.g Rifampin and probenecid) interfere 
with the rat uptake of bilirubin by the liver cell and may produce a mild unconjugated 
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hyperbilirubinemia. Bilirubin level rises in diseases of hepatocytes, obstruction to 
bilirubin excretion into duodenum, in haemolysis and defects of hepatic uptake and 
conjugation of Bilirubin pigment such as Gilbert’s disease.  
Elevation of total serum bilirubin may occur due to:  
1. Excessive haemolysis or destruction of the red blood cells.Eg:Haemolytic disease 
of the new born. 
2. Liver diseases.Eg.Hepatitis and cirrhosis. 
3. Obstruction of the biliary tract.Eg.Gall stones. 
  The method is based on the reaction of Sulfonilic acid with sodium nitrite to 
form azobilirubin which has maximum absorbance at 546nm in the aqueous solution. 
The intensity of the color Produced is directly proportional to the amount of direct or 
total bilurubin concentration present in the sample. 
Reagents 
1. Diazo A-(Reagent-R1) :Ready to use 
2. Diazo B-(Reagent-R2):Ready to use 
3. Bilirubin Activater :Ready to use 
Procedure 
  Kind & King’s method was followed for the estimation of Bilirubin. Five 
hundred µl of working reagent was added to 50 µl of rat serum & incubated for 5 min 
at 37°C. Absorbance was measured AT 546 NM in semi auto analyzer against the 
standard. 
The Bilirubin content was calculated using the following equation: 
Total bilirubin (mg/dt) = Abs of the sample blank x 15. 
Direct Bilirubin(mg/dt) = Abs of sample blank x 10. 
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5. ESTIMATION OF UREA 
Urea is the nitrogen-containing end product of protein catabolism. States 
associated with elevated levels of urea in blood are referred to as hyper uremia or 
azotemia.  
Method 
Estimation of urea was done by Urease-GLDH: enzymatic UV test.  
Principle 
Urea + 2H2O     Urease       2NH4 + 2HCO3 
2- Oxoglutarate +NH4+ +NADH      GLDH      L- Glutamate +NAD+ + H2O                                        
Table 14. Reagents 
 
 
 
 
 
 
 
 
Procedure 
a. Take 1000 µl of reagent-1 and 250 µl of reagent-2 in 5 ml test tube. 
b. To this, add 10 µl of serum. 
c. Mix well and immediately read the test sample at 340 nm Hg 334 nm Hg 365 
nm optical path 1 cm against reagent blank (2-point kinetic). 
d. And note down the value. 
Normal range: 10 – 50 mg/dl. 
R 1 
TRIS pH 7.8 120  mmol/l 
2-Oxoglutarate 7 mmol/l 
ADP 0.6 mmol/l 
Urease ≥ 6 KU/l 
GLDH ≥ 1 KU/l 
R 2 NADH 0.25 mmol 
R 3 Standard 40 mg/dl 
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6. ESTIMATION OF URIC ACID 
Uric acid and its salts are end products of the purine  metabolism. In gout the 
most common complication of  hyperuricemia, ie. Increased serum levels of uric acid 
lead to formation of  monosodium urate crystal around the joints. 
Method  
Enzymatic photometric test using  TOOS (N ethyl- N (hydroxyl -3- sulfopropyl)-m- 
toluidin) 
Principle  
Uric acid + H2O + O2       uricase         Allantoin +CO2 +H2O2 
TOOS + 4 aminoantipyrine + 2H2O2      POD       Indamine + 3H2O 
Table 15.reagents 
R1 Phosphate buffer pH 7.0 100mmol/l 
TOOS 1mmol/l 
Ascorbate oxidase ≥1 KU/l 
R2 Phosphate buffer pH 7.0 100mmol/l 
4- amino antipyrine 0.3mmol/l 
K4 (Fe( CN)6) 10µmol/l 
Peroxidase ≥1KU/l 
Uricase ≥50U/l 
Procedure 
a. Take 800µl of  reagents -1 in a2ml centrifuge tube. 
b. To this add 20µl of serum. 
c. Mix well and incubate at 30°c for 5 minutes. 
d. Then add 200µl of reagent2 
e. Mix well incubate for 5min at 37°c 
f. Measure the not down the values. 
Normal range: 1.9-8.2mg/dl 
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7. ESTIMATION OF CREATININE:  
Principle: 
Creatinine forms a coloured complex with picrate in alkaline medium.  
The rate of formation of the complex is measured.  
Reagents: 
Reagent 1    Standard Creatinine (2mg/100ml) 
Reagent 2    Picric acid solution. 
Reagent 3     sodium hydroxide solution  
Procedure: 
 Take 500 µl of reagent -2 and 500 µl of reagent -3 in a 5ml test tube. To this 
add 100 µl of serum. Mix well and immediately read the test sample at Hg 492 nm 
1cm light path and note down the values.  
Normal range is 0.6 -1.1 mg/dl. 
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TABLE: 1   EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF SANTHIRA 
PRAGASA MATHIRAI WITH CHUKKU KASAYAMON BODY WEIGHT IN 
Gram (PHYSICAL PARAMETER) 
GPs Control Low Dose Middle Dose High Dose 
 Male Female Male Female Male Female Male Female 
1stwk 132±4 136.5±1.5 137±5 127±1 
125.5±3.
5 126±4 134±2 128±2 
2ndw
k 
139.5±2.
5 143±1 146±3 
137.5±0.
5 
135.5±3.
5 
138.5±0.
5 145±3 136±2 
3rdwk 147.5±4.5 
151.5±2.
5 152±3 
145.5±2.
5 
146.5±1.
5 
151.5±5.
5 152±4 146±1 
 
4thwk 156±2 
160.5±1.
5 
161.5±2.
5 
152.5±3.
5 162±5 
161.5±3.
5 161±3 159±4 
Values are expressed as the mean ± S.D 
1st wk body weight
M F M F M F M F
0
50
100
150
w
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gh
t (
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2nd WK BODY WEIGHT
M F M F M F M F
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3rd WK BODY WEIGHT
M F M F M F M F
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4th WK BODY WEIGHT
M F M F M F M F
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 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAM ON FOOD INTAKE In Gram  
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 34 28 15 10 34 56 72 64 
DAY2 38 62 56 31 62 56 88 64 
DAY3 38 30 44 52 20 75 35 56 
Day 4 56 18 34 24 68 56 64 45 
DAY5 34 10 18 6 58 64 78 56 
Day 6 60 12 58 68 56 67 58 18 
DAY7 50 14 61 88 78 46 64 30 
DAY8 32 44 18 40 44 88 80 34 
Day 9 80 56 22 60 64 52 46 58 
DAY10 74 62 45 56 38 56 80 56 
Day 11 44 54 68 58 34 24 74 62 
DAY12 54 60 38 62 62 54 45 52 
DAY13 72 56 38 44 64 58 50 48 
Day 14 38 19 54 50 72 34 16 35 
DAY15 48 36 64 71 62 34 56 64 
Day 16 56 78 54 42 42 56 34 18 
DAY17 56 78 64 58 34 46 28 64 
DAY18 12 24 18 22 68 54 42 34 
Day 19 8 58 44 58 64 40 80 55 
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DAY20 34 14 32 38 56 64 42 56 
DAY21 42 22 58 34 58 68 45 32 
Day 22 38 26 26 64 61 88 36 58 
DAY23 58 64 48 56 54 56 64 56 
DAY24 62 74 64 74 72 57 74 48 
Day 25 58 62 30 62 56 16 74 78 
DAY26 77 34 56 64 56 82 56 56 
DAY27 74 48 24 58 56 56 80 28 
DAY28 56 62 70 66 44 44 56 62 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAMON WATER INTAKE IN ml 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 110 60 85 75 60 125 65 50 
DAY2 75 85 140 70 100 50 70 70 
DAY3 60 85 60 50 85 140 105 130 
Day 4 60 85 60 70 150 165 130 110 
DAY5 90 40 55 80 100 90 70 65 
Day 6 210 60 70 130 70 75 60 80 
DAY7 70 90 50 65 60 70 85 70 
DAY8 80 50 130 60 70 90 55 50 
Day 9 60 50 70 75 50 70 55 70 
DAY10 40 80 55 130 20 130 85 105 
Day 11 130 40 130 70 50 60 70 80 
DAY12 60 55 70 60 60 70 30 40 
DAY13 60 75 40 45 80 60 40 65 
Day 14 65 55 50 30 60 50 65 20 
DAY15 60 85 65 20 70 40 60 50 
Day 16 60 65 80 60 70 60 60 40 
DAY17 65 30 70 60 40 45 80 65 
DAY18 70 30 60 20 55 80 115 125 
Day 19 60 40 90 170 140 60 90 95 
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DAY20 120 20 95 185 140 70 60 85 
DAY21 50 65 60 75 50 70 40 60 
Day 22 130 90 50 95 85 70 95 60 
DAY23 105 70 60 90 60 140 90 75 
DAY24 65 80 95 70 50 60 60 125 
Day 25 60 70 50 60 70 110 110 90 
DAY26 110 85 60 70 60 130 90 50 
DAY27 60 50 70 110 40 70 120 80 
DAY28 70 40 110 60 140 70 50 60 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAMON ORGAN WEIGHT in gm 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
LIVER WEIGHT
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GROUP CONTROL 
 
Low Dose 
 
Middle Dose 
 
High Dose 
LIVER  
WEIGHT 
6.669±0.190
5 6.117±0.663 6.251±0.3805 6.549±0.017 
KIDNEY 
WEIGHT 
L 0.8005±0.01
15 0.813±0.01 0.758±0.022 0.7665±0.0115 
R 
0.734±0.05 
0.7245±0.027
5 0.671±0.006 0.6905±0.0015 
HEART 
WEIGHT 0.808±0.064 
0.8145±0.158
5 0.7275±0.0155 1.032±0.177 
LUNGS  
WEIGHT 
1.373±0.419
5 
0.7715±0.091
5 0.8205±0.0655 1.549±0.8195 
TESTIS 
WEIGH 2.768±0.58 2.803±0.321 1.798±0.57 1.705±0.5225 
UTERUS 0.4755±0.04
65 0.394±0.056 0.6675±0.0845 0.574±0.148 
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAM ON HAEMATOLOGICAL 
PARAMETERS 
Groups Control Low Dose Middle Dose High Dose 
Rbc (X106/µl) 
 
3.41±2.59 
 
5.795±0.635 
 
5.28±0.15 
 
5.765±0.345 
 
Wbc(X103/µl) 
 
10.55±1.75 
 
13.05±2.55 
 
14.7±0.1 
 
11.75±0.05 
 
 
Hb (g/dl) 
15.9±1.5 
 
14.4±1.9 
 
12.85±0.45 
 
14.25±1.05 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAMON BIOCHEMICAL PARAMETER 
(LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total 
Bilirubin(mg/dl) 
 
0.485±0.015 
 
0.89±0.17 
 
0.845±0.115 
 
0.57±0.2 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAMON BIOCHEMICAL PARAMETER 
(LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
 
SGOT (U/L) 
 
69±7.7 
 
88.8±6.4 
 
84.3±8.5 
 
69.5±8.8 
 
SGPT (U/L) 65.9±19.6 
 
37.75±3.85 
 
29.25±1.55 
 
21.8±0.3 
 
ALP (U/L) 278.2±5.45 
 
284.1±21.9 
 
186.4±71.9 
 
163.2±6 
 
Values are expressed as the mean ± S.D; Statistical significance (p) calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAMON BIOCHEMICAL PARAMETER 
(KIDNEY PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Urea (mg/dl) 
36.03±11.01 
 
48.75±15.05 
 
38.17±0.27 
 
31.69±3.815 
 
Uric acid 
(mg/dl) 
1.485±0.265 
 
1.85±0.61 
 
1.59±0.21 
 
1.21±0.17 
 
Creatinine 
(mg/dl) 
0.31±0.03 
 
0.305±0.025 
 
0.2±0.05 
 
0.23±0.03 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F SANTHIRA PRAGASA 
MATHIRAI WITH CHUKKU KASAYAMON BIOCHEMICAL PARAMETER 
(LIPID PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total 
cholesterol 
(mg/dl) 
42.2±4.3 51.25±5.65 47.8±5.2 37.45±4.85 
Triglycerides 
(mg/dl) 
102.1±5.75 
 
77.5±1.1 
 
65.18±5.58 
 
61±15.6 
 
HDL-
Cholesterol 
(mg/dl) 
7.775±2.525 
 
10.34±1.765 
 
6.45±2.25 
 
4.85±0.25 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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RESULTS: 
    CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals Table-1 from control and 
different dose groups exhibited comparable body weight gain throughout the dosing 
period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.4 Comparison of organ weights of treated animals with respective control 
animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations (Table 4) conducted on day 29 
revealed following significant changes in the values of different parameters 
investigated when compared with those of respective controls; however, the increase 
or decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
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Biochemical Investigations: 
Results of Biochemical investigations conducted on days 29 and recorded in 
Table 2 revealed the following significant changes in the values of hepatic serum 
enzymes studied. When compared with those of respective control. However, the 
increase or decrease in the values obtained was within normal biological and 
laboratory limits. 
Histopathology: 
In histopathological examination, revealed normal architecture in comparison 
with control and treated animal. 
 DISCUSSION: 
1)  All the animals from control and all the treated dose groups up to 500 mg/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain 
with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29 no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found 
to be comparable with that of respective controls. 
8) Histopathological examination revealed normal architecture in comparison with 
control and treated animal. 
  
170 
 
SUMMARY AND CONCLUSION:  
In conclusion SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAM can be considered safe, as it did not cause either any lethality or adverse 
changes with general behavior of rats and also there were no observable detrimental 
effects (100 to 300 mg/kg body weight) over a period of 28 days. Our results have 
demonstrated that the SANTHIRA PRAGASA MATHIRAI WITH CHUKKU 
KASAYAM is relatively safe when administered orally in rats. 
9.0 ABBRVIATION 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o.  peros 
mL  Milliliter 
%   percentage 
R&D   Research and Development 
EDTA  Ethylene Diamine Tetra Acetic Acid 
M   Male 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD  Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments  
on Animals 
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HISTOPATHOLOGY   -  TOXICITY STUDY 
SPECIMEN     : A) Liver.    Group –    : Santhira Pragasa Mathirai. 
 
                                                       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
 Section from liver shows lobular architecture with interface hepatitis. Individual Hepatocytes 
shows reactive atypia. Portal triad shows no significant pathology. Central vein and Sinusoids 
show dilatation. 
  
10x shows mild loss of architecture 40x shows central vein congestion 
40x shows bile uct hyperplasa 40x shows cytoplasmic vacuolation and 
binucleation 
40x shows periportal inflammation 40x shows sinusoidal dilatation 
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SPECIMEN    :  B) spleen. 
Group – :  Santhira Pragasa Mathirai 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
        Section studied from spleen shows normal white pulp and red pulp. Red pulp shows pigment 
laden macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming 
germinal centre. The pencillar artery shows normal morphology. Megakaryocytes 
10cx shows normal red pulp and white pulp 10x shows spleen with normal morphology 
40x shows normal lwhite pulp 40x shows normal white  pulp and red pulp with 
pigment laden macrophages 
40x shows white pulp with lymphocytic infiltrates 
and white pulp 
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   SPECIMEN  :  C)  Kidney. 
Group – :  Vishnu chakra mathirai 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE: 
 
 Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no significant 
pathology. Interstitium shows no significant pathology. Blood vessels show congestion. There is 
no evidence of toxic changes. 
10x shows kidney with both cortex and medulla 10x shows normal interstitium 
40x shows bllood vessels congestion 40x shows matrix expansion 
40x shows normal interstitium 
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SPECIMEN  :  D) Testis 
Group – :  Santhira Pragasa Mathirai 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
          Section from testes with seminiferous tubules showing maturation arrest with lacking of 
spermatogenesis.  
  
 
10x shows testis with maturation arrest 40x shows lacking of spermatogenesis 
40x shows maturation arreast 40x shows tubules (2) 
40x shows tubules 
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Name   : 
Ref. No. : [H0 326A/18] 
 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
 
HISTOPATHOLOGY 
                      
SPECIMEN                 :  Liver 
    
Group –I                 : Shanmuga priya- SPM . 
 
GROSS APPEARANCE: 
 
                     Received a specimen of liver measuring 3.0x2.2x1.2cms.                     
  
(PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section from liver shows mild loss of architecture. Individual 
Hepatocytes shows binucleation, cytoplasmic vacuolation. Portal triad shows 
periportal inflammation and necrosis. Central vein shows congestion. Sinusoids show 
dilatation. 
 
 
        
                                                                                                                             
Dr.C.R.Ajeethkumar.M.D. 
(Path). 
             
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
Checked 
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Name   : 
Ref. No. : [H0 326B/17] 
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
         Toxicity study                
 
SPECIMEN                   :  B) spleen. 
    
Group –I                  : Shanmuga priya- SPM.  
 
GROSS APPEARANCE:  
 
                     Received a specimen of spleen measuring 2.4x0.8x0.4cms. 
 
 (PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section studied from spleen shows normal white pulp and red pulp. Red 
pulp shows pigment laden macrophages and congested vessels. White pulp shows 
lymphocytic infiltrates forming germinal centre. The pencillar artery shows normal 
morphology. There is no evidence of toxic changes. 
 
                                                                                        
                                                                                Dr.C.R.Ajeeth kumar. M.D. (Path), 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path), Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
Checked 
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Name   :   
Ref. No. : [Ho 326C/18]                      
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : Kidney. 
 
Group – I                      : Shanmuga priya- SPM. 
 
GROSS APPEARANCE    : 
 
Received specimen of kidneys each measuring 1.3x0.6x0.5cms and 1.2x0.7x0.5cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from kidney shows both cortex and medulla. Glomeruli shows 
mesangeal matrix expansion and hypercellularity. Tubules show no significant 
pathology. Interstitium shows no significant pathology. Blood vessels show congestion.  
- Focal segmental proliferative glomerulonephritis. 
 
 
                                                                       Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
Checked 
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Name   :   
Ref. No. : [Ho 326D/18]                      
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : Testis. 
 
Group – I                      : Shanmuga priya- SPM.   
 
GROSS APPEARANCE    : 
 
Received specimen of both testis measuring each 1.0x0.6x0.5cms and 1.0x0.5x0.4cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from testes with seminiferous tubules shows maturation arrest with 
lacking of spermatogenesis. No evidence of granuloma/ malignancy. 
 
 
 
                                                                       Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
Checked 
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ANNEXURE – IV 
ASSESSMENT FORMS 
 
FORM I  : Screening and Selection Proforma 
FORM I A  : History Proforma on Enrollment 
FORM II  : Clinical assessment on enrollment 
FORM II A  : Clinical assessment during and after trial 
FORM III  : Laboratory Investigation on enrollment and conclusion  
  of trial 
FORM IV  : Consent Form 
FORM IV B  : Withdrawal form 
FORM IV C  : Patient information sheet 
FORM IV D  : Dietary Advice form 
FORM IV E  : Adverse Reaction form 
FORM IV F  : Discharge proforma 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 
TO EVALUATE THE CLINICAL EFFICACY OF  SIDDHA HERBO MINERAL 
FORMULATION “SANTHIRA PRAGASA MATHIRAI” INTERNAL & 
“SEMBAI THYLAM” EXTERNAL IN “KUMBA VATHAM”                   
(PERIARTHRITIS OF SHOULDER). 
 
FORM I – SCREENING & SELECTION PROFORMA 
 
1. OP / IP NO    : ___________ 
2. NAME   : ___________ 
3. RELIGION    : H / C / M / O 
4. AGE / GENDER  : ___________ 
5. OCCUPATION  : ___________ 
6. INCOME   : ___________ 
7. CONTACT NO  : ___________ 
8. INCLUSION CRITERIA :  
INCLUSION CRITERIA: 
• Sex:  Both Male and Female 
 
• Patient having main symptoms of  shoulder joint pain radiating towards 
upper arm and forearm, numbness, restricted movement of upper limb, 
loss of abduction and forward flexion followed by stiffness of the shoulder 
joints. 
• Patient willing to sign the informed consent stating that he/she will 
consciously stick to the treatment during 20-30 days. 
• Willing for doing laboratory investigations and X-Ray,  imaging. 
• Willing to cooperate with the proper clinical examination. 
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•  Controlled Diabetes mellitus 
•  Controlled  hypertension 
 
EXCLUSION CRITERIA: 
• Rheumatoid arthritis 
• Ischaemic heart diseases 
• Pregnancy and lactation 
• Recent shoulder dislocation. 
• Recent shoulder fracture. 
 
ADMITTED TO TRIAL: 
    YES  NO 
If Yes Serial Number : 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
TO EVALUATE THE CLINICAL EFFICACY OF  SIDDHA HERBO MINERAL 
FORMULATION “SANTHIRA PRAGASA MATHIRAI” INTERNAL & 
“SEMBAI THYLAM” EXTERNAL IN “KUMBA VATHAM”                   
(PERIARTHRITIS OF SHOULDER). 
 
FORM I A – HISTORY PROFORMA 
1. SL.NO     : ___________ 
2. OP / IP NO     : ___________ 
3. NAME    : ___________ 
4. RELIGION     : H / C / M / O 
5. AGE / GENDER   : ___________ 
6. OCCUPATION   : ___________ 
7. INCOME    : ___________ 
8. CONTACT NUMBER  : ___________ 
9. MARITAL STATUS   : Married / Unmarried 
10. COMPLAINTS & DURATION : 
 
11. PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES SPECIFY DURATION 
Smoking    
Tobacco Chewing    
Alcohol    
Narcotic Drug Addiction    
12. DRUG HISTORY: 
 Whether the Patient has underwent any allopathic Treatment  
1. Yes    2. No. 
 If yes specify the nature of the drug and treatment duration _____ 
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13. FAMILY HISTORY: 
 Whether this problem runs in family? 
1. Yes  2. No 
If yes, mention the relationship of affected person(s) 
1. ___________ 
2. ___________ 
14. DIETARY HABITS : 
 
   1. Pure vegetarian 
   2. Non-Vegetarian 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
TO EVALUATE THE CLINICAL EFFICACY OF  SIDDHA HERBO MINERAL 
FORMULATION “SANTHIRA PRAGASA MATHIRAI” INTERNAL & 
“SEMBAI THYLAM” EXTERNAL IN “KUMBA VATHAM”                   
(PERIARTHRITIS OF SHOULDER). 
 
FORM II AND II-A  CLINICAL ASSESSMENT ON ENROLLMENT AND ON 
VISITS 
 
1. OP / IP No     :  
2. BED No    :  
3. SL. NO    : 
4. NAME    : 
5. AGE     : 
6. GENDER    : 
7. OCCUPATION   : 
8. SOCIAL STATUS   : 
9. DATE OF ADMISSION  : 
10. DATE OF DISCHARGE  : 
11. POSTAL ADDRESS   : 
12. COMPLAINTS & DURATION : 
13. HISTORY OF PRESENT ILLNESS : 
14. PAST HISTORY   : 
15. FAMILY HISTORY   : 
 
16. MENSTRUAL HISTORY (If Applicable): 
17. HABITS: 
1. Smoker    : 
2. Alcoholic    : 
3. Tobbaco chewer   :  
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4. Betel nut chewer   : 
5. Non-Vegetarian   : 
6. Drug addiction   : 
 
18. GENERAL EXAMINATION: 
1. Body weight (Kg)   : 
2. Height (Cm)   :  
3. Body Temperature (F)  :  
4. Blood Pressure (mmHg)  : 
5. Pulse Rate (/min)   : 
6. Heart Rate (/min)   : 
7. Respiratory Rate (/min)  :  
8. Pallor    :  
9. Jaundice    : 
10. Clubbing    : 
11. Cyanosis    : 
12. Pedal Oedema   :  
13. Lymphadenopathy  :  
14. Jugular venous pulsation  : 
19. CLINICAL EXAMINATION: 
I. INSPECTION: 
1. Attitude    : 
2. Muscular spasm   : 
3. Muscle wasting – Proximal :  
4. Muscle wasting – Distal  : 
5. Minor Joint Swelling  : 
6. Major Joint Swelling  : 
7. Nodules    : 
8. Deformity    : 
II. PALPATION: 
1. Swelling    : 
2. Tenderness   :  
3. Joint Stiffness   : 
4. Muscle wasting   : 
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5. Local heat    : 
6. Local Lymphadenopathy  : 
7. Pitting Oedema   : 
8. Nodules    : 
III. MOVEMENTS: 
Restriction of joint movements 
1. Neck              :            Full            Partial    
2. Shoulder  : 
3. Elbow joint  : 
4. Knee joint  : 
5. Ankle joint  : 
6. Hip joint  : 
7. Minor joints  : 
IV. PAIN: 
1. Onset :   Sudden : Gradual : 
2. Early morning stiffness :  Present  : absent  : 
3. Nature of pain:  Mild  : Moderate :     Severe: 
4. Aggravating factor –Movements  : 
5. Relieving factor – rest   : 
6. Stiffness     : 
7. Tenderness    :  
V. CLINICAL ASSESSMENT :  
1. Arthritis of three or more Joints  : 
2. Arthritis of hand joints   : 
3. Morning Stiffness    : 
4. Fever     : 
5. Anorexia     : 
6. Anaemia     : 
7. Spindle appearance of fingers  : 
8. Restricted movements   : 
9. Rheumatoid Nodules   : 
10. Numbness     : 
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20. EXAMINATION OF OTHER SYSTEMS:  
1. CVS    : 
2. RS     : 
3. CNS    : 
4. ABDOMEN   : 
5. GENITO – URINARY  : 
 
EXAMINATION – SIDDHA ASPECTS 
1. NILAM: 
 1. Kurinji 2. Mullai 3. Marutham 4. Neithal 5. Paalai 
2. KAALAM: 
 1. Kaar Kaalam 2. Koothir Kaalam 3. Munpani Kaalam 
 4. Pinpani Kaalam 5. Elavenir Kaalam 6. Mudhuvenir Kaalam 
3. YAAKKAI:  
 1. Vatham   2. Pitham   3. Kabam 
 4. Vathapitham  5. Pithavatham  6. Kabavatham 
 7. Vathakabam  8. Pithakabam   9. Kabapitham 
4. GUNAM:  
 1. Sathuvam   2. Rasatham   3. Thamasam 
 
5. KANMENDHIRIUM / KANMAVIDAYAM 
 1. Kai   : 
 2. Kaal   : 
 3. Vaai   : 
 4. Eruvaai  : 
5. Karuvaai  : 
 
6. UYIR THATHUKKAL: 
I. VATHAM: 
1. Piraanan  : 
2. Abaanan  : 
3. Viyaanan  : 
4. Uthaanan  : 
5. Samaanan  : 
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6. Naagan  : 
7. Koorman  : 
8. Kirukaran  : 
9. Devathathan : 
10. Dhananjeyan : 
 
II. PITHAM : 
1. Analagam  : 
2. Ranjagam  : 
3. Saathagam  : 
4. Aalosagam : 
5. Praasagam  : 
 
III. KABAM: 
1. Avalambagam : 
2. Kilethagam : 
3. Pothagam  : 
4. Tharpagam : 
5. Santhigam  : 
 
7. UDAL THAATHUKKAL: 
1. Saaram  : 
2. Senneer  : 
3. Oon  : 
4. Kozhuppu  : 
5. Enbu  : 
6. Moolai  : 
7. Sukkilam / Suronitham: 
 
8. ENVAGAI THERVUGAL: 
1. Naadi  : 
2. Sparisam  : 
3. Naa  :  
4. Niram  : 
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5. Mozhi  : 
6. Vizhi  : 
 
7. Malam :  
i. Niram:  ii. Thanmai: iii. Irugal: iv.Ilagal: 
8. Moothiram : 
 
I. NEERKURI: 
 a. Niram : 
 b. Manam : 
 c. Edai  : 
 d. Nurai : 
 e. Enjal : 
II. NEIKURI: 
 Vatha Neer  :  Pittha Neer   :    Kaba Neer : 
   
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 
TO EVALUATE THE CLINICAL EFFICACY OF  SIDDHA HERBO MINERAL 
FORMULATION “SANTHIRA PRAGASA MATHIRAI” INTERNAL & 
“SEMBAI THYLAM” EXTERNAL IN “KUMBA VATHAM”                   
(PERIARTHRITIS OF SHOULDER). 
 
FORM III – LABORATORY INVESTIGATION 
1. BLOOD: 
1. TC   : (Cells / Cumm) 
2. DC (%)  : N : L : M : E : 
3. ESR (mm)  : ½ hr : 1 hr : 
4. Hb   : 
5. Blood Sugar : a) Fasting : b) Post Prandial : 
6. Renal function tests: 
Blood Urea:  Serum creatinine: 
7. Lipid profile : 
HDL:   LDL:  VLDL: 
Total Cholesterol : TGL : 
8. Liver Function tests: 
Serum Bilirubin :  Total  Direct  Indirect 
 
SPECIFIC INVESTIGATIONS 
 RA factor   : 
 ASO titre   : 
 C-Reactive Protein  : 
 SGOT    : 
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SGPT    : 
 Serum albumin & globulin : 
 Total protein   : 
II. URINE: 
1. Albumin   : 
2. Sugar   : 
3. Epithelial cells  : 
4. Pus cells   : 
5. Red blood cells  : 
6. Casts / Crystals  : 
III. MOTION: 
1. Ova   : 
2. Cyst   : 
3. Occult blood  : 
4. Pus cells   : 
IV. X-RAY FINDINGS 
 
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 
TO EVALUATE THE CLINICAL EFFICACY OF  SIDDHA HERBO MINERAL 
FORMULATION “SANTHIRA PRAGASA MATHIRAI” INTERNAL & 
“SEMBAI THYLAM” EXTERNAL IN “KUMBA VATHAM”                   
(PERIARTHRITIS OF SHOULDER). 
    
   FORM IV A – CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
Signature ______________ 
Date      ______________ 
Name    ______________ 
CONSENT BY PATIENT 
 I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up including 
the laboratory investigations to be performed to monitor and safeguard my body 
functions. 
 I am aware of my right to opt out of the trial at any time during the course of 
the trial without having to give the reasons for doing so. 
 I exercising my free power of choice, hereby give my consent to be included 
as a subject in the clinical trial of “SANTHIRA PRAGASA MATHIRAI” (Internal 
drug) and “CHITHIRAMOOLA ENNAI” (External drug) for the treatment of 
“KUMBA VATHAM” (PERIARTHRITIS OF SHOULDER)”. 
 
Place :        Signature  :  
Date :         Name  : 
        Witness Signature: 
        Name  :
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murpdH rpj;j kUj;Jtf; fy;Yhhp kw;Wk; kUj;Jtkid; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ;  
ghisaq;Nfhl;il; ;; ;; ;  
gl;lNkw;gbg;G rpwg;G kUj;Jtj;Jiw; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;  
 
‘re;jpu gpufhr khj;jpiu; ;; ;; ;  ” kw;Wk; ‘; ;; ;; ; nrk;ig ijyk;;; ;” ,tw;wpd; ghpfhpg;Gj; ; ; ; ; ;; ; ; ; ;; ; ; ; ;
jpwidf; fz;lwpAk; kUj;Jt Ma;T xg;Gjy; gbtk; Ma;thsuhy; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ;
rhd;wspf;fg;gl;lJ.; ; ; ;; ; ; ;; ; ; ;  
 
ehd; ,e;j Ma;itf; Fwpj;j midj;J tpguq;fisAk; Nehahspf;F 
GhpAk; tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
 
Njjp  :        ifnahg;gk;: 
,lk; :         ngaH: 
Nehahspapd; xg;Gjy;; ; ;; ; ;; ; ; 
 vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk; kUe;jpd; jd;ik 
kw;Wk; kUj;Jt topKiwiag; gw;wpAk; njhlHe;J vdJ cly; ,af;fj;ij 
fz;fhzpf;fTk;> mjidg; ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l 
ghpNrhjidfs; gw;wpAk; jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy; 
tpsf;fpf; $wg;gl;lJ. 
 ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;nghOJ 
Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;Jf; nfhs;Sk; 
chpikia njhpe;jpUf;fpd;Nwd;. 
 ehd; vd;Dila Rje;jpukhfj; NjHT nra;Ak; chpikiaf; nfhz;L 
Fk;gthjk; vd;Dk; Neha;f;fhd re;jpu gpufhr khj;jpiu kw;Wk; nrk;ig ijyk; 
Mfpatw;wpd; ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;F vd;id 
cl;gLj;j xg;Gjy; mspf;fpNwd;. 
 
Njjp :       ifnahg;gk;: 
,lk; :       ngaH :  
     
       rhl;rpf;fhuH ifnahg;gk;: 
       ngaH : 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
TO EVALUATE THE CLINICAL EFFICACY OF  SIDDHA HERBO MINERAL 
FORMULATION “SANTHIRA PRAGASA MATHIRAI” INTERNAL & 
“SEMBAI THYLAM” EXTERNAL IN “KUMBA VATHAM”                   
(PERIARTHRITIS OF SHOULDER). 
FORM IV B – WITHDRAWAL FORM 
 
1. SL.NO    : ___________ 
2. OP / IP NO    : ___________ 
3. NAME   : ___________ 
4. RELIGION    : H / C / M / O 
5. AGE / GENDER  : ___________ 
6. OCCUPATION  : ___________ 
7. SOCIAL STATUS  : ___________ 
8. CONTACT NO  : ___________ 
9. DATE OF TRIAL COMMENCEMENT  : ___________ 
10. DATE OF WITHDRAWAL FROM TRIAL : ___________ 
11. REASONS FOR WITHDRAWAL   : ___________ 
 Long absence at reporting   :  Yes / No 
 Irregular treatment    :  Yes / No 
 Shift of locality    :  Yes / No 
 Increase in severity of symptoms  :  Yes / No 
 Development of severe adverse drug reactions:  Yes / No 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III (SIRAPPU MARUTHUVAM) 
 
TO EVALUATE THE CLINICAL EFFICACY OF  SIDDHA HERBO MINERAL 
FORMULATION “SANTHIRA PRAGASA MATHIRAI” INTERNAL & 
“SEMBAI THYLAM” EXTERNAL IN “KUMBA VATHAM”                   
(PERIARTHRITIS OF SHOULDER). 
 
Name of the Drug : SANTHIRA PRAGASA MATHIRAI 
Drugs issued  : (Mg / Gram) 
Drugs returned : (Mg / Gram) 
 
S. NO DATE DRUG TAKEN TIME 
MORNING / TIME EVENING / TIME 
Day 1    
Day 2    
Day 3    
Day 4     
Day 5    
Day 6    
Day 7    
Day 13    
Day 14    
Day 15    
Day 16    
Day 17    
Day 18    
Day 19    
Day 25    
Day 26    
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Day 27    
Day 28    
Day 29    
Day 30    
Day 31    
Day 37    
Day 38    
Day 39    
Day 40    
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD  
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